<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005419" GROUP_ID="HIV" ID="799704021818035205" MERGED_FROM="" MODIFIED="2009-05-14 00:59:15 +0200" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.5&lt;/p&gt;" NOTES_MODIFIED="2009-05-13 15:30:39 -0700" NOTES_MODIFIED_BY="Tara Horvath" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2009-05-14 00:59:15 +0200" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2009-05-13 14:30:44 -0700" MODIFIED_BY="Tara Horvath">Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma</TITLE>
<CONTACT MODIFIED="2009-05-14 00:59:15 +0200" MODIFIED_BY="Tara Horvath"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><ZIP>2001</ZIP><REGION>Edo. Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 241 8712883</PHONE_1><FAX_1>+58 241 8712883</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-14 00:59:15 +0200" MODIFIED_BY="Tara Horvath"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><ZIP>2001</ZIP><REGION>Edo. Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 241 8712883</PHONE_1><FAX_1>+58 241 8712883</FAX_1></ADDRESS></PERSON><PERSON ID="14497" ROLE="AUTHOR"><FIRST_NAME>Andrés Felipe</FIRST_NAME><LAST_NAME>Cardona</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><POSITION>Fellow Research and Lecturer, Medical Oncologist</POSITION><EMAIL_1>a_cardonaz@yahoo.com</EMAIL_1><EMAIL_2>acardonaz@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medical Oncology</DEPARTMENT><ORGANISATION>Catalan Institute of Oncology, Hospital Germans Trias I Pujol</ORGANISATION><ADDRESS_1>Carretera de Canyet s/n</ADDRESS_1><CITY>Badalona</CITY><ZIP>08916</ZIP><REGION>Barcelona</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93497 8925</PHONE_1><FAX_1>+34 9349 78950</FAX_1></ADDRESS></PERSON><PERSON ID="9650C75082E26AA20071EDC043293FE4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Able</FIRST_NAME><LAST_NAME>Lawrence</LAST_NAME><SUFFIX>MD, DM</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>abledoc@gmail.com</EMAIL_1><MOBILE_PHONE>+91 9794129000</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Immunology</DEPARTMENT><ORGANISATION>Sanjay Gandhi Postgraduate Institute of Medical Sciences</ORGANISATION><ADDRESS_1>SGPGIMS,</ADDRESS_1><ADDRESS_2>Raebareli Road</ADDRESS_2><CITY>Lucknow</CITY><ZIP>226014</ZIP><REGION>Uttar Pradesh</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 522 2668800 ext 2315 (office)</PHONE_1><PHONE_2>+91 522 2668700 ext 3215(res)</PHONE_2><FAX_1>+91 522 2668812</FAX_1><FAX_2>+91 522 2668192</FAX_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-04-12 15:07:25 -0700" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 22/01/08&lt;/p&gt;" NOTES_MODIFIED="2009-04-12 15:07:25 -0700" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="1" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="4" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2009-04-13 12:11:14 -0700" MODIFIED_BY="Tara Horvath"/>
<HISTORY MODIFIED="2009-05-13 15:30:39 -0700" MODIFIED_BY="Tara Horvath"/>
<SOURCES_OF_SUPPORT MODIFIED="2009-04-06 09:40:14 -0700" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2009-04-06 09:40:14 -0700" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-02-17 07:46:24 -0800" MODIFIED_BY="[Empty name]">
<NAME>Centro Cochrane Iberoamericano</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-02-17 07:46:16 -0800" MODIFIED_BY="[Empty name]">
<NAME>HIV/AIDS Group, The Cochrane Collaboration</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-04-06 09:40:14 -0700" MODIFIED_BY="[Empty name]">
<NAME>Ecuatorian branch of the Iberoamerican Cochrane Network</NAME>
<COUNTRY CODE="EC">Ecuador</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-12 09:59:20 -0700" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-05-11 13:04:01 -0700" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-05-11 13:01:26 -0700" MODIFIED_BY="[Empty name]">Interventions for untreated patients with AIDS-associated non-Hodgkin's lymphoma</TITLE>
<SUMMARY_BODY MODIFIED="2009-05-11 13:04:01 -0700" MODIFIED_BY="[Empty name]">
<P>Lymphoma is a cancer of the lymphatic system. There are two general types: Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Non-Hodgkin's lymphoma is the most common AIDS-defining malignancy in HIV-infected patients. The most frequent clinical presentations of NHL during AIDS are systemic illness with the compromise of the primary central nervous system and with primary effusion. In people with HIV infection, most lymphomas have originated in an aggressive B-cell precursor and have a high-to-intermediate histology grade. Randomised controlled trials (RCTs) of different interventions for treating AIDS-associated NHL found unclear evidence for efficacy and safety.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-11 17:40:09 -0700" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-05-11 17:39:29 -0700" MODIFIED_BY="[Empty name]">
<P>Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin's lymphoma (NHL). The majority of lymphomas (&gt;80%) occurring during immunosuppression are aggressive B-cell in origin and have a high-to-intermediate histology grade. Treatment of NHL is not standardized.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-05-11 12:57:34 -0700" MODIFIED_BY="[Empty name]">
<P>To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and disease-free survival (DFS) for previously untreated patients with AIDS-related NHL.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-05-11 12:57:58 -0700" MODIFIED_BY="[Empty name]">
<P>The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2009), MEDLINE (1966-March 6, 2009), EMBASE (1988-March 6, 2009), LlLACS (1982 to February 17, 2009), Gateway (March 6, 2009), and AIDSearch (2006 -February 2008) were used to identify published, potentially eligible trials. Further, we searched several electronic sources. For additional information see the Cochrane HIV/AIDS Group search strategy.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-04-06 08:27:36 -0700" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) assessing the effectiveness of systemic treatments for previously untreated AIDS-related NHL. There were no age or language restrictions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-04-12 14:34:28 -0700" MODIFIED_BY="[Empty name]">
<P>Authors independently assessed relevant studies for inclusion; four RCTs were selected. No meta-analysis was attempted due to clinical heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-05-11 17:40:09 -0700" MODIFIED_BY="[Empty name]">
<P>Four RCTs that included 857 patients (number range: 30 to 485) met the inclusion criteria. The studies have a high risk of bias; three RCTs were conducted in the United States and one was a multi-national, multi-centre RCT performed in France and Italy. One of the trials included only men. It was impossible to pool data for any of the outcomes due to the differences in the interventions assessed in these RCTs. Overall survival did not differ significantly between treatment groups. Disease free survival (DFS) was reported in two of the four RCTs, but it was not statistically significant between treatment groups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-05-11 13:01:14 -0700" MODIFIED_BY="[Empty name]">
<P>We found no evidence that the systemic interventions for untreated patients with AIDS-related NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality. More adequately powered RCTs that have low risk of bias are necessary to determine the real benefit or harm of interventions to treat this population. Overall survival (OS), DFS, and quality of life should be included as endpoints. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-12 09:58:37 -0700" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-05-11 17:40:25 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>Description of the condition</B>
</P>
<P>Lymphomas represent a large group of neoplasms derived from white blood cells called lymphocytes; this disease is divided into two general types: HD and NHL, which are classified by the way the cells appear under a microscope in association with the immunohistochemistry pattern.</P>
<P>Since the first report of AIDS in 1981, it has been noted that there is a close association between HIV infection and the development of Kaposi sarcoma, NHL, and invasive cervical carcinoma (<LINK REF="REF-Cot_x00e9_-1997" TYPE="REFERENCE">Coté 1997</LINK>; <LINK REF="REF-Clarke-2001" TYPE="REFERENCE">Clarke 2001</LINK>; <LINK REF="REF-Kirk-2001" TYPE="REFERENCE">Kirk 2001</LINK>; <LINK REF="REF-Levine-2006" TYPE="REFERENCE">Levine 2006</LINK>; <LINK REF="REF-Sparano-2003" TYPE="REFERENCE">Sparano 2003</LINK>; <LINK REF="REF-Pantanowitz-2006" TYPE="REFERENCE">Pantanowitz 2006</LINK>; <LINK REF="REF-Patel-2008" TYPE="REFERENCE">Patel 2008</LINK>), which currently are considered to be AIDS-defining malignancies (<LINK REF="REF-Cooley-2003" TYPE="REFERENCE">Cooley 2003</LINK>). In addition, a number of other cancers also are increased substantially in the HIV-infected population, including anal cancer, HD, hepatocellular carcinoma, multiple myeloma, acute leukaemia, leiomyosarcomas in children, oral cavity cancer, and lung cancer (<LINK REF="REF-Grulich-2002" TYPE="REFERENCE">Grulich 2002</LINK>). These conditions are known as HIV-associated malignancies. Moreover, prior to the development of HAART, it has been estimated that up to 25% of all cancers in males less than 45 years of age in the United States were associated with HIV-infection, and up to 30% of all HIV-affected individuals will develop cancer (<LINK REF="REF-Goedert-2000" TYPE="REFERENCE">Goedert 2000</LINK>; <LINK REF="REF-Grulich-2005" TYPE="REFERENCE">Grulich 2005</LINK>; <LINK REF="REF-Grulich-2007" TYPE="REFERENCE">Grulich 2007</LINK>). In the same way, it has been expected that individuals with immune deficiency have between 10-fold and 150-fold greater risks of developing NHL (<LINK REF="REF-Biggar-1996" TYPE="REFERENCE">Biggar 1996</LINK>; <LINK REF="REF-Thomas-2001" TYPE="REFERENCE">Thomas 2001</LINK>), a disease which usually has a poor prognosis because of the aggressiveness of the tumours on immunosuppression. This aggression is due to an increase in hematological toxicity attributable to treatment and to a high rate of complications related to opportunistic infections.</P>
<P>About 4% of people with AIDS have NHL when the immunosuppression state is diagnosed, and at least the same proportion develops NHL during the next few years (<LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>). Recently, the mechanisms and pathways for explaining the development of AIDS-related lymphoma (ARL) had been described (<LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>) and NHL represents one of the most common initial AIDS-defining illnesses (<LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>).</P>
<P>NHL appears to be a late manifestation of HIV infection connected with significant immune suppression (CD4 cells &lt;200/mm<SUP>3</SUP>) and a prior history of an AIDS-defining illness (Volberding 2003; <LINK REF="REF-Sparano-2001" TYPE="REFERENCE">Sparano 2001</LINK>). The increased risk for HIV-related NHL is associated with multiple factors (<LINK REF="REF-Grogg-2007" TYPE="REFERENCE">Grogg 2007</LINK>); three features are significantly connected to the development of systemic NHL: age, nadir of CD4 cell count (the risk increases when count falls below 200/mm<SUP>3</SUP>) (<LINK REF="REF-Bhaskaran--2004" TYPE="REFERENCE">Bhaskaran 2004</LINK>) and no prior HAART (<LINK REF="REF-Matthews-2000" TYPE="REFERENCE">Matthews 2000</LINK>; <LINK REF="REF-Hoffmann-2003" TYPE="REFERENCE">Hoffmann 2003</LINK>; <LINK REF="REF-Stebbing-2004_x002d_a" TYPE="REFERENCE">Stebbing 2004-a</LINK>).</P>
<P>The most frequent clinical presentations of NHL during AIDS are systemic compromise (±80%), primary central nervous system (±20%), and primary effusion (<U>&lt;</U>3%) ( <LINK REF="REF-Kaplan-1989" TYPE="REFERENCE">Kaplan 1989</LINK>; <LINK REF="REF-Levine-2000" TYPE="REFERENCE">Levine 2000</LINK>; <LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>; <LINK REF="REF-Little-2003" TYPE="REFERENCE">Little 2003</LINK>; <LINK REF="REF-Moylett-2002" TYPE="REFERENCE">Moylett 2002</LINK>; <LINK REF="REF-Navarro-2006" TYPE="REFERENCE">Navarro 2006</LINK>; <LINK REF="REF-Sparano-2001" TYPE="REFERENCE">Sparano 2001</LINK>; <LINK REF="REF-Thirlwell-2003" TYPE="REFERENCE">Thirlwell 2003</LINK>). In people with HIV infection, the majority of lymphomas (&gt;80%) have aggressive B-cell origin and a high-to-intermediate histology grade (<LINK REF="REF-Cheung-2005" TYPE="REFERENCE">Cheung 2005</LINK>; <LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>; <LINK REF="REF-Lim-2005_x002d_b" TYPE="REFERENCE">Lim 2005-b</LINK>; <LINK REF="REF-Moylett-2002" TYPE="REFERENCE">Moylett 2002</LINK>; <LINK REF="REF-Navarro-2006" TYPE="REFERENCE">Navarro 2006</LINK>). Molecular heterogeneity of AIDS-related NHL reflects differences between its biological manifestations (<LINK REF="REF-Carbone-2005" TYPE="REFERENCE">Carbone 2005</LINK>). Although low-grade histology is rare (<LINK REF="REF-Sparano-2001" TYPE="REFERENCE">Sparano 2001</LINK>), there is recent evidence that the incidence of indolent NHL appears to be increased in persons with AIDS (<LINK REF="REF-Levine-2002" TYPE="REFERENCE">Levine 2002</LINK>; <LINK REF="REF-Little-2003" TYPE="REFERENCE">Little 2003</LINK>). Systemic HIV-related NHL is characterized by extra-nodal involvement (bone marrow 30%; central nervous system 10%-20%, and the gastrointestinal tract 10%-25%), although virtually any tissue may be compromised (<LINK REF="REF-Moylett-2002" TYPE="REFERENCE">Moylett 2002</LINK>; <LINK REF="REF-Scadden-2003" TYPE="REFERENCE">Scadden 2003</LINK>; <LINK REF="REF-Sparano-2001" TYPE="REFERENCE">Sparano 2001</LINK>). The incidence is higher than in the HIV-seronegative population (<LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>), as is the presence of B symptoms, plasma cellular differentiation, and association with Epstein Barr virus (EBV) (<LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>; <LINK REF="REF-Massarweh-2003" TYPE="REFERENCE">Massarweh 2003</LINK>; <LINK REF="REF-Van-Baarle-2002" TYPE="REFERENCE">Van Baarle 2002</LINK>).</P>
<P>
<B>Role of the highly active antiretroviral therapy (HAART)</B>
</P>
<P>HAART has had effects on HIV-related NHL (<LINK REF="REF-Thirlwell-2003" TYPE="REFERENCE">Thirlwell 2003</LINK>; <LINK REF="REF-Jacomet--2006" TYPE="REFERENCE">Jacomet 2006</LINK>); since 1996, with the regular use of antiretroviral treatment, the spectrum of AIDS-associated malignancies, including NHL, and the epidemiology of the disease has changed completely (<LINK REF="REF-Mocroft-1998" TYPE="REFERENCE">Mocroft 1998</LINK>; <LINK REF="REF-Palella-1998" TYPE="REFERENCE">Palella 1998</LINK>; <LINK REF="REF-Clifford-2005" TYPE="REFERENCE">Clifford 2005</LINK>; <LINK REF="REF-Engels-2008" TYPE="REFERENCE">Engels 2008</LINK>). Before the HAART era, the incidence of NHL in HIV-patients was more than 60 times higher than in people without HIV infection (<LINK REF="REF-Beral-1991" TYPE="REFERENCE">Beral 1991</LINK>; <LINK REF="REF-Biggar-1996" TYPE="REFERENCE">Biggar 1996</LINK>; <LINK REF="REF-Biggar-1996_x002d_b" TYPE="REFERENCE">Biggar 1996-b</LINK>); hence, during the HAART era, an overall decrease of 76% in disease incidence has been observed (<LINK REF="REF-Besson-2001" TYPE="REFERENCE">Besson 2001</LINK>; <LINK REF="REF-Kirk-2001" TYPE="REFERENCE">Kirk 2001</LINK>; <LINK REF="REF-Engels-2008" TYPE="REFERENCE">Engels 2008</LINK>), especially in primary central nervous system lymphoma (<LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>; <LINK REF="REF-Kirk-2001" TYPE="REFERENCE">Kirk 2001</LINK>; <LINK REF="REF-Launay-2003" TYPE="REFERENCE">Launay 2003</LINK>; <LINK REF="REF-Little-2003" TYPE="REFERENCE">Little 2003</LINK>; <LINK REF="REF-Skiest-2003" TYPE="REFERENCE">Skiest 2003</LINK>). In addition, the median survival among patients with AIDS-related lymphoma has increased from 4 to 18 months before the HAART era to nearly 2 years since HAART was established (<LINK REF="REF-Little-2003b" TYPE="REFERENCE">Little 2003b</LINK>). Until now, however, the studies for determining the impact of HAART on the incidence of AIDS-related lymphoma have been inconsistent ( <LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>; <LINK REF="REF-Powles-2009" TYPE="REFERENCE">Powles 2009</LINK>; <LINK REF="REF-Simcock-2007" TYPE="REFERENCE">Simcock 2007</LINK>).</P>
<P>
<B>Description of HIV-related NHL interventions</B>
</P>
<P>Treatment of HIV-related NHL represents a complex and multi-faceted challenge for the physician (<LINK REF="REF-Little-2000" TYPE="REFERENCE">Little 2000</LINK>; <LINK REF="REF-Berretta-2003" TYPE="REFERENCE">Berretta 2003</LINK>; <LINK REF="REF-Stebbing-2004_x002d_b" TYPE="REFERENCE">Stebbing 2004-b</LINK>). The marked toxicity, in particular the myelosuppression associated with an increased incidence of opportunistic infections, led to modifications of standard lymphoma regimens (<LINK REF="REF-Little-2000" TYPE="REFERENCE">Little 2000</LINK>). The stage of immunodeficiency and the lymphoma´s histology and stage are aspects taken into account to select therapy (<LINK REF="REF-Schmidt_x002d_Wolf-2003" TYPE="REFERENCE">Schmidt-Wolf 2003</LINK>).</P>
<P>The feasibility of combining chemotherapy with antiretroviral therapy was formally explored in several studies involving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) given with HAART. These studies found response rates between 47%-75%, with a median OS of up to 27 months and OS rates of 58% and 55% at 1 and 2 years, respectively (<LINK REF="REF-Levine-2004" TYPE="REFERENCE">Levine 2004</LINK>; <LINK REF="REF-Ratner-2001" TYPE="REFERENCE">Ratner 2001</LINK>; <LINK REF="STD-Vaccher-2001" TYPE="STUDY">Vaccher 2001</LINK>). Other treatment options include regimens with high-dose chemotherapy (<LINK REF="REF-Gastaldi-2001" TYPE="REFERENCE">Gastaldi 2001</LINK>; <LINK REF="STD-Gisselbrecht-1993" TYPE="STUDY">Gisselbrecht 1993</LINK>), low-dose chemotherapy (<LINK REF="REF-Kaplan-1997" TYPE="REFERENCE">Kaplan 1997</LINK>; <LINK REF="STD-Levine-1991" TYPE="STUDY">Levine 1991</LINK>), oral chemotherapy (<LINK REF="REF-Remick-1993" TYPE="REFERENCE">Remick 1993</LINK>; <LINK REF="REF-Remick-2001" TYPE="REFERENCE">Remick 2001</LINK>), continuous and infusion regimens (<LINK REF="REF-Little-2003b" TYPE="REFERENCE">Little 2003b</LINK>; <LINK REF="STD-Sparano-1996" TYPE="STUDY">Sparano 1996</LINK>; <LINK REF="STD-Sparano-2004" TYPE="STUDY">Sparano 2004</LINK>), and use of novel therapies such as rituximab (<LINK REF="STD-Tirelli-2002" TYPE="STUDY">Tirelli 2002</LINK>). Furthermore, the improvement in immune status and life expectancy of HIV-patients have encouraged the use of more aggressive therapies for NHL; nevertheless, the long-term impact of those treatments remains unclear (<LINK REF="REF-Dal-Maso-2003" TYPE="REFERENCE">Dal Maso 2003</LINK>) and ongoing trials are actively recruiting patients with this condition.</P>
<P>
<B>Why it is important to do this review</B>
</P>
<P>Even with the success of HAART on a number of AIDS-associated cancers, representing an increase in the longevity of treated individuals and the prolonged effects of immunosuppression, it is likely that HIV-associated malignancies will continue to be a major clinical manifestation of HIV-infected individuals. There is still a lack of widespread antiretroviral therapy in many developing countries where AIDS is epidemic, and HIV continues to spread. Better tools for detection and better regimens for management of these malignancies are necessary. Moreover, a better understanding of the biology and the pathogenesis of these cancers is needed. Although the evidence suggests an aggressive and curative approach for the management of HIV associated NHL, there are no systematic reviews to evaluate and to integrate all published evidence (<LINK REF="REF-Stebbing-2004_x002d_b" TYPE="REFERENCE">Stebbing 2004-b</LINK>).</P>
<P>Based on the epidemiological, clinical, and histopathological characteristics of the people with AIDS-related NHL, its treatment is not standardized, although the evidence currently supports an aggressive and curative approach (<LINK REF="REF-Mounier-2007" TYPE="REFERENCE">Mounier 2007</LINK>; <LINK REF="REF-Noy-2006" TYPE="REFERENCE">Noy 2006</LINK>; <LINK REF="REF-Noy-2007" TYPE="REFERENCE">Noy 2007</LINK>).</P>
<P>The aim of this review is to address the effectiveness and safety of interventions for previously untreated patients with systemic HIV-related NHL.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-05-11 13:42:30 -0700" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of single agent or combination chemotherapy, with or without rituximab or HAART, on OS and DFS for previously untreated patients with AIDS-associated NHL.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-11 13:49:28 -0700" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-05-11 13:46:16 -0700" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-05-11 13:44:30 -0700" MODIFIED_BY="[Empty name]">
<P>Included were RCTs about single-agent or combination chemotherapy plus another drug (rituximab), with or without concurrent HAART, for previously untreated patients with AIDS-related NHL which were completely published in a journal. Other sources of information, such as letters to the editor, abstracts, and proceedings of relevant scientific meetings were excluded because usually they are not peer reviewed and their information is not complete. For the evaluation of adverse effects, however, we considered non-randomised studies. Language limitations were not applied.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-05-11 13:44:50 -0700" MODIFIED_BY="[Empty name]">
<P>Patients with previously untreated, biopsy-proven HIV-related NHL were included. Working Formulation Criteria, Kiel, Revised European-American Lymphoma (REAL) and WHO (World Health Organization) classifications were use for describing histological features. Studies including patients who had relapsed HIV-related NHL, patients with HD, patients with HIV-related primary central nervous system lymphoma or body cavity-based lymphomas were excluded. We also considered children with HIV-related NHL.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-05-11 13:45:24 -0700" MODIFIED_BY="[Empty name]">
<P>Studies using the following interventions were included:</P>
<UL>
<LI>Chemotherapy versus chemotherapy;</LI>
<LI>Combination chemotherapy versus combination chemotherapy plus another drug;</LI>
<LI>Any chemotherapy regimen with or without HAART.</LI>
</UL>
<P>Radiotherapy was allowed as a co-intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-05-11 13:46:16 -0700" MODIFIED_BY="[Empty name]">
<P>1) <B>Primary outcome measures</B>:<BR/>1.1. Overall survival (period of time measured from the beginning of the clinical trial until the time of death);<BR/>1.2. Disease-free survival (period of time without cancer occurring or recurring).</P>
<P>2) <B>Secondary outcome measures</B>:<BR/>
</P>
<P>2.1. Quality of life (QoL);<BR/>2.2. Tumour response rate (the proportion of trial participants whose tumours was reduced in size by a specific amount);<BR/>2.3. Mortality related with therapeutic interventions;<BR/>2.4. Adverse events. The number and type of adverse events, defined as any untoward medical occurrence not necessarily having a causal relation with the treatment. We have defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-11 13:49:28 -0700" MODIFIED_BY="[Empty name]">
<P>We searched The Cochrane AIDS/HIV Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (Issue 1, 2009), <I>MEDLINE</I> (1966 to March 6, 2009), <I>EMBASE</I> (1988 to March 6, 2009), <I>AIDSearch (</I>2006-2008<I>), GATEWAY (</I>March 6, 2009<I>) </I>and <I>LILACS</I> (1982 to February 17, 2009). Full details of the Cochrane Human Immunodeficiency Virus Group methods and the journals hand searched are published in The Cochrane Library in the section on Collaborative Review Groups.</P>
<P>We searched the databases using the search terms - Lymphoma, Non-Hodgkin, AIDS, HIV infection - in combination with a search strategy previously developed by The Cochrane Collaboration (<A HREF="http://e1.mc552.mail.yahoo.com/mc/Higgins%202008">Higgins 2008</A>).</P>
<P>We also searched in the following web sites:</P>
<P>1.- ClinicalTrials.gov (http://www.clinicaltrials.gov) (February 17, 2009).</P>
<P>2.- Current Controlled Trials (http://controlled-trials.com/) (February 17, 2009).</P>
<P>3.- Sistema de Información Esencial en Terapéutica y Salud (http://www.icf.uab.es/informacion/Papyrus/sietes.asp) (February 17, 2009).</P>
<P>4.- The Latin American Clinical Trials Register (<A HREF="http://www.latinrec.org/">http://www.latinrec.org</A>) (February 2009).</P>
<P>5.- Conference on Retroviruses and Opportunistic Infections (1997 to 2009).</P>
<P>6.- Australian New Zealand Clinical Trials Registry (ANZCTR) (<U>http://www.anzctr.org.au/Survey/UserQuestion.aspx)</U> (March 2009).</P>
<P>7.- Chinese Clinical Trial Register (ChiCTR) (<U>http://www.chictr.org/)</U> (March 2009)</P>
<P>8.- Clinical Trials Registry - India (CTRI) (<U>http://www.ctri.in:8080/Clinicaltrials/trials_jsp/index.jsp)</U> (March 2009).</P>
<P>9.- German Clinical Trials Register (DRKS) (<U>http://www.germanctr.de/)</U> (March 2009).</P>
<P>10.- Japan Primary Registries Network (<U>http://rctportal.niph.go.jp/)</U> (March 2009).</P>
<P>11.- The Netherlands National Trial Register (NTR) (<U>http://www.trialregister.nl/trialreg/index.asp)</U> (March 2009). </P>
<P>Grey literature, such as conference abstracts/proceedings from international meetings (American Society of Hematology - ASH - 1990-2008) and the AIDS Society (1990-2008), published lists of theses and dissertations, worldwide letters and other literature outside of the main journal literature were searched where possible, but only were considered if there is complete information for the analysis. Other strategies were employed to evaluate references of review articles and chapters of books related to HIV-related NHL. The bibliographic references of all retrieved literature were reviewed for additional reports of trials.</P>
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for search strategies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-04-06 08:49:47 -0700" MODIFIED_BY="[Empty name]">
<P>This section describes the recommended approach for assessing risk of bias in studies included in Cochrane reviews (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The data were collected in the risk of bias table using the Review Manager (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). The aim of the risk of bias table and figures is help the reader to understand the potential for risk of bias in included studies.</P>
<P>All authors independently assessed each reference identified by the searches to see if they meet the inclusion criteria. Consensus was reached by discussion, and full copies of the trials will be retrieved if necessary.</P>
<P>
<B>1. Study selection </B>
</P>
<P>Titles and abstracts identified from the searches were checked independently by all reviewers. If it was clear that the study did not refer to a RCT on single agent or combined chemotherapy plus another drug (rituximab) with or without HAART, it was excluded. If it was unclear, then the full text study was obtained for independent assessment by two reviewers (AMC and AFC). The reviewers decided which trials fitted the inclusion criteria. Any disagreements were resolved by discussion between the reviewers, with referral to a third reviewer (AL) when necessary. Excluded studies and reasons for exclusion are described in the excluded studies table.</P>
<P>
<B>2. Assessment of methodological quality </B>
</P>
<P>Trials under consideration were assessed for methodological quality and for appropriateness for inclusion without consideration of their results. Data from included trials were processed as described in The Cochrane Collaboration Handbook (<A HREF="http://e1.mc552.mail.yahoo.com/mc/Higgins%202008">Higgins 2008</A>).</P>
<P>Each randomised trial identified by the search was evaluated independently by a pair of two reviewers. All review authors assessed the risk of bias of the included trial. We examined the risk of bias derived from the methods used to generate the allocation sequence; the concealment of allocation; the blinding (clinician, participant outcome assessor) in six outcomes subgroups (Overall survival, disease-free survival, quality of life; tumour response rate, mortality during chemotherapy, adverse events); incomplete outcome data, selective outcome reporting and other sources of bias. We assessed a judgement relating to the risk of bias for each of the six domains (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). This was achieved by answering a pre-specified question about the adequacy of the study in relation to the entry, such that a judgement of &#8216;Yes&#8217; indicates low risk of bias, &#8216;No&#8217; indicates high risk of bias, and &#8216;Unclear&#8217; indicates unclear or unknown risk of bias (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
<P>We grouped studies into two categories; low risk of bias when the allocation concealment was considered as adequate and participants and the providers of care where blinded to the allocations and high risk of bias otherwise.</P>
<P>
<B>3. Data extraction </B>
</P>
<P>Data extraction was carried out by one reviewer (AMC) using a pre-designed data extraction form that contents publication details, patient population, randomisation, allocation concealment, details of blinding measures, description of interventions and results (<LINK REF="REF-Zavala-2006" TYPE="REFERENCE">Zavala 2006</LINK>). This was checked by AFC. The first author of the paper was contacted for getting data missing.</P>
<P>
<B>4. Analysis </B>
</P>
<P>We used the statistical package (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) provided by The Cochrane Collaboration. We used a software package for transforming data of time-to event data in order to estimate hazard ratios (HR) (<LINK REF="REF-Zavala-2007" TYPE="REFERENCE">Zavala 2007</LINK>). Hazard ratio was calculated by using Generic inverse variance.For binary outcomes, we estimated treatment effect using relative risk (RR).</P>
<P>We summarized the information available. Quasi-randomised and non-randomised controlled studies were identified and listed, but were not further included or discussed. A qualitative description was provided for adverse effects when this was available. It was not possible to carry out a quantitative synthesis because of the multiple sources of heterogeneity between included studies; therefore, we performed a qualitative review of the selected reports.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-12 06:35:26 -0700" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-05-11 17:41:35 -0700" MODIFIED_BY="[Empty name]">
<P>The search strategy identified 1054 references; we excluded 1031 references after examining the title and abstract. Full reprints of the remaining 23 references were obtained for more detailed examination.</P>
<P>
<B>Included studies</B>
<BR/>Four RCTs (857 participants) met our inclusion criteria (<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>, <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>, and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>). These are described in the table of included studies. The clinical characteristics of patients are shown in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. RCTs varied in sample size, chemotherapy regimen, end-points, time for developing trial, gender, country, and number of the participant centres.</P>
<UL>
<LI>
<B>Sample size</B>: All RCTs were developed including less than 500 participants. One of them (<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>) reported 30 patients (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</LI>
</UL>
<UL>
<LI>
<B>Chemotherapy regimen</B>
</LI>
</UL>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> compared a modified standard multi-agent chemotherapy regimen named CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) versus alone CHOP (control group). (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> compared a chemotherapy regimen named m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) using standard-dose therapy versus low-dose therapy. In this trial, the participants assigned to standard-dose regimen received supportive GM-CSF therapy. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> compared CHOP versus CHOP plus rituximab. <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> compared a risk-adapted intensive chemotherapy. Participants were classified in three groups: low-risk (ACVBP consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone versus CHOP), intermediate-risk (CHOP versus low-dose CHOP), and high-risk (low-dose versus vincristine plus prednisolone). <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>. For further information, see the table of the characteristics of included studies.</P>
<UL>
<LI>
<B>Type of end points</B>
</LI>
</UL>
<P>1.- Primary outcomes:</P>
<UL>
<LI>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>: survival from the time of initiation of chemotherapy.</LI>
<LI>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>: complete response rate.</LI>
<LI>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>: overall survival.</LI>
</UL>
<P>2.- Secondary outcomes:</P>
<UL>
<LI>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>: complete response rate, the duration of anti-tumour response, the development of opportunistic infection, and toxic effects of treatment.</LI>
<LI>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>: time to progression, progression-free survival, and overall survival.</LI>
<LI>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>: event-free survival, response rate, and toxicity.</LI>
</UL>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> did not discriminated between primary and secondary outcomes. This RCT reported the following outcomes: increase the mean nadir absolute neutrophil count, shorten the duration of neutropenia, decrease the number of hospital admissions for febrile-neutropenic episodes in patients receiving aggressive combination chemotherapy for HIV-associated non-Hodgkin's lymphoma and effect of chemotherapy and rGM-CSF on HIV activity (assessed by serum HIV-1 p24 antigen levels). These outcomes were described in the 'Objective' section. However, the authors included 'tumour response to chemotherapy' and 'survival' in the 'Evaluation of Disease Activity' and 'Statistical Analyses' sections, respectively. Therefore, it is confusing whether this trial was designed primarily to answer those surrogate outcomes. This RCT has a strong relation with other reference presented by the authors in 1990 (<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>).</P>
<UL>
<LI>
<B>Numbers of participants</B>
</LI>
</UL>
<P>One RCT was performed with 30 participants (<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>), two RCTs were performed with less than 200 participants (<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>), while <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> included almost 500 participants.</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> randomised 30 participants. This RCT,however, analysed 24 participants. Analysis for tumour response rate was done using a per-protocol approach.</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> included 192 out of 198 randomised patients (one never had lymphoma, one had an acute opportunistic infection, and one was lost to follow-up after randomisation; there were three violations of the inclusion criteria). There is no information about the group to which these people belonged. Analysis for tumour response rate was done using a per-protocol approach.</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> studied a sample of 150 participants to ensure 120 participants. This sample size was considered to be sufficient to detect an improvement in complete response rate.</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> studied 485 participants.</P>
<P>Details describing the sample size calculation <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> are shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Sample size calculation details of <LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> is not shown because this RCT did not determine sample size.</P>
<UL>
<LI>
<B>Time period of performance of the trial</B>
</LI>
</UL>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> was conducted between August 1988 and March 1990.</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> was conducted between February 1991 and October 1994 at 27 AIDS Clinical Trials Group sites.</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> was performed between December 1998 and May 2002 at 22 AIDS-Malignancies Consortium sites.</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> was conducted between May 1993 and June 1999 at 55 centres from the Groupe d&#8217;Etude des Lymphomes de l&#8217;Adulte (GELA) and the Gruppo Italiano Cooperativo AIDS e Tumori (GICAT). Sixty percent of the participants was gathering from GELA.</P>
<UL>
<LI>
<B>Gender of participants</B>
</LI>
</UL>
<P>One RCT only included male patients (<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>). <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> included female and male patients.</P>
<UL>
<LI>
<B>Country</B>
</LI>
</UL>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> and <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> were conducted in the United States. <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> was conducted in France and Italy.</P>
<UL>
<LI>
<B>Number of the participant centres</B>
</LI>
</UL>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>, <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> were multi-centre RCTs. <LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> was a single-centre RCT.</P>
<P>
<B>Phase of the RCTs</B>
</P>
<P>All RCTs included were phase III studies (<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>).</P>
<P>
<B>Duplicate publications</B>
</P>
<P>Search strategy detected five duplicate publications. <LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> were associated with one duplicate publication. <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> was associated with two duplication publications.</P>
<P>
<B>Excluded studies</B>
</P>
<P>Nineteen studies were excluded (<LINK REF="STD-Antinori-2001" TYPE="STUDY">Antinori 2001</LINK>; <LINK REF="STD-Bou_x00e9_-2006" TYPE="STUDY">Boué 2006</LINK>; <LINK REF="STD-Feigal-1997" TYPE="STUDY">Feigal 1997</LINK>; <LINK REF="STD-Gabarre-1995" TYPE="STUDY">Gabarre 1995</LINK>; <LINK REF="STD-Gisselbrecht-1993" TYPE="STUDY">Gisselbrecht 1993</LINK>; <LINK REF="STD-Hoffmann-2004" TYPE="STUDY">Hoffmann 2004</LINK>; <LINK REF="STD-Levine-1991" TYPE="STUDY">Levine 1991</LINK>; <LINK REF="STD-Levine-2004" TYPE="STUDY">Levine 2004</LINK>; <LINK REF="STD-Newell-1996" TYPE="STUDY">Newell 1996</LINK>; <LINK REF="STD-Ribera-2008" TYPE="STUDY">Ribera 2008</LINK>; <LINK REF="STD-Sparano-1996" TYPE="STUDY">Sparano 1996</LINK>; <LINK REF="STD-Sparano-2004" TYPE="STUDY">Sparano 2004</LINK>; <LINK REF="STD-Spina-2005a" TYPE="STUDY">Spina 2005a</LINK>; <LINK REF="STD-Straus-1998" TYPE="STUDY">Straus 1998</LINK>; <LINK REF="STD-Tirelli-1992" TYPE="STUDY">Tirelli 1992</LINK>; <LINK REF="STD-Tirelli-2002" TYPE="STUDY">Tirelli 2002</LINK>; <LINK REF="STD-Vaccher-2001" TYPE="STUDY">Vaccher 2001</LINK>; <LINK REF="STD-Walsh-1993" TYPE="STUDY">Walsh 1993</LINK>; <LINK REF="STD-Weiss-2006" TYPE="STUDY">Weiss 2006</LINK>).</P>
<P>
<B>Ongoing studies</B>
<BR/>Three studies were classified as ongoing studies (<LINK REF="STD-NCT00002524" TYPE="STUDY">NCT00002524</LINK>; <LINK REF="STD-NCT00020384" TYPE="STUDY">NCT00020384</LINK>; <LINK REF="STD-NCT00049036" TYPE="STUDY">NCT00049036</LINK>). The characteristics of these trials are described in the 'Ongoing Studies' table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-05-11 14:00:22 -0700" MODIFIED_BY="[Empty name]">
<P>The risk of bias in the included trials is summarised in <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK> and <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>. According to the assumptions described in the 'Assessment of Methodological Quality' section, we classified them as trials with high risk of bias.</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> and <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> did not describe the randomisation method.</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> shows an imbalance between groups. This RCT compared 94% (15 of 16) of the assigned participants to the experimental group versus 64.3% (9 of 14) of the assigned participants to the control group. Overall, this RCT analysed 80% (24 of 30) of the randomised patients.</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> Most withdrawals were due to adverse events, disease progression, or death, but analysis was done using an intention-to-treat assessment (patients non-valuable for response were considered as non-responders).</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> used an adequate randomisation procedure.</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> did not report information about allocation concealment.</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>, <LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>, and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> did not provide information about any blinding component.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-12 06:35:26 -0700" MODIFIED_BY="[Empty name]">
<P>Results were based on 857 participants.<BR/>
</P>
<P>
<B>Primary outcome measures:</B>
<BR/>1.1.-Overall survival</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> reported a median OS of 35 weeks for patients within the low-dose group and 31 weeks for patients in the standard-dose group. Hazard risk of death was 1.17 (95% CI: 0.84 to 1.63; P = 0.25) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> reported a median of OS of 139 weeks in the R-CHOP group and 110 weeks in the CHOP group (P = 0.76).</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> reported no statistically significant difference for this outcome by any risk stratum (see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<UL>
<LI>HIV score 0 (ACVBP vs. CHOP): HR: 0.96 (95% CI: 0.71 to 1.29; P = 0.79).</LI>
<LI>HIV score 1 (CHOP vs. low-dose CHOP): HR: 1.25 (95% CI: 0.88 to 1.78; P = 0.22).</LI>
<LI>HIV score 2-3 (low-dose CHOP vs. VS): HR: 1.40 (95% CI: 0.89 to 2.20; P = 0.14).</LI>
</UL>
<P>1.2.-Disease-free survival</P>
<P>For <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>, the median of DFS was 56 weeks in the low-dose group and 38 weeks in the standard-dose group (P = 0.28). The hazard ratio for death or recurrent disease was 1.22 (95% CI: 0.71 to 2.09; P = 0.28). (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> did not evaluate this outcome.</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> reported no statistically significant difference for this outcome by any risk stratum (see <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<UL>
<LI>HIV score 0 (ACVBP vs. CHOP): HR: 0.94 (95% CI: 0.67 to 1.32; P = 0.72).</LI>
<LI>HIV score 1 (CHOP vs. low-dose CHOP): HR: 1.36 (95% CI: 0.95 to 1.94; P = 0.09).</LI>
<LI>HIV score 2-3 (low-dose CHOP vs. VS): HR: 1.52 (95% CI: 0.95 to 2.43; P = 0.08).</LI>
</UL>
<P>
<B>2) Secondary outcome measures:</B>
<BR/>2.1. Quality of life<BR/>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> reported a worse QoL for the group receiving standard-dose therapy; however, it did not achieve statistical significance.</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> and <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> did not evaluate this outcome.</P>
<P>2.2. Tumor response rate</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> (24 participants, 16 events, per-protocol analysis).</P>
<P>There was no significant differences for complete remission (RR: 1.00; 95 CI: 0.56 to 1.79; P = 1.00). By intention-to-treat analysis (30 participants, 16 events) either was significant between both groups (RR: 1.46; 95% CI: 0.71 to 2.98; P = 0.30). This RCT did not describe information about partial remission, stable disease, and disease progression.</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> reported this outcome within 175 participants.</P>
<P>Complete remission (RR 0.80; 95% CI: 0.58 to 1.10; P = 0.17); partial remission (RR 1.07; 95% CI: 0.65 to 1.75; P = 0.80); stable disease (RR 1.18; 95% CI: 0.50 to 2.80; P = 0.70); and disease progression (RR 1.55; 95% CI: 0.76 to 3.17; P = 0.23) (see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>
</P>
<P>Complete remission (RR 1.20; 95% CI: 0.86 to 1.68; P= 0.29); partial remission (RR 1.01; 95% CI: 0.32 to 3.19; P= 0.99); stable disease (RR 1.01; 95% CI: 0.32 to 3.19; P = 0.99); and disease progression (RR 0.37; 95% CI: 0.16 to 0.85; P = 0.02) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>
</P>
<P>Complete remission:</P>
<UL>
<LI>Good-risk subgroup (HIV score 0): there was no statistically significant difference between the ACVBP regimen and the CHOP regimen (RR 1.18 95% CI: 0.93 to 1.49; P = 0.17; 218 participants).</LI>
<LI>Intermediate-risk subgroup (HIV score 1): there was statistically significant difference between the CHOP regimen and the low-dose CHOP regimen (RR 1.56; 95% CI: 1.07 to 2.28; P = 0.02; 177 participants).</LI>
<LI>High-risk subgroup (HIV score 2-3): there was no statistically significant difference between the low-dose CHOP regimen and the VS regimen (RR 4.18; 95% CI: 0.97 to 18.02; P = 0.05; 90 participants.</LI>
</UL>
<P>See <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.</P>
<P>Partial remission:</P>
<UL>
<LI>Good-risk subgroup (HIV score 0): there was no statistically significant difference between the ACVBP regimen and the CHOP regimen (RR 1.06; 95% CI: 0.57 to 1.99; P = 0.85; 218 participants).</LI>
<LI>Intermediate-risk subgroup (HIV score 1): there was statistically significant difference between the CHOP regimen and the low-dose CHOP regimen (RR 0.60; 95% CI: 0.27 to 1.33; P =0.21; 177 participants).</LI>
<LI>High-risk subgroup (HIV score 2-3): there was no statistically significant difference between the low-dose CHOP regimen and the VS regimen (RR 0.84; 95% CI: 0.29 to 2.40; P = 0.74; 90 participants).</LI>
</UL>
<P>See <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>.</P>
<P>2.3.-Mortality during chemotherapy</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> reported no significant differences for overall mortality by per protocol analysis (16 events and 25 participants).</P>
<P>We did an intention-to treat analysis (16 of 30) and we found no statistical difference (RR 1.1; 95% CI: 0.60 to 2.07; P = 0.74 and RR 1.46; 95% CI: 0.71 to 2.89; P = 0.30) (see <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK> and <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). Overall, lymphoma was the most frequent cause of death (32%; 8 of 25). However, there was no significant differences by cause of death (25 participants): Lymphoma (RR 1.11; 95% CI: 0.34 to 3.64; P = 0.86 events: 8); <I>P. carinii</I> pneumonia (RR 0.67; 95% CI: 0.05 to 9.47; P = 0.76; events: 2); <I>Streptococcus aureus</I> sepsis (RR 0.23; 95% CI: 0.01 to 5.12; P = 0.35; event: 1); suicide (RR 0.23; 95% CI: 0.01 to 5.12; P = 0.35; event: 1); severe wasting syndrome (RR 3.44; 95% CI: 0.18 to 64.88; P = 0.41; events: 2); cytomegalovirus encephalitis (RR 2.06; 95% CI: 0.09 to 46.11; P = 0.65; event: 1); and undetermined cause (RR 2.06; 95% CI: 0.09 to 46.11; P = 0.65; event: 1).</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> reported three treatment-associated deaths due to respiratory failure secondary to ascending paralysis caused by cytarabine toxicity, one hepatic failure, and one sepsis related to neutropenia.</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> reported 14 deaths resulting from treatment-related infection (RCHOP: 13 vs. CHOP: 1). Risk ratio was 6.70 (95% CI: 0.90 to 49.77; P = 0.06) (see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>In the R-CHOP group, the rate of deaths associated with serious infections was 36% for patients with baseline CD4<SUP>+ </SUP>count less than 50 mm<SUP>3 </SUP>and 6% in patients with baseline CD4<SUP>+</SUP> counts greater than or equal to 50 mm<SUP>3</SUP>, a difference that was significant (P = 0.001). During six-month treatment with rituximab, eight patients presented HIV-associated opportunistic infections, while in the chemotherapy group there were no opportunistic infections (P = 0.096).</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> reported a mortality rate of 4.1% (9 of 218) in the good-risk group, 9.6% (17 of 177) in the intermediate-risk group, and 9.6% (17 of 177) in the poor-risk group. There were seven deaths due to treatment-related toxicity.</P>
<P>2.4.- Adverse events</P>
<P>Adverse events reported by included studies:</P>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> reported this outcome by chemotherapy cycles and by patients. The most frequent adverse events were diarrhoea, fatigue, fever, headache, and nausea. Overall by chemotherapy cycles (N = 99), risk ratio was 1.72 (95% CI: 1.13 to 2.63; P = 0.01; events: 55). Overall by patients (N = 26), there was no significant difference (RR 1.75; 95% CI: 0.92 to 3.34; P = 0.09; events:19).</P>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK> reported a non-statistically significant difference for the following adverse events: fever, abdominal pain, nausea, vomiting, allergic reaction, headache, diarrhoea, and opportunistic Illness (<A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#CMP-001.04#CMP-001.04">Analysis 1.4</A>). Except for grade 3 or higher-grade toxic effects for low-dose m-BACOD regimen (RR 0.73; 95% CI: 0.57 to 0.92; P = 0.008; 110 events, 192 participants) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK> reported statistically significant differences for absolute neutrophil count &lt;500 mm<SUP>3</SUP>, cycles outcome. There was an increased risk for rituximab-CHOP versus CHOP (RR 1.26; 95% CI: 1.08 to 1.48; P = 0.003; 135 events, 150 participants) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). There was also an increased risk for rituximab-CHOP versus CHOP related with toxic effects of grade 3 or higher with chemotherapy (absolute neutrophil count &lt;500/mm<SUP>3</SUP>; thrombocytopenia, grade 4; anaemia, grade 4; alkaline phosphatase, grade 3/4; and aspartate aminotransferase, grade 3/4) (RR 1.37; 95% CI: 1.13 to 1.66; P = 0.001; 128 events, 150 participants) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>There were statistically significant differences for absolute neutrophil count &lt;500/mm<SUP>3</SUP>; thrombocytopenia, grade 4; anaemia, grade 4; febrile neutropenia; alkaline phosphatase, grade 3/4; aspartate aminotransferase, grade 3/4; alanine aminotransferase; infusion reaction; and opportunistic illness (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>
</P>
<P>Good-risk subgroup (HIV score 0): there was a statistically significant difference between ACVBP regimen versus CHOP regimen for thrombocytopenia (RR 3.85; 95% CI: 2.22 to 6.66; P = 0.00001; 63 events, 218 participants); leukopenia (RR 2.10; 95% CI: 1.60 to 2.76; P = 0.00001; 121 events, 218 participants); infection (RR 4.67; 95% CI: 2.01 to 10.82; P = 0.0003; 34 events, 218 participants), and mucositis (RR 2.33; 95% CI: 1.12 to 4.86; P = 0.02; 30 events, 218 participants) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
<P>Intermediate-risk subgroup (HIV score 1): there was a statistically significant difference between the CHOP regimen versus the low-dose CHOP regimen for leukopenia (RR 1.69; 95% CI: 1.16 to 2.48; P = 0.07; 64 events, 177 participants). There was no statistically significant difference for thrombocytopenia (RR 1.80; 95% CI: 0.94 to 3.47; P = 0.08; 34 events, 177 participants); infection (RR 1.18; 95% CI: 0.57 to 2.42; P = 0.66; 26 events, 177 participants), and mucositis (RR 1.73; 95% CI: 0.16 to 18.69; P = 0.65; 3 events, 177 participants) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
<P>High-risk subgroup (HIV score 2-3): there was a statistically significant difference between the low-dose CHOP regimen versus the VS regimen for leukopenia (RR 3.35; 95% CI: 1.38 to 8.13; P = 0.008; 25 events, 90 participants). There was no statistically significant difference between thrombocytopenia (RR 0.17; 95% CI: 0.02 to 1.38; P = 0.10; 6 events, 90 participants); infection (RR 1.43: 95% CI: 0.62 to 3.31; P = 0.4; 19 events, 90 participants), and mucositis (RR 3.0; 95% CI: 0.13 to 71.89; P = 0.50; 1 event, 90 participants) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
<P>Adverse events reported by non-randomised clinical trial are shown in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-12 09:46:04 -0700" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-05-12 09:30:41 -0700" MODIFIED_BY="[Empty name]">
<P>Based on the results of three RCTs which enrolled more than 800 patients, this Cochrane review aimed to assess the clinical effectiveness of interventions for previously untreated patients with HIV-related NHL.</P>
<P>Previous studies have indicated that patients with HIV-related NHL have a poor prognosis (<A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#REF-Miralles-2007%23REF-Miralles-2007">Miralles 2007</A>; <LINK REF="REF-Palmieri-2006" TYPE="REFERENCE">Palmieri 2006</LINK>). Features contributing to this result include lymphoma-specific factors, such as aggressive histology, extranodal disease, MDR-1 multi-resistance gene expression and HIV-specific features, such as poor bone marrow reserve, reduced CD4 count, or opportunistic infection (<A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#REF-Kaplan-1989%23REF-Kaplan-1989">Kaplan 1989</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#REF-Strauss-1998%23REF-Strauss-1998">Strauss 1998</A>). The use of combination antiretroviral therapy simultaneously with improved prophylaxis of opportunistic infections has been found to delay progression of HIV infection to AIDS. This finding was followed by a substantial reduction in morbidity and mortality secondary to HIV infection (<A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#REF-Mocroft-1998%23REF-Mocroft-1998">Mocroft 1998</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#REF-Palella-1998%23REF-Palella-1998">Palella 1998</A>) which encourages the regular use of chemotherapy against AIDS-related malignancies, including NHL. Different chemotherapy schedules have been tested, but there is disagreement still regarding the optimal treatment for patients with HIV-related NHL, even in the post-HAART era (<A HREF="http://archie.cochrane.org/sections/documents/view?version=AA46EE9982E26AA200BC29506AE230E8&amp;format=REVMAN#REF-Miralles-2002%23REF-Miralles-2002">Miralles 2002</A>; <LINK REF="REF-Miralles-2007" TYPE="REFERENCE">Miralles 2007</LINK>).</P>
<P>It seems reasonable that the prognosis of patients with HIV-related NHL who respond favourably to HAART will be increasingly similar to that of the general population and will be less conditioned by the natural history of HIV infection. For this reason, the GESIDA/PETHEMA group in 2002 recommended the use of regimens which include anthracyclines such as CHOP or EPOCH (etoposide, adriamycin, vincristine, cyclophosphamide, and prednisone) using conventional doses because reduction in dose intensity decreases the proportion of complete remissions (<LINK REF="REF-Miralles-2002" TYPE="REFERENCE">Miralles 2002</LINK>). This recommendation was based principally on the experience of the Groupe d&#8217;Etude des Lymphomes de l&#8217;Adulte (GELA) and the Gruppo Italiano Cooperativo AIDS e Tumori (GICAT) that developed a risk-adapted approach to the treatment of HIV-related NHL (<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>). In this RCT, 485 patients were randomised to chemotherapy after stratification according to an &#8220;HIV score&#8221; based on poor performance status (ECOG performance status), prior AIDS diagnosis, and CD4 cell count below 100 cells/mL. The patients were randomly assigned to receive CHOP or a more intensive ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone) regimen, with no significant differences in the complete response rate or in the five-year OS in any of the treatment arms within each HIV risk group, although the outcome for those with an intermediate or high HIV score was clearly inferior to the outcome for those who had a low HIV score (<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>). Although this is a critical trial, the results need to be interpreted with caution because the sample size within each cohort limits the power to detect considerable differences between the treatment arms. In addition, 61% of the patients enrolled in the trial were entered pre-HAART, limiting the usefulness of the results to patients treated currently with this intervention in regular practice. <LINK REF="REF-Hebert-2002" TYPE="REFERENCE">Hebert 2002</LINK> had shown that papers with negative results lack sufficient data to determine its true validity.</P>
<P>The power of a study is its probability of detecting a clinically<SUP> </SUP>important effect of the experimental treatment, compared with<SUP> </SUP>the control arm, if a difference actually exists (<LINK REF="REF-Freiman-1978" TYPE="REFERENCE">Freiman 1978</LINK>). If a clinical<SUP> </SUP>trial fails to show a statistically significant benefit in favour<SUP> </SUP>of the experimental treatment, a researcher may erroneously<SUP> </SUP>conclude that the experimental treatment is of no benefit, even<SUP> </SUP>if not enough patients were enrolled to demonstrateconsistently a clinically meaningful effect (<LINK REF="REF-Moher-1994" TYPE="REFERENCE">Moher 1994</LINK>). All RCTs included in this Cochrane review reported negative results and they were underpowered (<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>; <LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>; <LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>; <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>). Some investigators have suggested that underpowered studies are unethical, given that they expose patients to the risks of research without providing a reasonable opportunity for the outcome to contribute to scientific knowledge (<LINK REF="REF-Altman-1980" TYPE="REFERENCE">Altman 1980</LINK>). Other investigators, however, have mentioned that well-conducted but underpowered studies may provide valuable point estimates of treatment effect and can be synthesized with other studies in meta-analyses to perform valid treatment comparisons (<LINK REF="REF-Edwards-1997" TYPE="REFERENCE">Edwards 1997</LINK>). In the same way, underpowered trials are unavoidable for rare cancers, including lymphomas related to HIV infection (<LINK REF="REF-Booth-2008" TYPE="REFERENCE">Booth 2008</LINK>). Increased effort is required to promote development of RCTs able to influence clinical practice and to assess the benefit of new treatments in the population of patients with AIDS-related NHL.</P>
<P>Currently, around 50% of cancer trials have had too few participants to detect a medium effect size in favour of the experimental arm for their primary end point with at least 80% statistical power (<LINK REF="REF-Bedard-2007" TYPE="REFERENCE">Bedard 2007</LINK>). Another study that reviewed 22 negative randomised haemato-oncology trials published in specialty journals during a 1-year period found that 73% of trials lacked adequate statistical power to detect a 50% improvement in median survival in favour of the experimental arm (<LINK REF="REF-Martins-1997" TYPE="REFERENCE">Martins 1997</LINK>). The lack of efficacy determined in the trials included in our review could be attributed to a relative low incidence of AIDS-related NHL, the presence of multiple competing trials, evidence of unexpected toxicity at the moment of interim analysis, and probably deficient financial support (almost all trials in this research line are sustained and developed by independent cooperative national or multinational groups).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-05-12 09:35:11 -0700" MODIFIED_BY="[Empty name]">
<P>There is a gap of almost two decades between the first RCT (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-Kaplan-1991#STD-Kaplan-1991">Kaplan 1991</A>) and the latest one (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-NHL_x002d_HIV_x002d_93-2006#STD-NHL_x002d_HIV_x002d_93-2006">NHL-HIV-93 2006</A>). Two RCTs were published in the last century (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-Kaplan-1991#STD-Kaplan-1991">Kaplan 1991</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-Kaplan-1997#STD-Kaplan-1997">Kaplan 1997</A>) and two in the last nine years (<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-NHL_x002d_HIV_x002d_93-2006#STD-NHL_x002d_HIV_x002d_93-2006">NHL-HIV-93 2006</A>). One of the most important questions to be answered is why trials regarding AIDS-related NHL were conducted exclusively in developed countries if over 95% of HIV-infected patients live in developing countries, including 25.3 million (70%) in sub-Saharian Africa (<LINK REF="REF-UNAIDS-2000" TYPE="REFERENCE">UNAIDS 2000</LINK>). Some ways to explain the minimal interest in the treatment of HIV-related malignancies which still exist today are directly associated to an economic environment of scarcity in areas of the world where the burden of HIV disease is greatest (N&#8217;Galy 1990). Despite the evolution of antiretroviral therapy and its impact on neoplastic complications of the epidemic, we need new trials designed to consider and stratify patients based on individual characteristics (<LINK REF="REF-Otieno-2002" TYPE="REFERENCE">Otieno 2002</LINK>). In the same way, it is a need to perform comparisons of modern aggressive regimens which are specific for histologic subtypes of lymphomas (e.g., diffuse large B cell, lymphoblastic lymphomas, Burkitt's lymphoma, and Burkitt-like lymphoma in separate trials with appropriate interventions) compared with conventional conservative regimens like CHOP and studies planned to assess the role of aggressive dosage intensity versus standard doses. In addition, the appropriate timing of the institution of HAART in relation to multi-agent chemotherapy has not yet been studied.</P>
<P>It is difficult to draw definitive conclusions or make recommendations for treatment of AIDS-related NHL on the basis of findings from few heterogeneous and underpowered RCTs. Nevertheless, HAART should be used with chemotherapy; addition of rituximab to classic CHOP therapy is associated with improved response rates, without an increase in infections, but optimal therapy for patients with AIDS-related NHL has not yet been defined.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-05-12 09:45:20 -0700" MODIFIED_BY="[Empty name]">
<P>The main limitations of this systematic review refer to the paucity of evidence, attributable especially to the low number of published randomised studies and the minimum number of patients included. Furthermore, <LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK> shows a high imbalance in patient&#8217;s baseline characteristics and group distribution. Only two RCTs had an adequate distribution sequence (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-AMCT_x002d_010--2005#STD-AMCT_x002d_010--2005">AMCT-010 2005</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-NHL_x002d_HIV_x002d_93-2006#STD-NHL_x002d_HIV_x002d_93-2006">NHL-HIV-93 2006</A>), none presented allocation concealment and there was no information about the blinding process.</P>
<P>Currently, around 50% of cancer trials have had too few participants to detect a medium effect size in favour of the experimental arm for their primary end point with at least 80% statistical power (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#REF-Bedard-2007#REF-Bedard-2007">Bedard 2007</A>). Another study that reviewed 22 negative randomised haemato-oncology trials published in specialised journals during a one-year period found that 73% of trials lacked adequate statistical power to detect a 50% improvement in median survival in favour of the experimental arm (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#REF-Martins-1997#REF-Martins-1997">Martins 1997</A>). The lack of efficacy determined in the trials included in our review could be attributed to a relatively low incidence of AIDS-related NHL, the presence of multiple low quality and heterogeneous competing trials, evidence of unexpected toxicity at the moment of interim analysis, and probably deficient financial support (almost all trials in this research line are sustained and developed by independent cooperative national or multinational groups).</P>
<P>Some researchers have suggested that underpowered studies are unethical, since  patiens are exposed to the risks of research without providing a reasonable opportunity for the outcome to contribute to scientific knowledge (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#REF-Altman-1980#REF-Altman-1980">Altman 1980</A>). However, it has been mentioned that well-conducted underpowered studies may provide valuable point estimates of treatment effect and can be synthesized with other studies in meta-analyses to perform valid treatment comparisons (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#REF-Edwards-1997#REF-Edwards-1997">Edwards 1997</A>). In the same way underpowered trials are unavoidable for rare cancers, including lymphomas related to HIV infection (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#REF-Booth-2008#REF-Booth-2008">Booth 2008</A>).</P>
<P>In patients without underlying HIV infection, there has been a suggested clinical advantage to the use of rituximab along with CHOP chemotherapy, when compared to CHOP alone, in patients with diffuse large B-cell lymphoma (<LINK REF="REF-Coiffier-2002" TYPE="REFERENCE">Coiffier 2002</LINK>). To ascertain if the addition of rituximab to CHOP provided the same advantage in HIV-infected patients, several phase II trials of R-CHOP were conducted. Nevertheless, a randomised phase III study of CHOP versus R-CHOP was subsequently conducted (<A HREF="http://archie.cochrane.org/sections/documents/view?version=48FB1D5882E26AA2004DD5A132DF356B&amp;format=REVMAN#STD-AMCT_x002d_010--2005#STD-AMCT_x002d_010--2005">AMCT-010 2005</A>); in this trial, rituximab was given at a dose of 375 mg/m<SUP>2</SUP> on the first day of each cycle, and CHOP was administered on day 3. Additional doses of rituximab were given monthly for three months at the completion of all chemotherapy, thus representing a higher cumulative dose of rituximab than had been used by Coiffier et al (<LINK REF="REF-Coiffier-2002" TYPE="REFERENCE">Coiffier 2002</LINK>; <LINK REF="REF-Levine-2008" TYPE="REFERENCE">Levine 2008</LINK>). A complete response rate of 57.6% was achieved with R-CHOP, with 14% of patients dying of the disease. In contrast, a 47% complete response rate was achieved among CHOP-treated patients, with 29% succumbing to lymphoma. Although these data indicate an advantage to the use of rituximab, the results were not positive because the AMC trial may not have been powered sufficiently to detect statistically significant differences in response rate (<LINK REF="REF-Levine-2008" TYPE="REFERENCE">Levine 2008</LINK>). In addition, it is possible that the biologic characteristics of HIV-infected versus HIV-uninfected NHL may differ. As an example, the presence of bcl-2 expression was shown to correlate with improved response to rituximab (<LINK REF="REF-Coiffier-2002" TYPE="REFERENCE">Coiffier 2002</LINK>), but HIV-infected patients appears to be less likely to have malignancies that express bcl-2. Following this idea, some researchers demonstrated that around 16% of HIV-infected patients with NHL expressed bcl-2, versus 41% of HIV-uninfected cases (<LINK REF="REF-Little-2003b" TYPE="REFERENCE">Little 2003b</LINK>). Nonetheless, although only a subset of cases were evaluated for bcl-2 in the AMC trial, the addition of rituximab to CHOP in patients with bcl-2 positive NHL was not associated with improvement in PFS or time to tumour progression (<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>).</P>
<P>
<LINK REF="STD-Spina-2005a" TYPE="STUDY">Spina 2005a</LINK> published a pooled analysis of the results of three prospective phase II trials evaluating rituximab (in combination with a 96h infusion of cyclophosphamide, doxorubicin and etoposide, R-CDE) and noted a 70% complete response rate with 59% two-year failure-free survival in 74 patients, of whom 76% received concomitant HAART. Opportunistic infections occurred in 14%, and 23% developed non-opportunistic infections; 8% died of infectious complications, suggesting the possibility of an increased rate in infections among HIV patients receiving rituximab plus chemotherapy. Actually, unusual infections have been reported, even in patients with non-HIV-related lymphoma who have been exposed to rituximab (<LINK REF="REF-Koo-2008" TYPE="REFERENCE">Koo 2008</LINK>; <LINK REF="REF-Spina-2005b" TYPE="REFERENCE">Spina 2005b</LINK>).</P>
<P>Classically, the objective of a phase II trial is to identifying active therapies and to evaluate toxicity; however, some researchers extended the usual aims of this type of study to identifying those compounds that are likely to be successful in pivotal trials (<LINK REF="REF-Holmgren-2008" TYPE="REFERENCE">Holmgren 2008</LINK>). It is therefore necessary to quantify the likelihood of either incorrectly halting the development of an active agent or continuing development of an ineffective agent (<LINK REF="REF-Stone-2007" TYPE="REFERENCE">Stone 2007</LINK>). We believe only RCTs with comparative intent and including a concurrent active control can reliably assess these risks corresponding to significance and power; this reason supports the exclusion of <LINK REF="STD-Spina-2005a" TYPE="STUDY">Spina 2005a</LINK> from our efficacy analysis.  </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-05-12 09:46:04 -0700" MODIFIED_BY="[Empty name]">
<P>Publication bias represents a major threat to the validity of systematic reviews, particularly reviews of small trials, as in our case. Contact with experts, conference proceedings, and review of the clinical trial registries, however, failed to uncover any registered completed trial that had remained unpublished.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-04-06 09:09:05 -0700" MODIFIED_BY="[Empty name]">
<P>None.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-05-12 09:58:37 -0700" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-05-12 09:46:51 -0700" MODIFIED_BY="[Empty name]">
<P>There is a lack of reliable evidence on interventions for treating HAART-naive patients who have HIV-related NHL. It was not possible, therefore, to determine the clinical effectiveness and safety of various chemotherapy approaches previously described for HIV-related NHL, including those which evaluate the combination of HAART or rituximab with chemotherapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-05-12 09:58:37 -0700" MODIFIED_BY="[Empty name]">
<P>This systematic review identified the need for well-designed, adequately-powered randomised controlled trials to assess benefits and harms of interventions for HAART-naive patients with HIV-related NHL. The RCTs should consider OS, DFS, and quality of life as primary outcomes. Trials should be structured and reported according to the 'Consort Statement' checklist to improve the evidence quality with the aim to standardize management.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-12 09:59:08 -0700" MODIFIED_BY="[Empty name]">
<P>We want to express our gratitude to Prof Nicolás Mounier for sending unpublished data from <LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK> to enhance the quality of this review; Mr Daniel Zavala for doing <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; Ms Joy Oliver and Mrs Elizabeth Pienaar for supported with the search of the references and their patience; Ms Tara Horvath for supported with the full texts of the references and every help asked by us, and peer reviewers for improving the quality of this review with their suggestions. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-07-07 11:18:17 -0700" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-12 09:59:20 -0700" MODIFIED_BY="[Empty name]">
<P>Arturo Martí-Carvajal (AMC) took the lead on writing the protocol based on the draft versions with inputs from Andrés Felipe Cardona (AFC) and Able Lawrence.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-03-20 08:37:01 -0700" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-04-06 12:00:10 -0700" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-04-06 12:00:10 -0700" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-03-20 08:55:43 -0700" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-AMCT_x002d_010--2005" MODIFIED="2009-03-09 09:58:00 -0700" MODIFIED_BY="[Empty name]" NAME="AMCT-010  2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-17 13:13:52 -0700" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A et al</AU>
<TI>Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<PG>1538-43</PG>
<IDENTIFIERS MODIFIED="2008-09-10 08:39:17 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-10 08:39:17 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15914552"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-09 09:57:05 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kaplan LD, Scadden DT</AU>
<TI>Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>564</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-17 13:13:00 -0700" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1991" MODIFIED="2009-03-13 10:08:15 -0700" MODIFIED_BY="[Empty name]" NAME="Kaplan 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-03-13 10:08:10 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kaplan L, Kahn J, Crowe S, Volberding P, Grossberg H, McManus N, Mills J; International Conference on AIDS</AU>
<TI>A randomized trial of chemotherapy with or without recombinant granulocyte monocyte colony stimulating factor (rGMCSF) in HIV-associated non-Hodgkin's lymphoma (NHL): effect of treatment on serum HIV p24 antigen levels</TI>
<SO>International Conference on AIDS</SO>
<YR>1990</YR>
<VL>6 (Suppl 3)</VL>
<PG>213 ( Abstract S.B.510)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-12 10:30:34 -0700" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H et al</AU>
<TI>Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>929-40</PG>
<IDENTIFIERS MODIFIED="2009-03-12 10:30:34 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-12 10:30:34 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2033429"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1997" MODIFIED="2009-03-10 14:50:45 -0700" MODIFIED_BY="[Empty name]" NAME="Kaplan 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-03-10 12:01:52 -0700" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP et al</AU>
<TI>Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>1641-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:01:52 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:01:52 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9171066"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-10 14:50:45 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD</AU>
<TI>Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>3601-6</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:50:45 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:50:45 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9817281"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-17 13:13:21 -0700" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NHL_x002d_HIV_x002d_93-2006" MODIFIED="2009-03-20 08:55:43 -0700" MODIFIED_BY="[Empty name]" NAME="NHL-HIV-93 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-09 09:41:38 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mounier N, Spina M, Gabarre J, Raphael M, Carbone A, Vaccher E et al</AU>
<TI>HIV-related Non-Hodgkin's Lymphomas before and after Haart: final analysis on 485 patients treated with risk-adapted intensive chemotherapy from the French-Italian Cooperative Group (GELAGICAT)</TI>
<SO>Haematologica</SO>
<YR>2005</YR>
<VL>90 Suppl 2</VL>
<PG>324</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-09 09:48:05 -0700" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB et al</AU>
<TI>AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>107</VL>
<PG>3832-40</PG>
<IDENTIFIERS MODIFIED="2008-09-10 08:33:46 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-10 08:33:46 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16410446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-20 08:55:43 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tirelli U, Spina M, Errante D, Vaccher E, Tavio M, Nasti G et al</AU>
<TI>Therapy of HIV-related non-Hodgkins lymphoma: An european multicentric randomized stduy in patients (PTS) stratified according to their prognostic factors: Preliminary results</TI>
<SO>Tumori</SO>
<YR>1997</YR>
<VL>83 Suppl 1</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-04-06 11:22:43 -0700" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Antinori-2001" MODIFIED="2009-03-10 11:01:41 -0700" MODIFIED_BY="[Empty name]" NAME="Antinori 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-10 11:01:41 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC et al</AU>
<TI>Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy</TI>
<SO>AIDS</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>1483-91</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:01:41 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:01:41 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11504980"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bou_x00e9_-2006" MODIFIED="2009-03-10 11:05:52 -0700" MODIFIED_BY="[Empty name]" NAME="Boué 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-10 11:05:52 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F et al</AU>
<TI>Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>4123-28</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:05:52 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:05:52 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16896005"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feigal-1997" MODIFIED="2009-03-20 08:00:36 -0700" MODIFIED_BY="[Empty name]" NAME="Feigal 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-03-20 08:00:36 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Feigal EG, Petroni GR, Freter C, Johnson JL, Barcos M, Peterson BA</AU>
<TI>Pilot trial of cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide + antiretrovirals + G-CSF + erythropoietin in AIDS-associated non-Hodgkin's lymphoma: CALGB 9155</TI>
<SO>ASCO Annual Meeting</SO>
<YR>1997</YR>
<VL>Abstract: 195</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gabarre-1995" MODIFIED="2009-03-10 11:09:04 -0700" MODIFIED_BY="[Empty name]" NAME="Gabarre 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-03-10 11:09:04 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabarre J, Lepage E, Thyss A, Tubiana R, Bastion Y, Schlaifer D et al</AU>
<TI>Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma</TI>
<SO>Annals of Oncology</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>1025-32</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:09:04 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:09:04 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8750156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gisselbrecht-1993" MODIFIED="2009-03-10 11:11:59 -0700" MODIFIED_BY="[Empty name]" NAME="Gisselbrecht 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-03-10 11:11:59 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gisselbrecht C, Oksenhendler E, Tirelli U, Lepage E, Gabarre J, Farcet JP et al</AU>
<TI>Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>95</VL>
<PG>88-96</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:11:59 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:11:59 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7689296"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffmann-2004" MODIFIED="2009-03-22 09:06:31 -0700" MODIFIED_BY="[Empty name]" NAME="Hoffmann 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-22 09:06:31 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoffmann C, Wolf E, Faetkenheuer G, Wyen C, Stellbrink HJ, van Lunzen J et al</AU>
<TI>The Short and Intensive B-ALL Protocol Is a Highly Effective Regimen in Patients with AIDS-associated Burkitt or Burkitt-like Lymphoma</TI>
<SO>Conference on Retroviruses and Opportunistic Infections (11th : 2004 : San Francisco, Calif, USA)</SO>
<YR>2004</YR>
<PG>abstract 787</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1991" MODIFIED="2009-03-12 09:25:10 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-03-12 09:25:10 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C et al</AU>
<TI>Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1991</YR>
<VL>266</VL>
<PG>84-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1710673"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2004" MODIFIED="2009-03-10 11:13:55 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-10 11:13:55 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD et al</AU>
<TI>Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2662-70</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:13:55 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:13:55 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15226333"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newell-1996" MODIFIED="2009-03-10 11:15:16 -0700" MODIFIED_BY="[Empty name]" NAME="Newell 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-09 10:29:03 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newell M, Goldstein D, Milliken S, Lewis C, Hoy J, Thomson B et al</AU>
<TI>Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma</TI>
<SO>Annals of Oncology</SO>
<YR>1996</YR>
<VL>7</VL>
<PG>1029-36</PG>
<IDENTIFIERS MODIFIED="2009-03-09 10:28:58 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-09 10:28:58 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9037361"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-03-10 11:15:16 -0700" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ribera-2008" MODIFIED="2009-03-10 11:17:19 -0700" MODIFIED_BY="[Empty name]" NAME="Ribera 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-03-10 11:17:19 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A et al</AU>
<TI>Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial</TI>
<SO>British Journal of Haematology</SO>
<YR>2008</YR>
<VL>140</VL>
<PG>411-9</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:17:19 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:17:19 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18162120"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparano-1996" MODIFIED="2009-03-10 11:19:05 -0700" MODIFIED_BY="[Empty name]" NAME="Sparano 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-10 11:19:05 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R et al</AU>
<TI>Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma</TI>
<SO>Journal Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>3026-35</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:19:05 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:19:05 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8918501"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparano-2004" MODIFIED="2009-03-10 11:19:49 -0700" MODIFIED_BY="[Empty name]" NAME="Sparano 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-10 11:19:49 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF et al</AU>
<TI>Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)</TI>
<SO>Journal Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>1491-500</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:19:49 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:19:49 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15084622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spina-2005a" MODIFIED="2009-04-06 11:22:43 -0700" MODIFIED_BY="[Empty name]" NAME="Spina 2005a" YEAR="2005">
<REFERENCE MODIFIED="2009-03-10 11:21:06 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M et al</AU>
<TI>Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>105</VL>
<PG>1891-7</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:21:06 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:21:06 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15550484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Straus-1998" MODIFIED="2009-03-10 14:11:19 -0700" MODIFIED_BY="[Empty name]" NAME="Straus 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-03-10 14:11:19 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD</AU>
<TI>Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>3601-6</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:11:19 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:11:19 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9817281"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tirelli-1992" MODIFIED="2009-03-10 11:23:24 -0700" MODIFIED_BY="[Empty name]" NAME="Tirelli 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-03-10 11:23:24 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tirelli U, Errante D, Oksenhendler E, Spina M, Vaccher E, Serraino D et al</AU>
<TI>Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group</TI>
<SO>Annals of Oncology</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>843-7</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:23:24 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:23:24 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1286047"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tirelli-2002" MODIFIED="2009-03-10 11:25:20 -0700" MODIFIED_BY="[Empty name]" NAME="Tirelli 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-10 11:25:20 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM et al</AU>
<TI>Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study</TI>
<SO>Recent Results Cancer Research</SO>
<YR>2002</YR>
<VL>159</VL>
<PG>149-53</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:25:20 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:25:20 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11785839"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaccher-2001" MODIFIED="2009-03-20 08:15:38 -0700" MODIFIED_BY="[Empty name]" NAME="Vaccher 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-20 08:15:38 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O et al</AU>
<TI>Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>91</VL>
<PG>155-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11148572"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-1993" MODIFIED="2009-03-27 07:42:46 -0700" MODIFIED_BY="[Empty name]" NAME="Walsh 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-03-27 07:41:41 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh C, Wernz JC, Levine A, Rarick M, Willson E, Melendez D et al</AU>
<TI>Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>1993</YR>
<VL>6</VL>
<PG>265-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7680712"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-2006" MODIFIED="2009-03-10 11:27:04 -0700" MODIFIED_BY="[Empty name]" NAME="Weiss 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-10 11:27:04 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U et al</AU>
<TI>Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial</TI>
<SO>Cancer</SO>
<YR>2006</YR>
<VL>106</VL>
<PG>1560-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:27:04 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:27:04 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16502436"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-03-26 09:45:00 -0700" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-04-06 12:00:10 -0700" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00002524" MODIFIED="2009-04-06 11:55:53 -0700" MODIFIED_BY="[Empty name]" NAME="NCT00002524" YEAR="">
<REFERENCE MODIFIED="2009-04-06 11:55:53 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>McLaughlin PW (Study chair)</AU>
<TI>Pilot study in AIDS-related lymphomas</TI>
<SO>http://www.clinicaltrials.gov.</SO>
<YR>Accessed Feb 21, 2009</YR>
<IDENTIFIERS MODIFIED="2009-03-10 11:28:51 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:28:51 -0700" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00002524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00020384" MODIFIED="2009-04-06 11:57:51 -0700" MODIFIED_BY="[Empty name]" NAME="NCT00020384" YEAR="">
<REFERENCE MODIFIED="2009-04-06 11:57:51 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wilson WH (Prinicpal investigator)</AU>
<TI>Short-course EPOCH-rituximab for untreated CD-20+ HIV-associated lymphomas</TI>
<SO>http://www.clinicaltrials.gov.</SO>
<YR>February 17, 2009</YR>
<IDENTIFIERS MODIFIED="2009-04-06 11:57:23 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 11:57:23 -0700" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00020384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00049036" MODIFIED="2009-04-06 12:00:10 -0700" MODIFIED_BY="[Empty name]" NAME="NCT00049036" YEAR="">
<REFERENCE MODIFIED="2009-04-06 12:00:10 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kaplan L (Investigator)</AU>
<TI>A randomized phase II trial of EPOCH given either concurrently or sequentially with rituximab In patients with intermediate or high-grade HIV-associated B-cell non-Hodgkin's lymphoma</TI>
<SO>http://www.clinicaltrials.gov.</SO>
<YR>Accessed Jan 18, 2009</YR>
<IDENTIFIERS MODIFIED="2009-04-06 11:59:00 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 11:59:00 -0700" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00049036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-04-06 11:22:27 -0700" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-04-06 11:22:27 -0700" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1980" MODIFIED="2009-03-10 11:32:35 -0700" MODIFIED_BY="[Empty name]" NAME="Altman 1980" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG</AU>
<TI>Statistics and ethics in medical research: III. How large a sample?</TI>
<SO>Brithish Medical Journal</SO>
<YR>1980</YR>
<VL>281</VL>
<PG>1336-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:32:35 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:32:35 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7437789"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bedard-2007" MODIFIED="2009-03-10 11:33:55 -0700" MODIFIED_BY="[Empty name]" NAME="Bedard 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF</AU>
<TI>Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>3482-7</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:33:55 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:33:55 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17687153"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beral-1991" NAME="Beral 1991" TYPE="JOURNAL_ARTICLE">
<AU>Beral V, Peterman T, Berkelman R, Jaffe H</AU>
<TI>AIDS-associated non-Hodgkin lymphoma</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8745</NO>
<PG>805-809</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berretta-2003" MODIFIED="2009-02-25 06:06:41 -0800" MODIFIED_BY="[Empty name]" NAME="Berretta 2003" TYPE="JOURNAL_ARTICLE">
<AU>Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U</AU>
<TI>Therapeutic approaches to AIDS-related malignancies</TI>
<SO>Oncogene</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>6646-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besson-2001" MODIFIED="2008-09-17 12:18:28 -0700" MODIFIED_BY="[Empty name]" NAME="Besson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP et al</AU>
<TI>Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy</TI>
<SO>Blood</SO>
<YR>2001</YR>
<VL>98</VL>
<PG>2339-44</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:18:03 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:18:03 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11588028"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bhaskaran--2004" MODIFIED="2009-03-16 09:12:38 -0700" MODIFIED_BY="[Empty name]" NAME="Bhaskaran  2004" TYPE="JOURNAL_ARTICLE">
<AU>Bhaskaran K, Brettle R, Porter K, Walker AS; CASCADE Collaboration</AU>
<TI>Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors</TI>
<SO>AIDS</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>673-81</PG>
<IDENTIFIERS MODIFIED="2009-03-16 09:12:24 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 09:12:24 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15090773"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Biggar-1996" MODIFIED="2009-03-10 11:35:24 -0700" MODIFIED_BY="[Empty name]" NAME="Biggar 1996" TYPE="JOURNAL_ARTICLE">
<AU>Biggar RJ, Rosenberg PS, Coté T</AU>
<TI>Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group</TI>
<SO>International Journal of Cancer</SO>
<YR>1996</YR>
<VL>68</VL>
<PG>754-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:35:24 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:35:24 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8980179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Biggar-1996_x002d_b" MODIFIED="2008-09-17 11:50:16 -0700" MODIFIED_BY="[Empty name]" NAME="Biggar 1996-b" TYPE="JOURNAL_ARTICLE">
<AU>Biggar RJ, Rabkin CS</AU>
<TI>The epidemiology of AIDS-related neoplasms</TI>
<SO>Hematology/Oncology Clinics of North America</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>997-1010</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:50:16 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:50:16 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8880192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Booth-2008" MODIFIED="2009-03-10 11:42:12 -0700" MODIFIED_BY="[Empty name]" NAME="Booth 2008" TYPE="JOURNAL_ARTICLE">
<AU>Booth CM, Tannock I</AU>
<TI>Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>6-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:42:12 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:42:12 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18165630"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carbone-2005" MODIFIED="2009-03-10 11:43:17 -0700" MODIFIED_BY="[Empty name]" NAME="Carbone 2005" TYPE="JOURNAL_ARTICLE">
<AU>Carbone A, Gloghini A</AU>
<TI>AIDS-related lymphomas: from pathogenesis to pathology</TI>
<SO>British Journal of Haematology</SO>
<YR>2005</YR>
<VL>130</VL>
<PG>662-700</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:43:17 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:43:17 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16115121"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cheung-2005" MODIFIED="2009-03-10 11:44:12 -0700" MODIFIED_BY="[Empty name]" NAME="Cheung 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cheung MC, Pantanowitz L, Dezube BJ</AU>
<TI>AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy</TI>
<SO>The Oncologist</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>412-26</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:44:12 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:44:12 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15967835"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2001" MODIFIED="2009-03-10 11:45:05 -0700" MODIFIED_BY="[Empty name]" NAME="Clarke 2001" TYPE="JOURNAL_ARTICLE">
<AU>Clarke CA, Glaser SL</AU>
<TI>Epidemiologic trends in HIV-associated lymphomas</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2001</YR>
<VL>13</VL>
<PG>354-9</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:45:05 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:45:05 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11555712"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clifford-2005" MODIFIED="2009-03-10 11:51:56 -0700" MODIFIED_BY="[Empty name]" NAME="Clifford 2005" TYPE="JOURNAL_ARTICLE">
<AU>Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A et al</AU>
<TI>Cancer risk in the Swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2005</YR>
<VL>97</VL>
<PG>425-32</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:51:56 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:51:56 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15770006"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coiffier-2002" MODIFIED="2009-04-06 09:31:25 -0700" MODIFIED_BY="[Empty name]" NAME="Coiffier 2002" TYPE="JOURNAL_ARTICLE">
<AU>Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al</AU>
<TI>CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>235-42</PG>
<IDENTIFIERS MODIFIED="2009-04-06 09:31:25 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 09:31:25 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11807147"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cooley-2003" MODIFIED="2009-03-10 11:52:15 -0700" MODIFIED_BY="[Empty name]" NAME="Cooley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cooley TP</AU>
<TI>Non-AIDS-defining cancer in HIV-infected people</TI>
<SO>Hematology/oncology clinics of North America</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>889-99</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:52:15 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:52:15 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12852661"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cot_x00e9_-1997" MODIFIED="2009-03-10 14:15:07 -0700" MODIFIED_BY="[Empty name]" NAME="Coté 1997" TYPE="JOURNAL_ARTICLE">
<AU>Coté TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ et al</AU>
<TI>Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group</TI>
<SO>International Journal of Cancer</SO>
<YR>1997</YR>
<VL>73</VL>
<PG>645-50</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:15:07 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:15:07 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9398040"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dal-Maso-2003" MODIFIED="2009-03-10 11:55:48 -0700" MODIFIED_BY="[Empty name]" NAME="Dal Maso 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dal Maso L, Franceschi S</AU>
<TI>Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS</TI>
<SO>Lancet Oncology</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>110-9</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:55:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:55:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12573353"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Edwards-1997" MODIFIED="2009-03-10 11:56:35 -0700" MODIFIED_BY="[Empty name]" NAME="Edwards 1997" TYPE="JOURNAL_ARTICLE">
<AU>Edwards SJ, Lilford RJ, Braunholtz D, Jackson J</AU>
<TI>Why "underpowered" trials are not necessarily unethical</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>804-7</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:56:35 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:56:35 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9298015"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Engels-2008" MODIFIED="2009-03-16 07:21:52 -0700" MODIFIED_BY="[Empty name]" NAME="Engels 2008" TYPE="JOURNAL_ARTICLE">
<AU>Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL et al</AU>
<TI>Cancer risk in people infected with human immunodeficiency virus in the United States</TI>
<SO>Internationsl Journal of Cancer</SO>
<YR>2008</YR>
<VL>123</VL>
<PG>187-94</PG>
<IDENTIFIERS MODIFIED="2009-03-16 07:21:23 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 07:21:23 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18435450"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freiman-1978" MODIFIED="2009-03-10 11:57:16 -0700" MODIFIED_BY="[Empty name]" NAME="Freiman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR</AU>
<TI>The importance of beta, the type II error, and sample size in the design and interpretation of the randomized controlled trial: A survey of 71 "negative" trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>299</VL>
<PG>690-4</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:57:16 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:57:16 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="355881"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gastaldi-2001" MODIFIED="2009-03-10 11:58:06 -0700" MODIFIED_BY="[Empty name]" NAME="Gastaldi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gastaldi R, Martino P, Gentile G, Cafolla A, Cordone I, Giannini G et al</AU>
<TI>High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study</TI>
<SO>Haematologica</SO>
<YR>2001</YR>
<VL>86</VL>
<PG>1051-9</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:58:06 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:58:06 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11602411"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goedert-2000" MODIFIED="2008-09-17 11:43:26 -0700" MODIFIED_BY="[Empty name]" NAME="Goedert 2000" TYPE="JOURNAL_ARTICLE">
<AU>Goedert JJ</AU>
<TI>The epidemiology of acquired immunodeficiency syndrome malignancies</TI>
<SO>Seminars in Oncology</SO>
<YR>2000</YR>
<VL>27</VL>
<PG>390-401</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:43:26 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:43:26 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10950365 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grogg-2007" MODIFIED="2009-03-10 11:59:13 -0700" MODIFIED_BY="[Empty name]" NAME="Grogg 2007" TYPE="JOURNAL_ARTICLE">
<AU>Grogg KL, Miller RF, Dogan A</AU>
<TI>HIV infection and lymphoma</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>2007</YR>
<VL>60</VL>
<PG>1365-72</PG>
<IDENTIFIERS MODIFIED="2009-03-10 11:59:13 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 11:59:13 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18042692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grulich-2002" MODIFIED="2008-09-17 11:32:07 -0700" MODIFIED_BY="[Empty name]" NAME="Grulich 2002" TYPE="JOURNAL_ARTICLE">
<AU>Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM</AU>
<TI>Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis</TI>
<SO>AIDS</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>1155-61</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:32:07 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:32:07 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12004274 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grulich-2005" MODIFIED="2009-02-25 06:11:58 -0800" MODIFIED_BY="[Empty name]" NAME="Grulich 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grulich AE, Vajdic CM</AU>
<TI>The epidemiology of non-Hodgkin lymphoma</TI>
<SO>Pathology</SO>
<YR>2005</YR>
<VL>37</VL>
<PG>409 -19</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:46:25 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:46:25 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16373224 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grulich-2007" MODIFIED="2008-09-17 11:37:17 -0700" MODIFIED_BY="[Empty name]" NAME="Grulich 2007" TYPE="JOURNAL_ARTICLE">
<AU>Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM</AU>
<TI>Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<PG>59-67</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:37:17 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:37:17 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17617273"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hebert-2002" MODIFIED="2009-03-10 14:24:44 -0700" MODIFIED_BY="[Empty name]" NAME="Hebert 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hebert RS, Wright SM, Dittus RS, Elasy TA</AU>
<TI>Prominent medical journals often provide insufficient information to assess the validity of studies with negative results</TI>
<SO>Journal of Negative Results in Biomedicine</SO>
<YR>2002</YR>
<VL>1</VL>
<PG>1</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:24:44 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:24:44 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12437785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-07-07 11:04:47 -0700" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.0.0 [updated February 2008]</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoffmann-2003" MODIFIED="2009-03-16 09:38:45 -0700" MODIFIED_BY="[Empty name]" NAME="Hoffmann 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoehr A, Plettenberg A et al</AU>
<TI>Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma</TI>
<SO>AIDS</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>1521-9</PG>
<IDENTIFIERS MODIFIED="2009-03-16 09:38:31 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 09:38:31 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12824790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holmgren-2008" MODIFIED="2009-04-06 11:03:41 -0700" MODIFIED_BY="[Empty name]" NAME="Holmgren 2008" TYPE="JOURNAL_ARTICLE">
<AU>Holmgren E</AU>
<TI>Are phase 2 screening trials in oncology obsolete?</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<PG>556-67</PG>
<IDENTIFIERS MODIFIED="2009-04-06 11:03:21 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 11:03:21 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17661436 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2009-02-24 08:33:20 -0800" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="OTHER">
<AU>European Federation of Pharmaceutical Industries Associations - EFPIA</AU>
<TI>International Conference on Harmonisation of Technical Requiements for Registration of Pharmaceuticals for Human Use</TI>
<SO>http://www.ich.org/cache/compo/276-254-1.html.</SO>
<YR>Accessed on February 24, 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacomet--2006" MODIFIED="2009-03-10 12:01:13 -0700" MODIFIED_BY="[Empty name]" NAME="Jacomet  2006" TYPE="JOURNAL_ARTICLE">
<AU>Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C et al</AU>
<TI>Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003</TI>
<TO>Lymphomes non hodgkiniens et hodgkiniens et infection VIH : fréquence, pronostic et reconstitution immune sous trithérapie antirétrovirale ; CHU de Clermont-Ferrand, 1991&#8211;2003</TO>
<SO>Médecine et Maladies Infectieuses</SO>
<YR>2006</YR>
<VL>36</VL>
<PG>157-62</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:01:13 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:01:13 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16503104"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1989" MODIFIED="2009-03-10 13:48:10 -0700" MODIFIED_BY="[Empty name]" NAME="Kaplan 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P et al</AU>
<TI>AIDS-associated non-Hodgkins lymphoma in San Francisco</TI>
<SO>JAMA</SO>
<YR>1989</YR>
<VL>261</VL>
<PG>719-24</PG>
<IDENTIFIERS MODIFIED="2009-03-10 13:48:10 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 13:48:10 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2536124"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1997" MODIFIED="2009-03-10 12:02:58 -0700" MODIFIED_BY="[Empty name]" NAME="Kaplan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP et al</AU>
<TI>Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>1641-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:02:58 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:02:58 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9171066"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kirk-2001" MODIFIED="2008-09-17 11:21:48 -0700" MODIFIED_BY="[Empty name]" NAME="Kirk 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM et al</AU>
<TI>Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy</TI>
<SO>Blood</SO>
<YR>2001</YR>
<VL>98</VL>
<PG>3406-12</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:21:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:21:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11719381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koo-2008" MODIFIED="2009-04-06 10:51:36 -0700" MODIFIED_BY="[Empty name]" NAME="Koo 2008" TYPE="JOURNAL_ARTICLE">
<AU>Koo S, Baden LR</AU>
<TI>Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy</TI>
<SO>Journal of the National Comprehensive Cancer Network</SO>
<YR>2008</YR>
<VL>6</VL>
<PG>2002-13</PG>
<IDENTIFIERS MODIFIED="2009-04-06 10:51:36 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 10:51:36 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18319052"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Launay-2003" MODIFIED="2009-03-10 12:03:57 -0700" MODIFIED_BY="[Empty name]" NAME="Launay 2003" TYPE="JOURNAL_ARTICLE">
<AU>Launay O, Guillevin L</AU>
<TI>Epidemiology of HIV-associated malignancies</TI>
<TO>Épidémiologie des tumeurs malignes associées á l´infection par le VIH</TO>
<SO>Bulletin du Cancer</SO>
<YR>2003</YR>
<VL>90</VL>
<PG>387-92</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:03:57 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:03:57 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12850760"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levine-2000" MODIFIED="2009-03-10 12:06:23 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 2000" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM</AU>
<TI>Acquired immunodeficiency syndrome-related lymphoma: clinical aspects</TI>
<SO>Seminars in Oncology</SO>
<YR>2000</YR>
<VL>27</VL>
<PG>442-53</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:06:23 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:06:23 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10950371"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levine-2002" MODIFIED="2009-03-10 12:07:04 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 2002" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B</AU>
<TI>Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<PG>1500-6</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:07:04 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:07:04 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11920507"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levine-2004" MODIFIED="2008-09-17 12:43:47 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 2004" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD et al</AU>
<TI>Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin&#8217;s lymphoma: results of therapy and correlates of response</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2662-70</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:43:47 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:43:47 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15226333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levine-2006" MODIFIED="2008-09-17 11:19:24 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 2006" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM</AU>
<TI>AIDS-related lymphoma</TI>
<SO>Seminars in Oncology Nursing</SO>
<YR>2006</YR>
<VL>22</VL>
<PG>80-9</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:19:24 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:19:24 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16720230"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levine-2008" MODIFIED="2009-04-06 09:39:20 -0700" MODIFIED_BY="[Empty name]" NAME="Levine 2008" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM</AU>
<TI>Management of AIDS-related lymphoma</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2008</YR>
<VL>20</VL>
<PG>522-8</PG>
<IDENTIFIERS MODIFIED="2009-04-06 09:39:20 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 09:39:20 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19106654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lim-2005" MODIFIED="2008-09-17 12:04:11 -0700" MODIFIED_BY="[Empty name]" NAME="Lim 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lim ST, Levine AM</AU>
<TI>Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma</TI>
<SO>CA : a Cancer Journal for Clinicians</SO>
<YR>2005</YR>
<VL>55</VL>
<PG>229-41; 260-1, 264</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:04:11 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:04:11 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16020424"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lim-2005_x002d_b" MODIFIED="2008-09-17 12:10:46 -0700" MODIFIED_BY="[Empty name]" NAME="Lim 2005-b" TYPE="JOURNAL_ARTICLE">
<AU>Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM</AU>
<TI>AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>4430-8</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:10:46 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:10:46 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15883411"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Little-2000" MODIFIED="2009-03-10 12:08:31 -0700" MODIFIED_BY="[Empty name]" NAME="Little 2000" TYPE="JOURNAL_ARTICLE">
<AU>Little RF, Yarchoan R, Wilson WH</AU>
<TI>Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>438-44</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:08:31 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:08:31 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10975551"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Little-2003" MODIFIED="2009-03-10 12:10:00 -0700" MODIFIED_BY="[Empty name]" NAME="Little 2003" TYPE="JOURNAL_ARTICLE">
<AU>Little RF, Wilson WH</AU>
<TI>Update on the pathogenesis, diagnosis, and therapy of AIDS-related lymphoma</TI>
<SO>Current Infectious Disease Reports</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>176-84</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:10:00 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:10:00 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12642005 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Little-2003b" MODIFIED="2009-04-06 09:32:15 -0700" MODIFIED_BY="[Empty name]" NAME="Little 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H et al</AU>
<TI>Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>101</VL>
<PG>4653-9</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:10:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:10:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12609827"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martins-1997" MODIFIED="2009-03-10 10:31:02 -0700" MODIFIED_BY="[Empty name]" NAME="Martins 1997" TYPE="CONFERENCE_PROC">
<AU>Martins RG, Finkelstein DM, Selden MV</AU>
<TI>The importance of beta, type II error, in negative trials in oncology</TI>
<SO>Proceeding of the American of Society of Clincial Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>415a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Massarweh-2003" MODIFIED="2008-09-17 12:29:36 -0700" MODIFIED_BY="[Empty name]" NAME="Massarweh 2003" TYPE="JOURNAL_ARTICLE">
<AU>Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR et al</AU>
<TI>HIV-related Hodgkin&#8217;s disease with central nervous system involvement and association with Epstein-Barr virus</TI>
<SO>American Journal of Hematology</SO>
<YR>2003</YR>
<VL>72</VL>
<PG>216-9</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:29:36 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:29:36 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12605396"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Matthews-2000" MODIFIED="2008-09-17 11:56:59 -0700" MODIFIED_BY="[Empty name]" NAME="Matthews 2000" TYPE="JOURNAL_ARTICLE">
<AU>Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG</AU>
<TI>Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>2730-4</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:56:59 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:56:59 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11023505"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miralles-2002" MODIFIED="2008-09-19 12:19:10 -0700" MODIFIED_BY="[Empty name]" NAME="Miralles 2002" TYPE="JOURNAL_ARTICLE">
<AU>Miralles P, Rubio C, Berenguer J, Ribera JM, Calvo F, Mediavilla JD et al</AU>
<TI>GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immune deficiency virus</TI>
<SO>Medicina Clínica (Barc)</SO>
<YR>2008</YR>
<VL>118</VL>
<PG>225-36</PG>
<IDENTIFIERS MODIFIED="2008-09-17 13:03:25 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 13:03:25 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11864547"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miralles-2007" MODIFIED="2009-03-10 12:12:04 -0700" MODIFIED_BY="[Empty name]" NAME="Miralles 2007" TYPE="JOURNAL_ARTICLE">
<AU>Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ et al</AU>
<TI>Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2007</YR>
<VL>44</VL>
<PG>167-73</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:12:04 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:12:04 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17117144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mocroft-1998" MODIFIED="2009-03-10 13:52:22 -0700" MODIFIED_BY="[Empty name]" NAME="Mocroft 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P et al</AU>
<TI>Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1725-30</PG>
<IDENTIFIERS MODIFIED="2009-03-10 13:52:22 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 13:52:22 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9848347"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1994" MODIFIED="2009-03-10 12:13:13 -0700" MODIFIED_BY="[Empty name]" NAME="Moher 1994" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Dulberg CS, Wells GA</AU>
<TI>Statistical power, sample size, and their reporting in randomized controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>122-4</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:13:13 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:13:13 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8015121"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mounier-2007" MODIFIED="2009-03-10 12:14:18 -0700" MODIFIED_BY="[Empty name]" NAME="Mounier 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mounier N, Spina M, Gisselbrecht C</AU>
<TI>Modern management of non-Hodgkin lymphoma in HIV-infected patients</TI>
<SO>British Journal of Haematology</SO>
<YR>2007</YR>
<VL>136</VL>
<PG>685-98</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:14:18 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:14:18 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17229246 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moylett-2002" MODIFIED="2009-03-10 12:15:06 -0700" MODIFIED_BY="[Empty name]" NAME="Moylett 2002" TYPE="JOURNAL_ARTICLE">
<AU>Moylett EH, Shearer WT</AU>
<TI>HIV: clinical manifestations</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2002</YR>
<VL>110</VL>
<PG>3-16</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:15:06 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:15:06 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12110810"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navarro-2006" MODIFIED="2009-03-10 12:16:25 -0700" MODIFIED_BY="[Empty name]" NAME="Navarro 2006" TYPE="JOURNAL_ARTICLE">
<AU>Navarro WH, Kaplan LD</AU>
<TI>AIDS-related lymphoproliferative disease</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>107</VL>
<PG>13-20</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:16:25 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:16:25 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16099881"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Noy-2006" MODIFIED="2009-03-10 12:17:16 -0700" MODIFIED_BY="[Empty name]" NAME="Noy 2006" TYPE="JOURNAL_ARTICLE">
<AU>Noy A</AU>
<TI>Update in HIV lymphoma</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2006</YR>
<VL>18</VL>
<PG>449-55</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:17:16 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:17:16 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16894292"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Noy-2007" MODIFIED="2009-03-10 12:17:44 -0700" MODIFIED_BY="[Empty name]" NAME="Noy 2007" TYPE="JOURNAL_ARTICLE">
<AU>Noy A</AU>
<TI>Update on HIV lymphoma</TI>
<SO>Current Oncology Reports</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>384-90</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:17:44 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:17:44 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17706167"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-N_x2019_Galy-1990" MODIFIED="2009-04-06 09:26:22 -0700" MODIFIED_BY="[Empty name]" NAME="N&#8217;Galy 1990" TYPE="JOURNAL_ARTICLE">
<AU>N'Galy B, Bertozzi S, Ryder RW</AU>
<TI>Obstacles to the optimal management of HIV infection/AIDS in Africa</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>430-7</PG>
<IDENTIFIERS MODIFIED="2009-04-06 09:24:35 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 09:24:35 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2313564"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Otieno-2002" MODIFIED="2009-04-06 09:36:10 -0700" MODIFIED_BY="[Empty name]" NAME="Otieno 2002" TYPE="JOURNAL_ARTICLE">
<AU>Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ghannoum M, Dowlati A et al</AU>
<TI>Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa</TI>
<SO>Journal of The National Journal Institute</SO>
<YR>2002</YR>
<VL>94</VL>
<PG>718-32</PG>
<IDENTIFIERS MODIFIED="2009-04-06 09:35:07 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 09:35:07 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12011222"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palella-1998" MODIFIED="2009-03-10 14:13:02 -0700" MODIFIED_BY="[Empty name]" NAME="Palella 1998" TYPE="JOURNAL_ARTICLE">
<AU>Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al</AU>
<TI>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>853-60</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:13:02 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:13:02 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9516219 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmieri-2006" MODIFIED="2009-03-10 12:18:27 -0700" MODIFIED_BY="[Empty name]" NAME="Palmieri 2006" TYPE="JOURNAL_ARTICLE">
<AU>Palmieri C, Treibel T, Large O, Bower M</AU>
<TI>AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>2006</YR>
<VL>99</VL>
<PG>811-26</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:18:27 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:18:27 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17085516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pantanowitz-2006" MODIFIED="2008-09-17 11:28:39 -0700" MODIFIED_BY="[Empty name]" NAME="Pantanowitz 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pantanowitz L, Schlecht HP, Dezube BJ</AU>
<TI>The growing problem of non-AIDS-defining malignancies in HIV</TI>
<SO>Seminars in Oncology</SO>
<YR>2006</YR>
<VL>18</VL>
<PG>469-78</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:28:39 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:28:39 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16894295"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patel-2008" MODIFIED="2009-03-16 07:15:29 -0700" MODIFIED_BY="[Empty name]" NAME="Patel 2008" TYPE="JOURNAL_ARTICLE">
<AU>Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators</AU>
<TI>Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>20</VL>
<PG>728-36</PG>
<IDENTIFIERS MODIFIED="2009-03-16 07:15:29 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 07:15:29 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18490686"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Powles-2009" MODIFIED="2009-03-16 07:06:02 -0700" MODIFIED_BY="[Empty name]" NAME="Powles 2009" TYPE="JOURNAL_ARTICLE">
<AU>Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B et al</AU>
<TI>Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection</TI>
<SO>Journal of Clincal Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>884-90</PG>
<IDENTIFIERS MODIFIED="2009-03-16 07:06:02 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 07:06:02 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19114688"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ratner-2001" MODIFIED="2009-02-25 06:18:39 -0800" MODIFIED_BY="[Empty name]" NAME="Ratner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B et al</AU>
<TI>Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy</TI>
<SO>Journal Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>2117-8</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:35:35 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:35:35 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11304769"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Remick-1993" MODIFIED="2009-03-10 12:19:48 -0700" MODIFIED_BY="[Empty name]" NAME="Remick 1993" TYPE="JOURNAL_ARTICLE">
<AU>Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H et al</AU>
<TI>Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma</TI>
<SO>Journal Clinical of Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>1691-702</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:19:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:19:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8355036"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Remick-2001" MODIFIED="2009-03-10 12:20:48 -0700" MODIFIED_BY="[Empty name]" NAME="Remick 2001" TYPE="JOURNAL_ARTICLE">
<AU>Remick SC, Sedransk N, Haase RF, Blanchard CG, Ramnes CR, Nazeer T et al</AU>
<TI>Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up</TI>
<SO>American Journal of Hematology</SO>
<YR>2001</YR>
<VL>66</VL>
<PG>178-88</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:20:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:20:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11279624 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-02-25 06:19:38 -0800" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) [Computer program]. Version 5.0</TI>
<YR>2008</YR>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scadden-2003" MODIFIED="2009-03-10 12:23:48 -0700" MODIFIED_BY="[Empty name]" NAME="Scadden 2003" TYPE="JOURNAL_ARTICLE">
<AU>Scadden DT</AU>
<TI>AIDS-related malignancies</TI>
<SO>Annual Reviews of Medicine</SO>
<YR>2003</YR>
<VL>54</VL>
<PG>285-303</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:23:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:23:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12525676"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schmidt_x002d_Wolf-2003" MODIFIED="2009-03-10 12:24:57 -0700" MODIFIED_BY="[Empty name]" NAME="Schmidt-Wolf 2003" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt-Wolf IG, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J et al</AU>
<TI>Treatment options of AIDS-related lymphoma</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>1331-43</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:24:57 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:24:57 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12877641"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simcock-2007" MODIFIED="2009-03-10 14:22:01 -0700" MODIFIED_BY="[Empty name]" NAME="Simcock 2007" TYPE="JOURNAL_ARTICLE">
<AU>Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L et al</AU>
<TI>Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study</TI>
<SO>Antiviral Therapy</SO>
<YR>2007</YR>
<VL>12</VL>
<PG>931-39</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:22:01 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:22:01 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17926647"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Skiest-2003" MODIFIED="2009-03-10 12:29:48 -0700" MODIFIED_BY="[Empty name]" NAME="Skiest 2003" TYPE="JOURNAL_ARTICLE">
<AU>Skiest DJ, Crosby C</AU>
<TI>Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma</TI>
<SO>AIDS</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>1787-93</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:29:48 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:29:48 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12891064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sparano-2001" MODIFIED="2009-03-10 14:17:11 -0700" MODIFIED_BY="[Empty name]" NAME="Sparano 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sparano JA</AU>
<TI>Clinical aspects and management of AIDS-related lymphoma</TI>
<SO>European Journal of Cancer</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>1296-1305</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:17:09 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 14:17:09 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11423261"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sparano-2003" MODIFIED="2009-03-10 12:31:22 -0700" MODIFIED_BY="[Empty name]" NAME="Sparano 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sparano JA</AU>
<TI>Human immunodeficiency virus associated lymphoma</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>372-8</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:31:22 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:31:22 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12960519"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Spina-2005b" MODIFIED="2009-04-06 11:22:27 -0700" MODIFIED_BY="[Empty name]" NAME="Spina 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Tirelli U</AU>
<TI>Rituximab for HIV-associated lymphoma: weighing the benefits and risks</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>462-5</PG>
<IDENTIFIERS MODIFIED="2009-03-16 07:30:00 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 07:30:00 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16093796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stebbing-2004_x002d_a" MODIFIED="2008-09-23 10:52:04 -0700" MODIFIED_BY="[Empty name]" NAME="Stebbing 2004-a" TYPE="JOURNAL_ARTICLE">
<AU>Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V et al</AU>
<TI>Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2177-83</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:01:42 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:01:42 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15169806 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stebbing-2004_x002d_b" MODIFIED="2009-02-25 06:21:12 -0800" MODIFIED_BY="[Empty name]" NAME="Stebbing 2004-b" TYPE="JOURNAL_ARTICLE">
<AU>Stebbing J, Marvin V, Bower M</AU>
<TI>The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma</TI>
<SO>Cancer Treatment Review</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>249-53</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:59:20 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:59:20 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15059648"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stone-2007" MODIFIED="2009-04-06 10:59:24 -0700" MODIFIED_BY="[Empty name]" NAME="Stone 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stone A, Wheeler C, Barge A</AU>
<TI>Improving the design of phase II trials of cytostatic anticancer agents</TI>
<SO>Contemporary Clinical Trials</SO>
<YR>2007</YR>
<VL>28</VL>
<PG>138-45</PG>
<IDENTIFIERS MODIFIED="2009-04-06 10:58:32 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 10:58:32 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16843736"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thirlwell-2003" MODIFIED="2009-03-10 12:34:36 -0700" MODIFIED_BY="[Empty name]" NAME="Thirlwell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thirlwell C, Sarker D, Stebbing J, Bower M</AU>
<TI>Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy</TI>
<SO>Clinical lymphoma</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>86-92</PG>
<IDENTIFIERS MODIFIED="2009-03-10 12:34:36 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-10 12:34:36 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12960519"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2001" MODIFIED="2008-09-17 11:53:22 -0700" MODIFIED_BY="[Empty name]" NAME="Thomas 2001" TYPE="JOURNAL_ARTICLE">
<AU>Thomas JO</AU>
<TI>Acquired immunodeficiency syndrome-associated cancers in sub-Saharan Africa</TI>
<SO>Seminars in Oncology</SO>
<YR>2001</YR>
<VL>28</VL>
<PG>198-206</PG>
<IDENTIFIERS MODIFIED="2008-09-17 11:53:22 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 11:53:22 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11301383"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-UNAIDS-2000" MODIFIED="2009-04-06 09:48:43 -0700" MODIFIED_BY="[Empty name]" NAME="UNAIDS 2000" TYPE="OTHER">
<AU>Joint United Nations Programme on HIV / AIDS [UNAIDS]; World Health Organization [WHO]</AU>
<TI>AIDS epidemic update: December 2000</TI>
<SO>Geneva, Switzerland, UNAIDS, 2000. 23, [5] p. (UNAIDS/00.44EWHO/CDS/CSR/EDC/2000.9)</SO>
<IDENTIFIERS MODIFIED="2009-04-06 09:48:43 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 09:48:43 -0700" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="164367 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Baarle-2002" MODIFIED="2008-09-17 12:33:46 -0700" MODIFIED_BY="[Empty name]" NAME="Van Baarle 2002" TYPE="JOURNAL_ARTICLE">
<AU>Van Baarle D, Wolthers KC, Hovenkamp E, Niesters HG, Osterhaus AD, Miedema F et al</AU>
<TI>Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>186</VL>
<PG>405-9</PG>
<IDENTIFIERS MODIFIED="2008-09-17 12:33:46 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-17 12:33:46 -0700" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12134237"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2006" MODIFIED="2008-07-07 11:26:47 -0700" MODIFIED_BY="[Empty name]" NAME="Zavala 2006" TYPE="COMPUTER_PROGRAM">
<AU>Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián G</AU>
<TI>
<I>Software to help manage the characteristics of included studies in Cochrane (www.cochrane.fcs.edu.ve/hrs)</I>
</TI>
<YR>2006</YR>
<PB>Universidad de Carabobo</PB>
<CY>Venezuela</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2007" MODIFIED="2008-07-07 11:35:31 -0700" MODIFIED_BY="[Empty name]" NAME="Zavala 2007" TYPE="COMPUTER_PROGRAM">
<AU>Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián-Carrasco G</AU>
<TI>Software for data transformation for time-to-event outcomes [Available at www.cochrane.fcs.uc.edu.ve/deted]</TI>
<YR>2007</YR>
<PB>Universidad de Carabobo</PB>
<CY>Valencia</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-11 17:43:09 -0700" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-11 17:43:09 -0700" MODIFIED_BY="[Empty name]" SORT_BY="YEAR" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-11 17:43:09 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaplan-1991">
<CHAR_METHODS MODIFIED="2009-05-11 17:43:09 -0700" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled trial.</P>
<P>Study type:single centre study. National (USA): San Francisco General Hospital.</P>
<P>Study phase:III</P>
<P>Randomization: Not described.</P>
<P>Allocation Concealment: Not declared.</P>
<P>Blinding: Not declared.</P>
<P>Intention to treat: Not declared.</P>
<P>Per-protocol analysis: Declared</P>
<P>Follow-up period: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-13 09:04:58 -0700" MODIFIED_BY="[Empty name]">
<P>Randomised participants = 30 (Intervention:16/ Control:14).</P>
<P>Treated participants = 26 (Intervention:16/ Control:10).</P>
<P>Analysed participants: 24 (Intervention:15/ Control:9).</P>
<P>Loss after randomisation: 4 (Control group: HIV seronegative (N = 2), severe thrombocytopenia (N = 1), active P carinii pneumonia (N = 1).</P>
<P>Loss after received treatment: Two death (one for each group).</P>
<P>Gender: Male patients.</P>
<P>Age<B> (</B>years)</P>
<UL>
<LI>Experimental group - mean (Range):</LI>
</UL>
<OL>
<LI>Early rGM-CSF: 46 (34 to 67).</LI>
<LI>Delayed rGM-CSF: 41 (26 to 61).</LI>
</OL>
<UL>
<LI>Control group: 40 (27 to 53).</LI>
</UL>
<P>Inclusion criteria:</P>
<UL>
<LI>HIV-seropositive patients;</LI>
<LI>Age: &#8805;18 years;</LI>
<LI>Biopsy- or cytology-proven intermediate-grade large-cell lymphoma, high-grade immunoblastic lymphoma, or high grade small noncleaved lymphoma;</LI>
<LI>Karnofsky performance score &gt; 60%;</LI>
<LI>Creatinine level &lt; 221 &#956;mol/L;</LI>
<LI>Aminotransferase level less than 2.5 times the upper limit of normal;</LI>
<LI>Bilirubin less than 34.2 &#956;mol/L;</LI>
<LI>Haemoglobin &#8805; 90 g/L;</LI>
<LI>Absolute neutrophils count &#8805; 1.25 x 10<SUP>9</SUP>/L;</LI>
<LI>Platelet count &gt; 100 x 10<SUP>9</SUP>/L.</LI>
</UL>
<P>Exclusion criteria:<B> </B>
</P>
<UL>
<LI>Active opportunistic infection;</LI>
<LI>Ongoing therapy with potentially myelosuppressive drugs;</LI>
<LI>Prior chemotherapy for lymphoma.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-13 09:12:21 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>1.- Experimental group</B>: Modified-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy with granulocyte-macrophage colony-stimulating factor (GM-CSF).</P>
<P>
<B>1.1.- Early GM-CSF</B>: </P>
<P>"10 &#956;g/kg self-administered subcutaneous injection each day, from days 1 (simultaneously with chemotherapy)<BR/>to 10 of each chemotherapy cycle (early rGM-CSF)".</P>
<P>"Patients who became severely neutropenic (ANC &lt; 0.5 x 10<SUP>9</SUP>/L) during any one cycle had their rGM-CSF dosage<BR/>escalated in each subsequent cycle by increments of 5 &#956;g/kg/d to a maximum total dosage of 20 &#956;g/kg/d".</P>
<P>
<B>1.2.- Delayed GM-CSF:</B>
<BR/>"... the starting dose of rGM-CSF was increased to 15 &#956;g/kg/d and was administered from days 4 through 13 of<BR/>each treatment cycle (delayed rGM-CSF)". </P>
<P>"rGM-CSF was increased to 20 &#956;g/kg/d in subsequent cycles following any cycle complicated by severe neutropenia (ANC &lt; 0.5 x 10<SUP>9</SUP>/L).</P>
<P>
<B>2.- Control group</B>: Modified-dose CHOP without GM-CSF.</P>
<P>Schedule: At least every 21 days (Absence of grade III or IV hematologic or other toxicities).</P>
<P>Co-interventions:</P>
<UL>
<LI>Zidovudine was not allowed during chemotherapy cycles.</LI>
</UL>
<UL>
<LI>Prophylactic intrathecal methotrexate (12 mg/week for a total of 4 weeks) for patients without cytologic evidence of non-Hodgkin's lymphoma in the cerebrospinal fluid. </LI>
</UL>
<UL>
<LI>3-day regimen (cytarabine (60 mg) intrathecally on days 1 and 2, and methotrexate (12 mg) intrathecally on day 3). It was administered three times on alternate weeks, beginning on day 1 of the first cycle to patients without cytologic evidence of non-Hodgkin's lymphoma in the cerebrospinal fluid.</LI>
<LI>Aerosolized pentamidine (300 mg) was administered for preventing Pneumocystis carinii pneumonia.</LI>
</UL>
<P>Duration treatment: six cycles at least. Two cycles additional if complete remission was achieved.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-13 09:16:17 -0700" MODIFIED_BY="[Empty name]">
<P>Outcomes were not classified as primary or secondary. </P>
<OL>
<LI>Increase the mean nadir absolute neutrophil count;</LI>
<LI>Shorten the duration of neutropenia;</LI>
<LI>Decrease the number of hospital admissions for febrile-neutropenic episodes in patients receiving aggressive combination chemotherapy for HIV-associated non-Hodgkin's lymphoma;</LI>
<LI>Effect of chemotherapy and rGM-CSF on HIV activity (assessed by serum HIV-1 p24 antigen levels).</LI>
</OL>
<P>These outcomes above mentioned were gotten from the RCT's objective. </P>
<P>Explicitly, the trialists did not describe 'Complete response ("disappearance of all evidence of malignant disease")' and 'survival' as outcomes. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-13 09:16:52 -0700" MODIFIED_BY="[Empty name]">
<P>This study was conducted between August 1988 and March 1990.</P>
<P>Modification of the original GM-CSF dosage was induced by "concern that the observed severe and prolonged neutropenia might be due to the administration of rGMCSF while cytotoxic agents were still active led to a modification in the rGM-CSF administration schedule". </P>
<P>Total of number of cycles of chemotherapy received: 58 (Experimental group) versus 42 (Control group).</P>
<P>World Health Organization criteria were using for grading toxicity.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-03-13 11:05:32 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaplan-1997">
<CHAR_METHODS MODIFIED="2009-03-13 11:05:32 -0700" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled trial.</P>
<P>Study type:multicenter study. National (USA): 27 centres AIDS Clinical Trials Group.</P>
<P>Study phase:III</P>
<P>Randomization: Not described.</P>
<P>Allocation Concealment: Not described.</P>
<P>Blinding: unclear.</P>
<P>Intention to treat: YES. Not for "Tumor response rate" end point.</P>
<P>Follow-up period: low-dose group (10.6±1.05 months) versus standard-dose group (9.1±0.94 months).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-10 08:45:22 -0700" MODIFIED_BY="[Empty name]">
<P>N = 198 (Intervention:98 / Control: 94).</P>
<P>Loss after randomisation: 6.</P>
<P>Gender: Men: 96 / Control group: 90 / Total: 186</P>
<P>Age<B> </B>(Male and female):</P>
<P>Experimental group - median: 38 (Range:22 to 64) / Control group: 39 (Range: 24 to 68).</P>
<P>Inclusion criteria:HIV-seropositive with 12 years old or older, with previously untreated intermediate- or high-grade lymphoma. confirmed by biopsy or cytologic study, at any stage and had no acute opportunistic infection.</P>
<P>Exclusion criteria:<B> </B>No information was provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-10 08:45:37 -0700" MODIFIED_BY="[Empty name]">
<P>Experimental group: Reduced-dose m-BACOD chemotherapy without routine GM-CSF.</P>
<P>Control group: Standard-dose chemotherapy with methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone, (m-BACOD) with GM-CSF support, beginning with the first cycle of chemotherapy.</P>
<P>Co-interventions: antiretroviral therapy use was optional. Zidovudine was excluded for myelosuppression</P>
<P>effect.</P>
<P>Duration Treatment: four cycles at least. Two cycles additional if complete remission was achieved.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-24 07:26:13 -0800" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Survival from the time of initiation of chemotherapy.</P>
<P>Secondary outcomes: Rate of complete response, the duration of antitumour response, the development of opportunistic infection, and toxic effects of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-08 10:50:01 -0700" MODIFIED_BY="[Empty name]">
<P>This study was conducted between February 1991 and October 1994. </P>
<P>Complete response: "absence of clinically detectable disease and normal radiographic studies at any previously abnormal sites for at least four weeks." </P>
<P>Partial response: "decrease of at least 50 percent in the measurable tumour burden lasting for at least one month." </P>
<P>Stable disease: "reduction of less than 50 percent in measurable disease in the absence of progression." Progressive disease: "25 percent or greater increase in measurable disease, or the appearance of disease at a new site."</P>
<P>Cycles of chemotherapy received (mean±SE):3.8±1.8 (Experimental group) versus 3.2±1.7 (control group).</P>
<P>We asked to Dr. Kaplan for some items of this paper. He sent me this information "There is not likely any means of collecting this for the NEJ study." (March 11, 2008).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-03-16 12:45:27 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AMCT_x002d_010--2005">
<CHAR_METHODS MODIFIED="2009-02-17 05:33:16 -0800" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled trial.</P>
<P>Study type:Multicentre study. National (USA) 22 sites National Cancer Institute-sponsored AIDS-Malignancies Consortium.</P>
<P>Study phase:III</P>
<P>Randomization: Random numbers generated by computer.</P>
<P>Allocation Concealment: unclear.<BR/>
</P>
<P>Blinding: no information was provided.</P>
<P>Intention to treat: yes.</P>
<P>Follow-up period: Unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-10 08:46:04 -0700" MODIFIED_BY="[Empty name]">
<P>N: 150 (Experimental group: 99 versus Control group: 51).</P>
<P>Age:</P>
<P>Experimental group: Mean: 43.5 (Range: 26-69) versus Control group: 40 (26-73).</P>
<P>Total Group: 42 (26-73).</P>
<P>Gender: unclear.</P>
<P>Inclusion criteria:</P>
<P>1.- HIV-positive.</P>
<P>2.- Had previously untreated histologically or cytologically documented CD20<SUP>+ </SUP>(50% of cells express CD20) B-cell non-Hodgkin lymphoma of any stage.</P>
<P>3.- With measurable or assessable disease.</P>
<P>4.- Karnofsky performance score&#8805; 70.</P>
<P>5.- Adequate hematologic function.</P>
<P>6.- Creatinine less than 176.8 &#956;M/L.</P>
<P>7.- Bilirubin &lt;34.2 &#956;M/L.</P>
<P>8.- Hepatic transaminases &lt;7 times the upper limit of normal.</P>
<P>Exclusion criteria:</P>
<P>1.- Parenchymal brain or spinal cord lymphoma.</P>
<P>2.- Acute HIV-associated opportunistic infection requiring treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-10 08:46:10 -0700" MODIFIED_BY="[Empty name]">
<P>Experimental group: Standard-dose cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Partial or complete responders to R-CHOP was supplied 3 monthly maintenance doses of rituximab at 375 mg/m<SUP>2</SUP> by slow IV.</P>
<P>Control group: Standard-dose cyclophosphamide, doxorubicin, vincristine, and prednisone.</P>
<P>Co-intervention:</P>
<P>1.- Antiretroviral therapy.</P>
<P>2.- Pneumocystis carinii prophylaxis (cotrimoxazole, dapsone, or inhaled pentamidine).</P>
<P>3.- Meningeal prophylaxis at the discretion.</P>
<P>4.- Granulocyte-colony-stimulating factor (G-CSF) was received for all participants.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-08 12:03:54 -0700" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Complete response rate.</P>
<P>Secondary outcomes: time to progression, progression-free survival, and overall survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-16 12:45:27 -0700" MODIFIED_BY="[Empty name]">
<P>This study was conducted from December 1998 until May 2002.</P>
<P>We asked to Dr. Kaplan for some items of this paper. He sent me this information "for the Blood article you can contact Dr Jeanette Lee at University of Alabama, who was the AMC 010 statistician:  <A HREF="mailto:jeanette.lee@ccc.uab.edu">jeanette.lee@ccc.uab.edu</A>. We sent an e-mail to Dr. Lee. However, it was bounced back from.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-24 07:43:58 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<CHAR_METHODS MODIFIED="2009-02-24 07:43:58 -0800" MODIFIED_BY="[Empty name]">
<P>Randomised, Open-label.</P>
<P>Study type: Multicentre study. International: France and Italy (55 centres).<BR/>Study phase: III<BR/>Randomization: Centrally randomised after stratification according to center and HIV score (block randomisation within strata).<BR/>Allocation Concealment: unclear.<BR/>Blinding: unclear.<BR/>Intention to treat: Declared.<BR/>Follow-up period: 6 years (median).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-10 10:17:28 -0700" MODIFIED_BY="[Empty name]">
<P>Elegible: 485.</P>
<P>Included: 485 (414 male (85%) and 71 women (15%). </P>
<P>1.- Good-risk patients (HIV score 0): 218</P>
<P>2.- intermediate-risk patients (HIV score 1):177</P>
<P>3.- Poor-risk patients (HIV score 2-3): 90</P>
<P>
<B>Age</B> (median - y- (range)):</P>
<P>Overall: 37 (18-67)</P>
<P>1.- Good-risk patients (HIV score 0): 37 (18-67)</P>
<P>2.- intermediate-risk patients (HIV score 1): 39 (23 - 67)</P>
<P>3.- Poor-risk patients (HIV score 2-3): 36 (24-61)</P>
<P>
<B>Gender</B>: </P>
<P>1.- Good-risk patients (HIV score 0): 86% (male).</P>
<P>2.- intermediate-risk patients (HIV score 1): 84% (male).</P>
<P>3.- Poor-risk patients (HIV score 2-3): 86% (male).</P>
<P>
<B>Inclusion criteria</B>:</P>
<P>1.- Untreated patients;</P>
<P>2.- Biopsy-confirmed aggressive NHL in HIV-infected patients over 18 years old. </P>
<P>3.- All high-grade histologic subtypes (Patients with meningeal or secondary brain involvement were included).<BR/>
<BR/>
<B>Exclusion criteria</B>:<BR/>1.- Leukemic forms of Burkitt lymphoma;</P>
<P>2.- Primary cerebral lymphoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-10 10:13:59 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>1.- Good-risk patients (HIV score 0):</B>
</P>
<P>ACVBP (3 courses every 2 weeks of doxorubicin 75 mg/m<SUP>2</SUP> on day 1, cyclophosphamide 1200 mg/m<SUP>2</SUP> on day 1, vindesine<BR/>2 mg/m<SUP>2</SUP> on days 1 and 5, bleomycin 10 mg on days 1 and 5, and prednisolone 60 mg/m<SUP>2</SUP> on days 1 to 5) <I>versus</I> standard CHOP (4 cycles every 3 weeks of doxorubicin 50 mg/m<SUP>2</SUP>, cyclophosphamide 750 mg/m<SUP>2</SUP>, vincristine 1.4 mg/m<SUP>2</SUP>, and prednisolone 60 mg/m<SUP>2</SUP>).</P>
<P>
<B>2.- intermediate-risk patients (HIV score 1):</B>
</P>
<P>Standard CHOP <I>versus</I> low-dose CHOP (4 cycles every 3 weeks of doxorubicin 25 mg/m<SUP>2</SUP>, cyclophosphamide<BR/>400 mg/m<SUP>2</SUP>, vincristine 1.4 mg/m<SUP>2</SUP>, and prednisolone 60 mg/m<SUP>2</SUP>).</P>
<P>
<B>3.- Poor-risk patients (HIV score 2-3)</B>:</P>
<P>Low-dose CHOP <I>versus</I> VS (12 cycles every 2 weeks of vincristine 2 mg on day 1 and prednisolone<BR/>60 mg/m<SUP>2</SUP> on days 1 to 5).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-10 10:40:32 -0700" MODIFIED_BY="[Empty name]">
<P>Primary outcome: overall survival.<BR/>Secondary outcomes: event-free survival, response rate, and toxicity.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-09 07:32:46 -0700" MODIFIED_BY="[Empty name]">
<P>This study was conducted from May 1, 1993 until June 1, 1999.</P>
<P>World Health Organization-Revised European-American Lymphoma (WHO-REAL) classification was used.</P>
<P>Ann Arbor system was used.</P>
<P>Dr. Nicolas Mounier provided the unpublished data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-03-27 07:44:22 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Antinori-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bou_x00e9_-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-20 08:01:09 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feigal-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-20 08:01:09 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gabarre-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gisselbrecht-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-20 08:12:07 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffmann-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-20 08:12:07 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-12 09:27:30 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-12 09:27:30 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-12 09:27:27 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-12 09:27:27 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-12 09:27:39 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newell-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-12 09:27:39 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ribera-2008">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sparano-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sparano-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spina-2005a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of pooled results from 3 phase 2 trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-26 09:44:14 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Straus-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-26 09:44:14 -0700" MODIFIED_BY="[Empty name]">
<P>Duplicate publication from Kaplan 1997.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tirelli-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-07 07:25:41 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tirelli-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-07 07:25:41 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-20 08:16:10 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaccher-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-20 08:16:10 -0700" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-27 07:44:22 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walsh-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-27 07:44:22 -0700" MODIFIED_BY="[Empty name]">
<P>Phase I Non-controlled clinical trial </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiss-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-03-26 09:45:00 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-02-17 08:02:44 -0800" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-02-17 08:02:44 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00002524">
<CHAR_STUDY_NAME>
<P>Pilot study in AIDS-related lymphomas.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 08:02:44 -0800" MODIFIED_BY="[Empty name]">
<P>Randomized.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Previously untreated, HIV-related intermediate- and high-grade lymphoma with no previous diagnosis of Kaposi's sarcoma Pathology reviewed at M.D. Anderson Cancer Center. </P>
<P>Ages eligible for study: 15 Years and older. <BR/>Genders eligible for study: Both. <BR/>Accepts Healthy Volunteers: No.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-07 06:22:17 -0700" MODIFIED_BY="[Empty name]">
<P>Patients are assigned to Regimens A, B, and C according to histology and extent of disease and the degree of immunosuppression as follows: Regimen A: Patients with Ann Arbor stage I intermediate grade or immunoblastic lymphoma with measurable non bulky disease (less than 7 cm), low LDH (less than 686), and no prior opportunistic infection irrespective of T4 count; also those with non measurable stage I extranodal primaries (infiltration of less than 2/3 of an organ site, e.g., stomach, rectum, oesophagus, sinus cavity) irrespective of T4 count. Regimen B: All patients (except primary brain lymphoma patients) not assigned to Regimen A who have T4 counts of at least 200 and no history of opportunistic infection; includes all stages of small noncleaved cell lymphoma and bulky stage I and stages II-IV intermediate grade and immunoblastic lymphoma. Regimen C: Patients not assigned to Regimen A or B, i.e., those with T4 counts less than 200 and/or a history of opportunistic infection and those with primary brain lymphoma.</P>
<P>Chemotherapy regimen: no described.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-07 06:22:24 -0700" MODIFIED_BY="[Empty name]">
<P>1.- Complete remission rate. 2.- Lymphoma-free survival.<BR/>3.- Overall survival.<BR/>4.- Effects on long-term outlook of concurrent antiretroviral therapy, prophylactic antibiosis with trimethoprim/sulphamethoxazole or aerosolized pentamidine, and prn use of granulocyte colony-stimulating factor for severe myelosuppression.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>June 1993</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Peter W. McLaughlin, MD M.D. Anderson Cancer Center.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 08:02:39 -0800" MODIFIED_BY="[Empty name]">
<P>Phase: II</P>
<P>This study is ongoing, but not recruiting participants.<BR/>PURPOSE: To study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.</P>
<P>ClinicalTrials.gov processed this record on February 16, 2009.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-17 07:03:20 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00020384">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 06:56:20 -0800" MODIFIED_BY="[Empty name]">
<P>Short-Course EPOCH-Rituximab For Untreated CD-20+ HIV-Associated Lymphomas.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 06:56:22 -0800" MODIFIED_BY="[Empty name]">
<P>Treatment, Open Label.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 06:57:52 -0800" MODIFIED_BY="[Empty name]">
<P>Patients With Previously Untreated AIDS-Related Non-Hodgkin's Lymphoma.</P>
<P>&#8805;9 years.</P>
<P>Gender: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 06:55:58 -0800" MODIFIED_BY="[Empty name]">
<P>Etoposide IV, doxorubicin IV, and vincristine IV continuously on days 1-4, and cyclophosphamide IV over 30 minutes on day 5. Patients also receive rituximab IV immediately prior to chemotherapy on days 1 and 5. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts recover.</P>
<P>Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 1 additional course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-17 06:54:42 -0800" MODIFIED_BY="[Empty name]">
<P>Primary Outcome Measures: Progression-free survival at 1 year after completion of study treatment [ Designated as safety issue: No ]<BR/>
<BR/>Secondary Outcome Measures: Toxicity during and 1 year after completion of study treatment [ Designated as safety issue: Yes ]<BR/>Response rate and duration at completion of study treatment and 5 years later [ Designated as safety issue: No ]<BR/>Ability of positron emission tomography (PET) scans to predict freedom from relapse at completion of study treatment and 5 years later [ Designated as safety issue: No ]<BR/>Effects of short course etoposide, vincristine, cyclophosphamide, doxorubicin, and rituximab (SC-EPOCH-R) on CD4 cell depletion and recovery at completion of study treatment and 18 months later [ Designated as safety issue: No ]<BR/>Response to antiretroviral therapy following SC-EPOCH-R 18 months after completion of study treatment [ Designated as safety issue: No ]</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 07:00:02 -0800" MODIFIED_BY="[Empty name]"/>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 07:03:20 -0800" MODIFIED_BY="[Empty name]">
<P>Principal Investigator: Wyndman H. Wilson , MD, PhD.</P>
<P>National Cancer Institute.</P>
<P>Sponsors and Collaborators</P>
<P>
<A HREF="http://www.clinicaltrials.gov/ct2/bye/7QoPWw4lZX-i-iSxuBc5udNzlXNiZiJ.">National Cancer Institute (NCI)</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 06:53:54 -0800" MODIFIED_BY="[Empty name]">
<P>This study is currently recruiting participants. Verified by National Cancer Institute (NCI), January 2009.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-17 08:01:16 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00049036">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 07:59:01 -0800" MODIFIED_BY="[Empty name]">
<P>A Randomized Phase II Trial Of EPOCH Given Either Concurrently Or Sequentially With Rituximab In Patients With Intermediate Or High-Grade HIV-Associated B-Cell Non-Hodgkin's Lymphoma.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 07:59:19 -0800" MODIFIED_BY="[Empty name]">
<P>Treatment, Randomized, Open Label, Active Control</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 06:22:50 -0700" MODIFIED_BY="[Empty name]">
<P>Patients characteristics:<BR/>18 and older.<BR/>Gender: both.<BR/>Performance status:</P>
<P>Karnofsky 50-100% or<BR/>ECOG 0-2.</P>
<P>Disease Characteristics:</P>
<P>Documented HIV infection by serologic, culture, or quantitative assays<BR/>Histologically or cytologically confirmed B-cell non-Hodgkin's lymphoma (NHL) of any of the following histological subtypes:</P>
<P>Diffuse large B-cell lymphoma<BR/>High-grade immunoblastic large cell lymphoma<BR/>Anaplastic large cell lymphoma<BR/>Burkitt's lymphoma<BR/>High-grade B-cell lymphoma<BR/>Burkitt-like (small noncleaved cell) lymphoma<BR/>Stage I, I_E, II, III, or IV disease<BR/>Previously untreated<BR/>CD20-positive disease<BR/>Measurable or evaluable disease<BR/>No primary CNS lymphoma (parenchymal brain or spinal cord tumour).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Arm I: patients receive etoposide IV continuously, doxorubicin IV continuously, and vincristine IV continuously on days 1-4; oral prednisone on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Patients also receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously (SC) once daily until blood counts recover or pegfilgrastim SC once approximately 24 hours after the completion of each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks. </P>
<P>Arm II: patients receive etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide, and G-CSF as in arm I. Treatment repeats every 3 weeks for 4-6 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-07 06:23:05 -0700" MODIFIED_BY="[Empty name]">
<P>Primary:<BR/>Complete response as measured by tumour response after completion of study treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-09 07:51:34 -0700" MODIFIED_BY="[Empty name]">
<P>Lawrence D. Kaplan, MD; Joseph A. Sparano, MD and Yelena Novik, MD.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 08:01:16 -0800" MODIFIED_BY="[Empty name]">
<P>Estimated enrolment: 70</P>
<P>Phase: II</P>
<P>This study is currently recruiting participants.<BR/>Purpose: this phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with HIV-associated stage I, stage II, stage III, or stage IV non-Hodgkin's lymphoma.</P>
<P>This study is ongoing, but not recruiting participants.</P>
<P>ClinicalTrials.gov processed this record on February 16, 2009.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:33:01 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "Permuted block randomization was performed centrally".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-12 12:51:51 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 06:55:44 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:55:59 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "Patients were centrally randomized after stratification according to center and HIV score (block randomization within strata)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:32:54 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-12 12:52:07 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 07:03:06 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Insufficient information about the allocation concealment process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 06:03:34 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Blinding of outcomes assessors?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Blinding of patients bias?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Blinding of caregivers bias?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 07:09:00 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-17 05:33:39 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-02-17 05:33:42 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-12 12:52:12 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-12 12:52:16 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-03-12 12:52:21 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 07:03:34 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-17 05:22:16 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-02-17 05:22:19 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-17 06:03:15 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-17 06:03:17 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-02-17 06:03:20 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-17 05:46:46 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Information about each outcomes was described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-13 09:30:05 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Inadequate. </P>
<P>Comments: Authors did a pre-protocol analysis. Experimental group was divided in two small group. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-17 05:26:33 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: The trialists reported data from 91 percent of participants. Itention-to treat analysis was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-17 05:48:41 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Dr. Nicolas Mounier sent us the unpublished data to determine overall survival and disease free survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:40:20 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "detect an improvement in complete response rate, the primary study endpoint" and "Secondary endpoints included time to progression, progression-free survival, and overall survival".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 09:30:26 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Comments:</P>
<P>1.- Adequate for the objectives (primary outcomes?) of this RCT.</P>
<P>2.- It is unclear whether tumour response and survival were outcomes included early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-24 08:04:45 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: All planned outcomes were described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 06:05:25 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Trialist included relevant clinical outcomes. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Free of attrition bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:45:28 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 09:37:22 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Quote: "Four patients, all randomized to control, were deemed ineligible before beginning therapy...:".</P>
<P>Comments: There was 14% (4/30) of post-randomisation. Further, there were two deaths (one by group) post-treatment. Therefore, this RCT included 94% of the participants from experimental group and 64.3% of the control group. </P>
<P>Overall, this RCT only analysed 80% of its original sample size. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:29:42 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 06:16:27 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Free of academic bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.03" NO="3">
<NAME>Head-to-head comparisons?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Is this the right outcome?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Underpowered study?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-02-17 05:37:25 -0800" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Comment: Expected rate of improve was very high. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2009-02-17 05:37:51 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2009-02-17 05:43:21 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-03-12 13:47:38 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Comment: There was not described sample size calculation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2009-03-13 09:39:02 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Comment: Insufficient information about the response and survival to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217; those clinical outcomes were primarily objectives of this RCT. The objective of this RCT were surrogate outcomes. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2009-03-13 09:51:43 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: RCT compared two chemotherapy approaches. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-02-17 05:19:58 -0800" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Comment: Assumptions for sample size calculation were not reported by trialists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2009-02-17 05:07:35 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "The primary end point was survival from the time of initiation of chemotherapy. Secondary end points included the rate of complete response, the duration of antitumor response, the development<BR/>of opportunistic infection, and toxic effects of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2009-02-17 05:06:02 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "we evaluated the response rates, survival, and toxic effects in HIV-infected patients with non-Hodgkin&#8217;s lymphoma who were treated with reduced-dose chemotherapy or a standard-dose therapy with granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-02-17 06:12:27 -0800" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Quote: "Calculation of sample size was based on primary OS end point. To detect a change at 2 years of 15% (null hypothesis: 30%; alternative hypothesis: 45%) with an intensified chemotherapy regimen, we calculated that 400 patients would be required to provide the study with 80% power at an overall 5% significance level. This stratified approach 15% difference between intensive and less intensive regimens was applied to all the patients without specific goal within stratum".</P>
<P>Comment: Trialists considered the same clinical improvement for the three stratum. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2009-02-17 05:51:14 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "The primary end point was overall survival (OS). The secondary end points were event-free survival (EFS), response rate, and toxicity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2009-02-17 05:50:22 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "Patients received CHOP-based chemotherapy after a pretreatment stratification of dose intensity according to their HIV score"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Free of baseline imbalance?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:41:27 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Participants were well matched for important characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 09:40:39 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Quote: "although there was a trend toward more advanced stage and more frequent bone marrow<BR/>involvement among patients in the control group as compared with patients in either of the rGMCSF<BR/>groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:08:46 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Participants were well matched for important characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 06:13:10 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Participants were well matched for important characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Free of early stopping bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 05:45:02 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Intended number of people was recruited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 09:44:44 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Unclear.</P>
<P>Comment: This RCT was underpowered. The trialists did not describe why they only selected 30 participants. It is described the follow up of this RCT. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-24 08:05:38 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Intended number of people was recruited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 06:13:27 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Comment: Intended number of people was recruited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2009-03-20 08:27:01 -0700" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Free drug company bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-24 07:37:51 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AMCT_x002d_010--2005">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "This National Cancer Institute&#8211;sponsored AIDS-Malignancies Consortium (AMC) study".</P>
<P>Comment: NCI is an USA public entity. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 09:49:25 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1991">
<DESCRIPTION>
<P>Unclear.</P>
<P>Quote: "rGM-CSF was supplied by Schering-Plough/Sandoz Corporation, Kenilworth, NJ, and Basel, Switzerland".</P>
<P>Comment: This RCT did not describe the role academic of the drug company. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-24 07:54:39 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaplan-1997">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote:"Supported by the National Institute of Allergy and Infectious Diseases ACTG and in part by grants from the National Institutes of Health".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-24 07:46:19 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>Quote: "Supported in part by research funding from the Ensemble Contre le Sida (ECS, formerly named SIDACTION) (France), the Associazione Italiana per la Ricerca sul Cancro (AIRC), and Istituto Superiore di Sanita` (Italy)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-03-27 08:16:27 -0700" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-03-13 09:53:46 -0700" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Search strategies</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>STRATEGY</P>
</TH>
<TH>
<P>RESULTS</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>1988 March 6, 2009</P>
</TD>
<TD>
<P>#1 (('human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus infection') OR ('human immunodeficiency virus infection'/de OR 'human immunodeficiency virus infection')) OR ((('human immunodeficiency virus'/exp OR 'human immunodeficiency virus') OR ('human immunodeficiency virus'/de OR 'human immunodeficiency virus'))) OR (hiv:ti OR hiv:ab) OR ('hiv-1':ti OR 'hiv-1':ab) OR ('hiv-2':ti OR 'hiv-2':ab) OR ('human immunodeficiency virus':ti OR 'human immunodeficiency virus':ab) OR ('human immuno-deficiency virus':ti OR 'human immuno-deficiency virus':ab) OR ('human immunedeficiency virus':ti OR 'human immunedeficiency virus':ab) OR ('human immune-deficiency virus':ti OR 'human immune-deficiency virus':ab) OR ('acquired immune-deficiency syndrome':ti OR 'acquired immune-deficiency syndrome':ab) OR ('acquired immunedeficiency syndrome':ti OR 'acquired immunedeficiency syndrome':ab) OR ('acquired immunodeficiency syndrome':ti OR 'acquired immunodeficiency syndrome':ab) OR ('acquired immuno-deficiency syndrome':ti OR 'acquired immuno-deficiency syndrome':ab)</P>
<P>#2 (random*:ti OR random*:ab) OR (factorial*:ti OR factorial*:ab) OR (cross?over*:ti OR cross?over:ab OR crossover*:ti OR crossover*:ab) OR (placebo*:ti OR placebo*:ab) OR (((doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab))) OR (((singl*:ti AND blind*:ti) OR (singl*:ab AND blind*:ab))) OR (assign*:ti OR assign*:ab) OR (volunteer*:ti OR volunteer*:ab) OR ((('crossover procedure'/de OR 'crossover procedure') OR ('crossover procedure'/de OR 'crossover procedure'))) OR ((('double-blind procedure'/de OR 'double-blind procedure') OR ('double-blind procedure'/de OR 'double-blind procedure'))) OR ((('single-blind procedure'/de OR 'single-blind procedure') OR ('single-blind procedure'/de OR 'single-blind procedure'))) OR ((('randomized controlled trial'/de OR 'randomized controlled trial') OR ('randomized controlled trial'/de OR 'randomized controlled trial'))) OR (allocat*:ti OR allocat*:ab)</P>
<P>((('non-hodgkin lymphoma'/exp OR 'non-hodgkin lymphoma') OR ('non-hodgkin lymphoma'/de OR 'non-hodgkin lymphoma')) OR (('non-hodgkin lymphoma'/de OR 'non-hodgkin lymphoma') OR ('non-hodgkin lymphoma'/de OR 'non-hodgkin lymphoma'))) OR (((('non-hodgkins lymphoma'/exp OR 'non-hodgkins lymphoma') OR ('non-hodgkins lymphoma'/de OR 'non-hodgkins lymphoma')) OR (('non-hodgkins lymphoma'/de OR 'non-hodgkins lymphoma') OR ('non-hodgkins lymphoma'/de OR 'non-hodgkins lymphoma')))) OR ('non-hodgkin'sAND lymphoma') or ('non AND hodgkin AND lymphoma') or ('non AND hodgkinsAND lymphoma') or ('non AND hodgkin's lymphoma') OR (((('lymphoma, non-hodgkin'/exp OR lymphoma, non-hodgkin' ) OR ('lymphoma, non-hodgkin'/de OR 'lymphoma, non-hodgkin')) OR (('lymphoma, non-hodgkin'/de OR 'lymphoma, non-hodgkin') OR ('lymphoma, non-hodgkin'/de OR 'lymphoma, non-hodgkin')))) OR ('lymphoma, non-hodgkins') OR ('lymphoma, non-hodgkin's') or ('lymphoma, AND non AND hodgkin') or ('lymphoma, AND non AND hodgkins') or ('lymphoma, AND non AND hodgkin's').</P>
<P>#4 #1 AND #2AND #3</P>
<P/>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>1966 to March 6 , 2009</P>
</TD>
<TD>
<P>#1 HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "sexually transmitted diseases, viral"[MH]</P>
<P>#2 randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])</P>
<P># 3 NON-HODGKIN LYMPHOMA OR NON-HODGKINS LYMPHOMA OR NON-HODGKIN'S LYMPHOMA OR NON HODGKIN LYMPHOMA OR NON HODGKINS LYMPHOMA OR NON HODGKIN'S LYMPHOMA OR LYMPHOMA, NON-HODGKIN OR LYMPHOMA, NON-HODGKINS OR LYMPHOMA, NON-HODGKIN'S OR LYMPHOMA, NON HODGKIN OR LYMPHOMA, NON HODGKINS OR LYMPHOMA, NON HODGKIN'S</P>
<P>#4 #1 AND #2 AND #3</P>
</TD>
<TD>
<P>743</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>Issue 1 2009</P>
</TD>
<TD>
<P># 1 NON-HODGKIN LYMPHOMA&#8221; OR &#8220;NON-HODGKINS LYMPHOMA&#8221; OR &#8220;NON-HODGKIN'S LYMPHOMA&#8221; OR &#8220;NON HODGKIN LYMPHOMA&#8221; OR &#8220;NON HODGKINS LYMPHOMA&#8221; OR &#8220;NON HODGKIN'S LYMPHOMA&#8221; , from 1966 to 2009</P>
<P># "HIV Infections" OR HIV OR hiv OR "hiv-1*" OR "hiv-2*" OR hiv1 OR hiv2 OR "hiv infect*" OR "human immunodeficiency virus" OR "human immunedeficiency virus" OR "human immuno-deficiency virus" OR "human immune-deficiency virus" OR ("human immun*" AND "deficiency virus") OR "acquired immunodeficiency syndrome" OR "acquired immunedeficiency syndrome" OR "acquired immuno-deficiency syndrome" OR "acquired immune-deficiency syndrome" OR ("acquired immun*" AND "deficiency syndrome") OR "viral sexually transmitted diseases", from 1966 to 2009.</P>
<P>(#1 AND #2)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>LILACS</P>
</TD>
<TD>
<P>1982 to February 17, 2009</P>
</TD>
<TD>
<P/>
<P>((Pt ENSAYO CONTROLADO ALEATORIO OR Pt ENSAYO CLINICO CONTROLADO OR Mh ENSAYOS CONTROLADOS ALEATORIOS OR Mh DISTRIBUCIÓN ALEATORIA OR Mh METODO DOBLE CIEGO OR Mh METODO SIMPLECIEGO OR Pt ESTUDIO MULTICÉNTRICO) or ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((Ct ANIMALES OR Mh ANIMALES OR Ct CONEJOS OR Ct RATÓN OR MH Ratas OR MH Primates OR MH Perros OR MH Conejos OR MH Porcinos) AND NOT (Ct HUMANO AND Ct ANIMALES)) [Palavras] and Non Hodgkin's lymphoma [Palavras] and AIDS [Palavras] OR HIV [Palavras].</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>GATEWAY</P>
</TD>
<TD>
<P>March 6, 2009</P>
</TD>
<TD>
<P>((((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME))) OR (((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)))) AND ((((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (CLINICAL TRIAL) OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL*) AND (MASK* OR BLIND* )))) OR ((PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*))) AND (NON-HODGKIN LYMPHOMA OR NON-HODGKINS LYMPHOMA OR NON-HODGKIN'S LYMPHOMA OR NON HODGKIN LYMPHOMA OR NON HODGKINS LYMPHOMA OR NON HODGKIN'S LYMPHOMA OR LYMPHOMA, NON-HODGKIN OR LYMPHOMA, NON-HODGKINS OR LYMPHOMA, NON-HODGKIN'S OR LYMPHOMA, NON HODGKIN OR LYMPHOMA, NON HODGKINS OR LYMPHOMA, NON HODGKIN'S) Limit: 1966:2009, AIDS</P>
</TD>
<TD>
<P>111</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>AIDSearch</P>
</TD>
<TD>
<P>2006 - 2008</P>
</TD>
<TD>
<P>PT=RANDOMIZED CONTROLLED TRIAL OR PT=CONTROLLED CLINICAL TRIAL.</P>
<P>(RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE BLIND METHOD) OR (SINGLE BLIND METHOD) OR PT=CLINICAL TRIAL.</P>
<P>CLINICAL TRIALS OR CLINICAL TRIALS, PHASE 1 OR CLINICAL TRIALS, PHASE II OR CLINICAL TRIALS, PHASE III OR CLINICAL TRIALS, PHASE IV OR CONTROLLED CLINICAL TRIALS OR MULTICENTER STUDIES.</P>
<P>(SINGLE* OR DUBL* OR TRIPL* OR TREBL*) NEAR6 (BLIND* OR MASK*).</P>
<P>CLIN* NEAR6 TRIAL OR PLACEBO OR PLACEBOS OR RESEARCH DESIGN.</P>
<P>#1 OR #2 OR #3 OR #4 OR #5</P>
<P>ANIMALS NOT (HUMAN NOT ANIMALS)</P>
<P>#6 NOT #7</P>
<P>NON-HODGKIN LYMPHOMA OR NON-HODGKINS LYMPHOMA OR NON-HODGKIN'S LYMPHOMA OR NON HODGKIN LYMPHOMA OR NON HODGKINS LYMPHOMA OR NON HODGKIN'S LYMPHOMA OR LYMPHOMA, NON-HODGKIN OR LYMPHOMA, NON-HODGKINS OR LYMPHOMA, NON-HODGKIN'S OR LYMPHOMA, NON HODGKIN OR LYMPHOMA, NON HODGKINS OR LYMPHOMA, NON HODGKIN'S</P>
<P>#8 AND #9 AND PY=2006-2008</P>
<P/>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Clinicaltrials.gov</P>
</TD>
<TD>
<P>February 17, 2009</P>
</TD>
<TD>
<P>Non-Hodgkin' Lymphoma AND AIDS</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Current Controlled Trials (http://controlled-trials.com/)</P>
</TD>
<TD>
<P>February</P>
<P>17, 2009</P>
</TD>
<TD>
<P>Non-Hodgkin's Lymphoma AND AIDS</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sistema de Información Esencial en Terapéutica y Salud. (http://www.icf.uab.es/informacion/Papyrus/sietes.asp) </P>
</TD>
<TD>
<P>February</P>
<P>17, 2009</P>
</TD>
<TD>
<P>Linfoma Non-Hodgkin and AIDS</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-03-13 12:59:19 -0700" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-03-12 07:48:31 -0700" MODIFIED_BY="[Empty name]">Clinical characteristics of HIV patients with Non-Hodgkin's lymphoma</TITLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TD ALIGN="CENTER">
<P>Study/year</P>
</TD>
<TD ALIGN="CENTER">
<P>Histology</P>
</TD>
<TD ALIGN="CENTER">
<P>Stage III/IV</P>
</TD>
<TD ALIGN="CENTER">
<P>B symptoms</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8805; 2 extranodal sites</P>
</TD>
<TD ALIGN="CENTER">
<P>Bone marrow involvement</P>
</TD>
<TD ALIGN="CENTER">
<P>AIDS prior to NHL</P>
</TD>
<TD ALIGN="CENTER">
<P>CD4 cells level</P>
</TD>
<TD ALIGN="CENTER">
<P>Prior HAART</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>
</P>
</TD>
<TD>
<P>Small noncleaved cell: 10% to 36%</P>
<P>Diffuse large-cell:10% to 12.5%</P>
<P>Immunoblastic: 50% to 80%</P>
</TD>
<TD ALIGN="CENTER">
<P>44% to 70%</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>75% to 90%</P>
</TD>
<TD ALIGN="CENTER">
<P>12.5% to 50%</P>
</TD>
<TD ALIGN="CENTER">
<P>10% to 18.7%</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>
</P>
</TD>
<TD>
<P>Large cell: 62%</P>
<P>Small noncleaved cell: 24% to 28%</P>
<P>High grade, not otherwise specified: 10% to 15%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>64% to 71%</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>79% (Overall)</P>
</TD>
<TD ALIGN="CENTER">
<P>15%</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 200 cells/mm<SUP>3</SUP>: 27% to 31%.</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>
</P>
</TD>
<TD>
<P>Diffuse large B cell: 78% to 81%</P>
<P>Burkitt: 8% to 12%</P>
<P>High-grade non-Hodgkin lymphoma not otherwise<BR/>specified: 4% to 10%.</P>
<P>Aggressive B-cell lymphoma: 96%</P>
</TD>
<TD ALIGN="CENTER">
<P>78% to 80%</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>&#8804; 50 cells/mm3</P>
<P>22% to 25%</P>
</TD>
<TD ALIGN="CENTER">
<P>None: 21% to 46%</P>
<P>Any three drugs:53% to 67%</P>
<P>Protease inhibitor: 48% to 59%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>
</P>
</TD>
<TD>
<P>Diffuse large cell: 54%;</P>
<P>Burkitt: 20%</P>
<P>Immunoblastic:18%.</P>
<P>Unclassified types of large cell NHL: 8%</P>
</TD>
<TD ALIGN="CENTER">
<P>58% to 66%</P>
</TD>
<TD ALIGN="CENTER">
<P>41% to 67%</P>
</TD>
<TD ALIGN="CENTER">
<P>31% to 36%</P>
</TD>
<TD ALIGN="CENTER">
<P>15% to 17%</P>
</TD>
<TD ALIGN="CENTER">
<P>0% to 77%</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8804; 100/mm<SUP>3</SUP>
</P>
<P>3% to 86%</P>
</TD>
<TD ALIGN="CENTER">
<P>39%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-03-13 11:42:17 -0700" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-07-07 08:29:50 -0700" MODIFIED_BY="[Empty name]">Components of the sample size of the included studies</TITLE>
<TABLE COLS="8" ROWS="5">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Study/year</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Power</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>P value</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Relative reduction</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Event Rate</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Follow-up</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>% Drop-out</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>N REPORTED</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kaplan-1991" TYPE="STUDY">Kaplan 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>30%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kaplan-1997" TYPE="STUDY">Kaplan 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>80</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="LEFT">
<P>No information provided.</P>
<P>Increase in survival</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>6 to 8 months</P>
</TD>
<TD ALIGN="CENTER">
<P>No information provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>198</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-AMCT_x002d_010--2005" TYPE="STUDY">AMCT-010 2005</LINK>
</P>
</TD>
<TD>
<P>81</P>
<P> </P>
<P> </P>
<P> </P>
<P>67</P>
</TD>
<TD>
<P/>
<P>0.05 (one sided)</P>
<P> </P>
<P> </P>
<P> </P>
<P>0.05 (one sided)</P>
<P> </P>
</TD>
<TD>
<P>50% with CHOP alone</P>
<P>75% with R-CHOP (complete response rate).</P>
<P> </P>
<P>50% increase in median time to progression. from 35 weeks on CHOP alone to 53 weeks with R-CHOP</P>
</TD>
<TD>
<P>No information provided.</P>
</TD>
<TD>
<P>Unclear</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P>35 weeks on CHOP alone to 53 weeks with R-CHOP</P>
</TD>
<TD>
<P>No information provided.</P>
</TD>
<TD>
<P>120</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-NHL_x002d_HIV_x002d_93-2006" TYPE="STUDY">NHL-HIV-93 2006</LINK>
</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>0.05</P>
</TD>
<TD>
<P>Based on primary end point ( overall survival)</P>
<P>To detect a change at 2 years of 15% (null hypothesis: 30%; alternative hypothesis:<BR/>45%) with an intensified chemotherapy regimen.</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
<TD>
<P>No information provided.</P>
</TD>
<TD>
<P>No information provided.</P>
</TD>
<TD>
<P>400</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-03-27 08:16:27 -0700" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-09-23 11:31:47 -0700" MODIFIED_BY="[Empty name]">Adverse events from non-randomised controlled trial</TITLE>
<TABLE COLS="8" ROWS="18">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Study / year</B>
</P>
<P>
<B>(patients)</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Hematological </B>
</P>
<P>
<B>(Grade  3- 4)  </B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Neurological</B>
</P>
<P>
<B> Grade  (3 - 4) </B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Gastrointestinal</B>
</P>
<P>
<B> Grade  (3 - 4)</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Infection</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Neutropenic</B>
</P>
<P>
<B>Fever</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Criteria</B>
</P>
<P>
<B>Toxicity</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Antinori 2001</P>
<P>(44)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modified high-dose CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), 1 course of high-dose methotrexate,  1 course of Cytarabine/Filgastrim</P>
</TD>
<TD VALIGN="TOP">
<P>Severe neutropenia:</P>
<P>81.5% (31/38) at least 1 day.</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
<P/>
<P>-</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Mucositis: 2 cases / 2 cases</P>
</TD>
<TD VALIGN="TOP">
<P>Documented bacterial infections: 7 cases of septicaemia.</P>
</TD>
<TD VALIGN="TOP">
<P> 71% (27/38): at least 1 day.</P>
</TD>
<TD VALIGN="TOP">
<P>WHO</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Weiss 2006</P>
<P>(72)</P>
</TD>
<TD VALIGN="TOP">
<P>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus HAART (Highly active antiretroviral therapy)</P>
</TD>
<TD VALIGN="TOP">
<P>Leukopenia by chemotherapy/cycles</P>
<P>Standard risk group: 40%  (100/249)</P>
<P>High risk group: 69% (70/102)</P>
</TD>
<TD VALIGN="TOP">
<P>Standard risk<U> </U>group: 3.21%  (8/249 cycles)</P>
<P>High risk group: 1.96%  (2/102 cycles)</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>
<U>Standard risk group:</U> 11% (28 cycles)</P>
<P>
<U>High risk group:</U> 30% (31 cycles)</P>
</TD>
<TD VALIGN="TOP">
<P>WHO</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Sparano 2004</P>
<P>(112)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Infusional cyclophosphamide, doxorubicin, etoposide.</P>
<P>With or without HAART</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<U>Before HAART</U>
<B>:</B> Granulocytopenia:75%;</P>
<P>Thrombocytopenia:52%/2%; Anaemia: 27%</P>
<P>
<U>With HAART</U>
</P>
<P>Granulocytopenia:17%/73%; thrombocytopenia:26%/31%; anaemia: 45%/9%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<U>Before HAART</U>: 2%</P>
<P>
<U>With HAART</U>: 11%/3%</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<U>Before HAART</U>:</P>
<P>Nausea: 0%; Vomiting: 2%; Diarrhea: 0%; Stomatitis: 2%</P>
<P>
<U>With HAART</U>
</P>
<P>Nausea: 9%; Vomiting: 8%; Diarrhea: 8%; Stomatitis: 11%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<U>Before HAART</U>: 19%</P>
<P>
<U>With HAART</U>: 8%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<U>Before HAART</U>:</P>
<P>17% / 10%; Grade 5: 8%</P>
<P>With HAART</P>
<P>14% / 6%; Grade 5: Not reported.</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>National Cancer Institute</P>
<P>Common Toxicity</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Levine 2004</P>
<P>(24)</P>
</TD>
<TD VALIGN="TOP">
<P>Liposome-encapsulated Doxorrubicin plus cyclophosphamide, vincristine, prednisone</P>
</TD>
<TD VALIGN="TOP">
<P> Neutropenia:13% / 75%</P>
<P> Anemia: 4% / 29%</P>
</TD>
<TD VALIGN="TOP">
<P>Peripheral neuropathy:</P>
<P>4% (1 pt)</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhea: 4%; Mucositis: 0%; Vomiting: 8%</P>
</TD>
<TD VALIGN="TOP">
<P> 8%</P>
</TD>
<TD VALIGN="TOP">
<P> 12%</P>
<P/>
</TD>
<TD>
<P>National Cancer Institute</P>
<P>Common Toxicity</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Sparano 1996</P>
<P>(25)</P>
</TD>
<TD VALIGN="TOP">
<P>Infusional cyclophosphamide, doxorubicin, etoposide plus didanosine.</P>
<P>Filgrastim</P>
</TD>
<TD VALIGN="TOP">
<P>Nadir white blood cells, neutrophil and platelet counts.</P>
<P>Analysis for didanosine (yes versus[vs] no) includes only cycles 1 and 2:</P>
<P>White blood cells: 3.33 vs 1.49, P = 0.03</P>
<P>Neutrophil: 2.38 vs 1.07, P = 0.03</P>
<P>Platelet: 76 vs 48 P = 0.059</P>
<P>Days with absolute neutrophil count (&lt;500 /&#956;L:2.6 vs 3.1 P = &gt;0.05)</P>
</TD>
<TD VALIGN="TOP">
<P>One case of mild peripheral neuropathy.</P>
<P>4 patients</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Nausea/vomiting: 72%; Stomatitis: 56%; diarrhoea (1patient);stomatitis (1 patient)</P>
</TD>
<TD VALIGN="TOP">
<P>Herpes simplex: 16%</P>
<P>No opportunistic: 9</P>
<P>Bacteraemic episodes: 7 patients.</P>
</TD>
<TD VALIGN="TOP">
<P>Analysis for didanosine includes only cycles 1 and 2:</P>
<P>Ddl (yes):</P>
<P>33%</P>
<P>Ddl (no): 48%</P>
<P>P = &gt;0.05</P>
</TD>
<TD VALIGN="TOP">
<P>National Cancer Institute</P>
<P>Common Toxicity</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Gisselbrecht  1993</P>
<P>(89)</P>
</TD>
<TD VALIGN="TOP">
<P> ACVB (Doxorubicin, Cyclophosphamide, vindesine, bleomycin, prednisone)</P>
<P>Methotrexate (high dose)-folinic acid,</P>
<P>Ifosfamide, etoposide, L-asparaginase, cytarabine.</P>
</TD>
<TD VALIGN="TOP">
<P>White blood cells x 10<SUP>6</SUP>/L nadir:</P>
<P>&lt; 500: 57% (cycle 1), 59% (cycle 2), 46% (cycle 3).</P>
<P>&gt;1000: 20% (cycle 1), 15% (cycle 2), 16% (cycle 3).</P>
<P> Platelets x 10<SUP>6</SUP>/L nadir:</P>
<P>&lt; 20,000: 18% (cycle 1), 11% (cycle 2), 16% (cycle 3).</P>
<P>&gt;50,000: 61% (cycle 1), 65% (cycle 2), 70% (cycle 3).</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>25% (cycle 1); 20% (cycle 2); 18% (cycle 3)</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>WHO</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> Tirelli 1992</P>
<P>(37)</P>
</TD>
<TD VALIGN="TOP">
<P>Ciclophosphamide, doxorubicin, teniposide, prednisone,vincristine, bleomycin</P>
<P>HAART (Highly active antiretroviral therapy)</P>
<P>(Toxicity criteria no described)</P>
</TD>
<TD VALIGN="TOP">
<P>Leukopenia: 9 patients /18 patients</P>
<P>Thrombocytopenia: 6 patients / 5 patients.</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Little 2003</P>
<P>(39)</P>
</TD>
<TD VALIGN="TOP">
<P>EPOCH (Etoposide, Doxorubicin, Vincristine, Cyclosphosphamide, Prednisone)</P>
<P>Filgastrim<SUP> </SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Neutropenia 30% cycles (209); Anaemia: 17%; Thrombocytopenia: 21% cycles.</P>
</TD>
<TD VALIGN="TOP">
<P>Peripheral: 2 cases.</P>
</TD>
<TD VALIGN="TOP">
<P>Serious stomatitis: &lt;3%.</P>
</TD>
<TD VALIGN="TOP">
<P>Cytomegalovirus: 2 cases.</P>
<P>Mycobacterium avium complex: 1 case.</P>
</TD>
<TD VALIGN="TOP">
<P>13% cycles</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Gabarre 1995</P>
<P>(32)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Doxorubicin, Cyclophosphamide, vindesine, bleomycin, prednisone/ Filgrastim</P>
<P>Zidovudine</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>White blood cells x 10<SUP>9</SUP>/l nadir:</P>
<P>&lt; 500: 86% (cycle 1), 86% (cycle 2), 92% (cycle 3).</P>
<P>&gt;1000: 4% (cycle 1), 10% (cycle 2), 0% (cycle 3).</P>
<P> Platelets x 10<SUP>9</SUP>/l nadir:</P>
<P>&lt; 20,000: 41% (cycle 1), 27% (cycle 2), 46% (cycle 3).</P>
<P>&gt;50,000: 26% (cycle 1), 19% (cycle 2), 15% (cycle 3).</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Cycle 1: 22%; Cycle 2: 22%; Cycle 3: 13%</P>
</TD>
<TD VALIGN="TOP">
<P>Cycle 1: 30%; Cycle 2: 25%; Cycle 3: 17%</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>WHO</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P> Ribera 2007</P>
<P>(81)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> Rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</P>
</TD>
<TD VALIGN="TOP">
<P>Based on 426 R-CHOP cycles</P>
<P>Neutropenia: 49% (208/426)</P>
</TD>
<TD VALIGN="TOP">
<P>426 R-CHOP cycles: 1% (3/426).</P>
</TD>
<TD VALIGN="TOP">
<P>426 R-CHOP cycles: 6% (24/426).</P>
</TD>
<TD VALIGN="TOP">
<P>426 R-CHOP cycles: 10% (42/426).</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD>
<P>National Cancer Institute</P>
<P>Common Toxicity</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Costello 2004</P>
<P>(38)</P>
</TD>
<TD VALIGN="TOP">
<P>Modified high-dose CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), 1 course of high-dose MTX,  1 course of Cytarabine. Filgastrim.</P>
</TD>
<TD VALIGN="TOP">
<P>Severe neutropenia:</P>
<P>81.5% (31/38) at least 1 day.</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Mucositis: 2 cases / 2 cases.</P>
</TD>
<TD VALIGN="TOP">
<P>Documented bacterial infections: 7 cases of septicaemia.</P>
</TD>
<TD VALIGN="TOP">
<P> 71% (27/38): at least 1 day.</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Boué 2006</P>
<P>(61)</P>
</TD>
<TD VALIGN="TOP">
<P>Rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</P>
</TD>
<TD VALIGN="TOP">
<P>Neutropenia: 32.7 (20/61); Anemia: 72 episodes; Thrombocytopenia: 35 episodes.</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Nausea, vomiting, fatigue:12 cases.</P>
<P>Mucositis: 2 cases.</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P> 25% (15/61)</P>
</TD>
<TD>
<P>National Cancer Institute</P>
<P>Common Toxicity</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Arzoo 2004</P>
<P>(11)</P>
</TD>
<TD VALIGN="TOP">
<P>Several regimens</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Vaccher 2001</P>
<P>(104)</P>
</TD>
<TD VALIGN="TOP">
<P>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOP-like regimen with or not HAART(Highly active antiretroviral therapy).</P>
</TD>
<TD VALIGN="TOP">
<P>Leukopenia: 50% (CHOP) vs 51% (CHOP-HAART).</P>
<P>Anemia: 33% (CHOP) vs 7% (CHOP-HAART).</P>
<P>Thrombocytopenia: 43% (CHOP) vs 21% (CHOP-HAART)</P>
</TD>
<TD VALIGN="TOP">
<P>Autonomic neurotoxicity</P>
<P>17%  (CHOP) vs 0% (CHOP-HAART)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Oral: 2 cases (CHOP) vs 6 cases (CHOP-HAART)</P>
<P>Nausea and emesis:</P>
<P>1 case (CHOP) vs 3 cases with CHOP-HAART)</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Ratner 2001</P>
<P>(65)</P>
</TD>
<TD VALIGN="TOP">
<P>Modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) vs full dose CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</P>
<P>HAART (Highly active antiretroviral therapy)</P>
</TD>
<TD VALIGN="TOP">
<P>Neutropenia: 22 versus 8</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Nausea or vomiting: 1 vs 2</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Tirelli 2002</P>
<P>(30)</P>
<P>Based on 26 patients and abstract</P>
</TD>
<TD VALIGN="TOP">
<P>ICDE (Infusional cyclophosphamide, doxorubicin, etoposide;) plus Rituximab</P>
<P>HAART (Highly active antiretroviral therapy)</P>
<P>Filgrastrim</P>
</TD>
<TD VALIGN="TOP">
<P>Neutropenia: 79%;</P>
<P>Anaemia: 45%;</P>
<P>Thrombocytopenia: 34%</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Mucositis: 17%</P>
</TD>
<TD VALIGN="TOP">
<P>Bacterial: 34%</P>
<P>Opportunistic:7%</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Walsh 1993</P>
<P>(18)</P>
</TD>
<TD>
<P>Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, GM-CSF, cytosine arabinoside.</P>
<P>Doxorubicin and cyclophosphamide were escalated by three levels. </P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Neutropenia (&lt; 500 neutrophils/mm<SUP>3</SUP>): 10 patients/17 (one was unevaluated).</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>One patient.</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhea: two patients.</P>
</TD>
<TD VALIGN="TOP">
<P>One patient.</P>
<P>Oportunistic:</P>
<P>Two P. carinii pneumonia.</P>
<P>One C. species.</P>
</TD>
<TD VALIGN="TOP">
<P>12/17: 71%</P>
</TD>
<TD VALIGN="TOP">
<P>Eastern Cooperative Oncology Group (ECOG).</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-03-16 09:52:12 -0700" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-09-24 07:52:41 -0700" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Low-dose mBACOD versus Standard-dose mBACOD</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.6294359522813069" CI_START="0.840100363951617" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="1.1699956139009136" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.2120372944621212" LOG_CI_START="-0.07566882714450011" LOG_DATA="YES" LOG_EFFECT_SIZE="0.06818423365881052" MODIFIED="2008-09-24 07:52:41 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.35289216381376" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0" Z="0.9289940828402367">
<NAME>Risk of death</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.6294359522813069" CI_START="0.840100363951617" EFFECT_SIZE="1.1699956139009136" ESTIMABLE="YES" ESTIMATE="0.157" LOG_CI_END="0.2120372944621212" LOG_CI_START="-0.07566882714450011" LOG_EFFECT_SIZE="0.06818423365881052" MODIFIED="2008-07-07 12:37:27 -0700" MODIFIED_BY="[Empty name]" ORDER="31" SE="0.169" STUDY_ID="STD-Kaplan-1997" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="2.0692583867750782" CI_START="0.7180685249593717" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="1.2189623938216427" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3158147240848549" LOG_CI_START="-0.14383410925116724" LOG_DATA="YES" LOG_EFFECT_SIZE="0.08599030741684385" MODIFIED="2008-07-07 12:48:02 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.46335515490427026" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0" Z="0.7333333333333333">
<NAME>Disease-free survival (Risk for death or recurrent disease)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.0692583867750782" CI_START="0.7180685249593717" EFFECT_SIZE="1.2189623938216427" ESTIMABLE="YES" ESTIMATE="0.198" LOG_CI_END="0.3158147240848549" LOG_CI_START="-0.14383410925116724" LOG_EFFECT_SIZE="0.08599030741684385" MODIFIED="2008-07-07 12:27:54 -0700" MODIFIED_BY="[Empty name]" ORDER="30" SE="0.27" STUDY_ID="STD-Kaplan-1997" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="3.5469883789138525" CI_END="1.2977461315660213" CI_START="0.7436313090691359" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9823668635778832" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" I2="15.421205836635686" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11318974297023993" LOG_CI_START="-0.12864233343791356" LOG_EFFECT_SIZE="-0.007726295233836854" METHOD="MH" MODIFIED="2008-09-10 11:54:35 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.31471897307574914" P_Q="0.0" P_Z="0.9003352810857237" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013744166989313187" TOTALS="SUB" TOTAL_1="376" TOTAL_2="324" WEIGHT="400.0" Z="0.1252378147445217">
<NAME>Tumor response rate</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.276839264300151E-31" CI_END="1.1006535337830208" CI_START="0.5816936615742052" DF="0.0" EFFECT_SIZE="0.8001519756838906" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" I2="100.0" ID="CMP-001.03.01" LOG_CI_END="0.04165063228137729" LOG_CI_START="-0.2353056684662775" LOG_EFFECT_SIZE="-0.09682751809245015" MODIFIED="2008-09-10 11:54:35 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.170544069483193" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0" Z="1.3704577051418447">
<NAME>Complete remission</NAME>
<DICH_DATA CI_END="1.1006535337830208" CI_START="0.5816936615742052" EFFECT_SIZE="0.8001519756838906" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.04165063228137729" LOG_CI_START="-0.2353056684662775" LOG_EFFECT_SIZE="-0.09682751809245015" MODIFIED="2008-07-08 08:53:53 -0700" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.16268550201497164" STUDY_ID="STD-Kaplan-1997" TOTAL_1="94" TOTAL_2="81" VAR="0.026466572565863343" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7455201287851947" CI_START="0.6520750385275091" DF="0.0" EFFECT_SIZE="1.0668693009118542" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.24192486132546734" LOG_CI_START="-0.18570242429376768" LOG_EFFECT_SIZE="0.02811121851584981" MODIFIED="2008-07-08 08:55:21 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7966485534786167" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0" Z="0.25768690495423724">
<NAME>Partial response</NAME>
<DICH_DATA CI_END="1.7455201287851947" CI_START="0.6520750385275091" EFFECT_SIZE="1.0668693009118542" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" LOG_CI_END="0.24192486132546734" LOG_CI_START="-0.18570242429376768" LOG_EFFECT_SIZE="0.02811121851584981" MODIFIED="2008-07-08 08:55:21 -0700" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.25119038436194163" STUDY_ID="STD-Kaplan-1997" TOTAL_1="94" TOTAL_2="81" VAR="0.06309660919589997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8024325754382104" CI_START="0.5009386653147695" DF="0.0" EFFECT_SIZE="1.184840425531915" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.44753517257213804" LOG_CI_START="-0.30021544568167297" LOG_EFFECT_SIZE="0.07365986344523257" MODIFIED="2008-07-08 08:56:29 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6993881001909101" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0" Z="0.386146600041433">
<NAME>Stable disease</NAME>
<DICH_DATA CI_END="2.8024325754382104" CI_START="0.5009386653147695" EFFECT_SIZE="1.184840425531915" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.44753517257213804" LOG_CI_START="-0.30021544568167297" LOG_EFFECT_SIZE="0.07365986344523257" MODIFIED="2008-07-08 08:56:29 -0700" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.4392324145875448" STUDY_ID="STD-Kaplan-1997" TOTAL_1="94" TOTAL_2="81" VAR="0.19292511402440482" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.166324260935083" CI_START="0.7598081579186582" DF="0.0" EFFECT_SIZE="1.5510638297872341" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.5005553885818261" LOG_CI_START="-0.11929604781731179" LOG_EFFECT_SIZE="0.19062967038225717" MODIFIED="2008-07-08 08:57:37 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.22799562758378633" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="81" WEIGHT="100.0" Z="1.2055381867127848">
<NAME>Progression of disease</NAME>
<DICH_DATA CI_END="3.166324260935083" CI_START="0.7598081579186582" EFFECT_SIZE="1.5510638297872341" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5005553885818261" LOG_CI_START="-0.11929604781731179" LOG_EFFECT_SIZE="0.19062967038225717" MODIFIED="2008-07-08 08:57:37 -0700" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.36410380205494897" STUDY_ID="STD-Kaplan-1997" TOTAL_1="94" TOTAL_2="81" VAR="0.13257157867086947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.197449357923315" CI_END="1.103386901416525" CI_START="0.8348528043506989" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9597737488238642" ESTIMABLE="YES" EVENTS_1="408" EVENTS_2="408" I2="47.66665792881975" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.04272782403327677" LOG_CI_START="-0.07839008965824834" LOG_EFFECT_SIZE="-0.01783113281248577" METHOD="MH" MODIFIED="2008-07-08 08:59:39 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.045712308337881424" P_Q="0.0" P_Z="0.5638740920735938" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02175020764937359" TOTALS="SUB" TOTAL_1="980" TOTAL_2="940" WEIGHT="1000.0" Z="0.5770967654715793">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4749718082267736E-30" CI_END="1.046504736628379" CI_START="0.7405702174669555" DF="0.0" EFFECT_SIZE="0.8803466592116299" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" I2="100.00000000000001" ID="CMP-001.04.01" LOG_CI_END="0.019741198357373705" LOG_CI_START="-0.13043375738222496" LOG_EFFECT_SIZE="-0.055346279512425635" NO="1" P_CHI2="0.0" P_Z="0.14855027149961725" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="1.444671170214806">
<NAME>Fever</NAME>
<DICH_DATA CI_END="1.046504736628379" CI_START="0.7405702174669555" EFFECT_SIZE="0.8803466592116299" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" LOG_CI_END="0.019741198357373705" LOG_CI_START="-0.13043375738222496" LOG_EFFECT_SIZE="-0.055346279512425635" ORDER="1" O_E="0.0" SE="0.0882135123794602" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.007781623766321176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1204648493492695" CI_START="0.3325186655234748" DF="0.0" EFFECT_SIZE="0.6103896103896104" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.049398236620210347" LOG_CI_START="-0.4781839710937392" LOG_EFFECT_SIZE="-0.21439286723676443" NO="2" P_CHI2="1.0" P_Z="0.11117458958715644" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="1.5929358199818813">
<NAME>Abdominal Pain</NAME>
<DICH_DATA CI_END="1.1204648493492695" CI_START="0.3325186655234748" EFFECT_SIZE="0.6103896103896104" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.049398236620210347" LOG_CI_START="-0.4781839710937392" LOG_EFFECT_SIZE="-0.21439286723676443" ORDER="2" O_E="0.0" SE="0.30990440038522105" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.0960407373781234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5215981701195265" CI_START="0.9135348654462527" DF="0.0" EFFECT_SIZE="1.1789965986394557" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="48" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.18229997730924957" LOG_CI_START="-0.039274872961728005" LOG_EFFECT_SIZE="0.07151255217376075" NO="3" P_CHI2="1.0" P_Z="0.20581980062590888" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="1.2651438241452027">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.5215981701195265" CI_START="0.9135348654462527" EFFECT_SIZE="1.1789965986394557" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="48" LOG_CI_END="0.18229997730924957" LOG_CI_START="-0.039274872961728005" LOG_EFFECT_SIZE="0.07151255217376075" ORDER="3" O_E="0.0" SE="0.13015416386237025" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.016940106370712728" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6232183728865257" CI_START="0.8383940460995669" DF="0.0" EFFECT_SIZE="1.1665747380033094" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="37" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.21037694974613533" LOG_CI_START="-0.07655181451503043" LOG_EFFECT_SIZE="0.06691256761555245" NO="4" P_CHI2="1.0" P_Z="0.3606444237099893" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="0.9141378556261668">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="1.6232183728865257" CI_START="0.8383940460995669" EFFECT_SIZE="1.1665747380033094" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="37" LOG_CI_END="0.21037694974613533" LOG_CI_START="-0.07655181451503043" LOG_EFFECT_SIZE="0.06691256761555245" ORDER="4" O_E="0.0" SE="0.16854337644729847" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.02840686974425577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1191102022759267" CI_START="0.5909411752339531" DF="0.0" EFFECT_SIZE="0.813220940550133" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.04887285496782917" LOG_CI_START="-0.22845574846357133" LOG_EFFECT_SIZE="-0.08979144674787108" NO="5" P_CHI2="1.0" P_Z="0.2043819295676339" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.2691658888990553">
<NAME>Stomatitis</NAME>
<DICH_DATA CI_END="1.1191102022759267" CI_START="0.5909411752339531" EFFECT_SIZE="0.813220940550133" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" LOG_CI_END="0.04887285496782917" LOG_CI_START="-0.22845574846357133" LOG_EFFECT_SIZE="-0.08979144674787108" ORDER="5" O_E="0.0" SE="0.16290419445433185" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.026537776570814763" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0798750910550257" CI_START="0.513021621243353" DF="0.0" EFFECT_SIZE="1.032967032967033" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.3180372537635084" LOG_CI_START="-0.28986433120629806" LOG_EFFECT_SIZE="0.014086461278605102" NO="6" P_CHI2="1.0" P_Z="0.9276247799069985" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="0.09083363971507111">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="2.0798750910550257" CI_START="0.513021621243353" EFFECT_SIZE="1.032967032967033" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3180372537635084" LOG_CI_START="-0.28986433120629806" LOG_EFFECT_SIZE="0.014086461278605102" ORDER="6" O_E="0.0" SE="0.3570844001726411" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.12750926884665487" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.615369499579185" CI_START="0.9461557583511365" DF="0.0" EFFECT_SIZE="1.236281179138322" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="0.20827187853942383" LOG_CI_START="-0.024037363149829055" LOG_EFFECT_SIZE="0.09211725769479738" NO="7" P_CHI2="1.0" P_Z="0.12009772540495789" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.5543635382177785">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.615369499579185" CI_START="0.9461557583511365" EFFECT_SIZE="1.236281179138322" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" LOG_CI_END="0.20827187853942383" LOG_CI_START="-0.024037363149829055" LOG_EFFECT_SIZE="0.09211725769479738" ORDER="7" O_E="0.0" SE="0.13645959851755962" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.01862122202757356" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5127705201886315" CI_START="0.7508366861339356" DF="0.0" EFFECT_SIZE="1.0657596371882085" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="36" I2="0.0" ID="CMP-001.04.08" LOG_CI_END="0.17977305269304408" LOG_CI_START="-0.12445451575728624" LOG_EFFECT_SIZE="0.027659268467878896" NO="8" P_CHI2="1.0" P_Z="0.7215517743318036" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="0.3563856511223294">
<NAME>Diarrhea</NAME>
<DICH_DATA CI_END="1.5127705201886315" CI_START="0.7508366861339356" EFFECT_SIZE="1.0657596371882085" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="36" LOG_CI_END="0.17977305269304408" LOG_CI_START="-0.12445451575728624" LOG_EFFECT_SIZE="0.027659268467878896" ORDER="8" O_E="0.0" SE="0.17870477965847553" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.03193539827278429" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9186482578024627" CI_START="0.5747863389905318" DF="0.0" EFFECT_SIZE="0.7266542980828695" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="66" I2="0.0" ID="CMP-001.04.09" LOG_CI_END="-0.03685074425792717" LOG_CI_START="-0.24049356233936492" LOG_EFFECT_SIZE="-0.13867215329864604" NO="9" P_CHI2="1.0" P_Z="0.0076008327853154915" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="2.6693052933030263">
<NAME>Grade 3 or higher-grade toxic effects of chemotherapy</NAME>
<DICH_DATA CI_END="0.9186482578024627" CI_START="0.5747863389905318" EFFECT_SIZE="0.7266542980828695" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="66" LOG_CI_END="-0.03685074425792717" LOG_CI_START="-0.24049356233936492" LOG_EFFECT_SIZE="-0.13867215329864604" ORDER="9" O_E="0.0" SE="0.11962079938924364" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.014309135646521672" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6114462551371136" CI_START="0.5709363973618505" DF="0.0" EFFECT_SIZE="0.9591836734693877" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-001.04.10" LOG_CI_END="0.20721582552529194" LOG_CI_START="-0.24341226971088434" LOG_EFFECT_SIZE="-0.01809822209279622" NO="10" P_CHI2="1.0" P_Z="0.8749036179325619" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="0.15743298680698875">
<NAME>Opportunistic Illness</NAME>
<DICH_DATA CI_END="1.6114462551371136" CI_START="0.5709363973618505" EFFECT_SIZE="0.9591836734693877" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.20721582552529194" LOG_CI_START="-0.24341226971088434" LOG_EFFECT_SIZE="-0.01809822209279622" ORDER="10" O_E="0.0" SE="0.2647011737867768" STUDY_ID="STD-Kaplan-1997" TOTAL_1="98" TOTAL_2="94" VAR="0.07006671140409743" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-09-23 08:37:20 -0700" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Rituximab-CHOP versus CHOP</NAME>
<DICH_OUTCOME CHI2="6.740403617253901" CI_END="1.546247103335223" CI_START="0.46373886733436676" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8467909307023321" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="43" I2="55.49227953767216" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.18927889905159456" LOG_CI_START="-0.33372650306592516" LOG_EFFECT_SIZE="-0.07222380200716529" METHOD="MH" MODIFIED="2008-07-08 12:20:48 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08064882088178094" P_Q="0.0" P_Z="0.5882885983500179" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2009820169657663" TOTALS="SUB" TOTAL_1="396" TOTAL_2="200" WEIGHT="400.0" Z="0.541317738545224">
<NAME>Tumor response rate</NAME>
<GROUP_LABEL_1>R-CHOP</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours R-CHOP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHOP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.675815757641306" CI_START="0.8585598549860702" DF="0.0" EFFECT_SIZE="1.1994949494949494" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="24" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.22422626976079885" LOG_CI_START="-0.06622942236209046" LOG_EFFECT_SIZE="0.07899842369935423" MODIFIED="2008-07-08 09:26:44 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.286357732229537" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="100.0" Z="1.066145849334299">
<NAME>Complete remission</NAME>
<DICH_DATA CI_END="1.675815757641306" CI_START="0.8585598549860702" EFFECT_SIZE="1.1994949494949494" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="24" LOG_CI_END="0.22422626976079885" LOG_CI_START="-0.06622942236209046" LOG_EFFECT_SIZE="0.07899842369935423" MODIFIED="2008-07-08 09:26:44 -0700" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.1706151113318494" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="50" VAR="0.029109516214779366" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.193444046865914" CI_START="0.3194995859120877" DF="0.0" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.5042593111781242" LOG_CI_START="-0.4955297003732238" LOG_EFFECT_SIZE="0.0043648054024501125" MODIFIED="2008-07-08 09:28:55 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9863462018804292" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="100.0" Z="0.01711333349234097">
<NAME>Partial remission</NAME>
<DICH_DATA CI_END="3.193444046865914" CI_START="0.3194995859120877" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.5042593111781242" LOG_CI_START="-0.4955297003732238" LOG_EFFECT_SIZE="0.0043648054024501125" MODIFIED="2008-07-08 09:28:55 -0700" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.5872810144206859" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="50" VAR="0.34489898989898987" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.193444046865914" CI_START="0.3194995859120877" DF="0.0" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.5042593111781242" LOG_CI_START="-0.4955297003732238" LOG_EFFECT_SIZE="0.0043648054024501125" MODIFIED="2008-07-08 12:20:48 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9863462018804292" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="100.0" Z="0.01711333349234097">
<NAME>Stable disease</NAME>
<DICH_DATA CI_END="3.193444046865914" CI_START="0.3194995859120877" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.5042593111781242" LOG_CI_START="-0.4955297003732238" LOG_EFFECT_SIZE="0.0043648054024501125" MODIFIED="2008-07-08 12:20:48 -0700" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.5872810144206859" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="50" VAR="0.34489898989898987" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6534802125876656E-31" CI_END="0.8549613157994449" CI_START="0.15780390949109613" DF="0.0" EFFECT_SIZE="0.3673094582185491" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="100.0" ID="CMP-002.01.04" LOG_CI_END="-0.06805353523078907" LOG_CI_START="-0.8018822416248361" LOG_EFFECT_SIZE="-0.4349678884278126" MODIFIED="2008-07-08 09:33:00 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.020152907826999796" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="100.0" Z="2.3234888150918627">
<NAME>Progression of disease</NAME>
<DICH_DATA CI_END="0.854961315799445" CI_START="0.1578039094910961" EFFECT_SIZE="0.3673094582185491" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="-0.06805353523078901" LOG_CI_START="-0.8018822416248362" LOG_EFFECT_SIZE="-0.4349678884278126" MODIFIED="2008-07-08 09:33:00 -0700" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.4310546146465443" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="50" VAR="0.1858080808080808" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.796851836180684" CI_END="2.3494443844572266" CI_START="0.44913642522174896" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0272395300476083" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="23" I2="43.16148443656358" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.37096516895496523" LOG_CI_START="-0.34762172197733354" LOG_EFFECT_SIZE="0.011671723488815807" METHOD="MH" MODIFIED="2008-07-08 09:48:28 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11744670449116479" P_Q="0.0" P_Z="0.9492331168945031" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4085300045024086" TOTALS="SUB" TOTAL_1="594" TOTAL_2="306" WEIGHT="600.0" Z="0.063669844146223">
<NAME>Cause of death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9166532348551055" CI_START="0.252196143296098" DF="0.0" EFFECT_SIZE="0.4808080808080808" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.03779492460327016" LOG_CI_START="-0.5982615591508433" LOG_EFFECT_SIZE="-0.3180282418770568" NO="1" P_CHI2="1.0" P_Z="0.026128042974721172" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="2.2243033277040354">
<NAME>Lymphoma</NAME>
<DICH_DATA CI_END="0.9166532348551055" CI_START="0.252196143296098" EFFECT_SIZE="0.4808080808080808" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.03779492460327016" LOG_CI_START="-0.5982615591508433" LOG_EFFECT_SIZE="-0.3180282418770568" ORDER="23" O_E="0.0" SE="0.32922087548782974" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.10838638485697309" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.43725190963194" CI_START="0.19523177367801298" DF="0.0" EFFECT_SIZE="1.0303030303030303" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.7353794544710346" LOG_CI_START="-0.7094495001422993" LOG_EFFECT_SIZE="0.012964977164367635" NO="2" P_CHI2="1.0" P_Z="0.971940242184607" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="0.03517494333347615">
<NAME>HIV progression</NAME>
<DICH_DATA CI_END="5.43725190963194" CI_START="0.19523177367801298" EFFECT_SIZE="1.0303030303030303" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7353794544710346" LOG_CI_START="-0.7094495001422993" LOG_EFFECT_SIZE="0.012964977164367635" ORDER="24" O_E="0.0" SE="0.848699679958544" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.720291146761735" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.16111846915855" CI_START="0.1271606052442599" DF="0.0" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="1.7255941095896157" LOG_CI_START="-0.8956474136479794" LOG_EFFECT_SIZE="0.4149733479708181" NO="3" P_CHI2="1.0" P_Z="0.5348821398492243" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="0.6205706794711787">
<NAME>Infection, not treatment-related</NAME>
<DICH_DATA CI_END="53.16111846915855" CI_START="0.1271606052442599" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7255941095896157" LOG_CI_START="-0.8956474136479794" LOG_EFFECT_SIZE="0.414973347970818" ORDER="25" O_E="0.0" SE="1.5397302461045672" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="2.370769230769231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="49.76712364624514" CI_START="0.9011853576455233" DF="0.0" EFFECT_SIZE="6.696969696969697" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="1.696942540871366" LOG_CI_START="-0.04518587325691952" LOG_EFFECT_SIZE="0.8258783338072232" NO="4" P_CHI2="1.0" P_Z="0.06312753607898236" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.8582921634787253">
<NAME>Treatment-related infection</NAME>
<DICH_DATA CI_END="49.76712364624514" CI_START="0.9011853576455233" EFFECT_SIZE="6.696969696969697" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.696942540871366" LOG_CI_START="-0.04518587325691952" LOG_EFFECT_SIZE="0.8258783338072232" ORDER="26" O_E="0.0" SE="1.0233348541336857" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="1.0472142236848119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1596951706862773" CI_START="0.24084274986733545" DF="0.0" EFFECT_SIZE="0.7212121212121212" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="0.33439245715500715" LOG_CI_START="-0.6182664227977582" LOG_EFFECT_SIZE="-0.1419369828213755" NO="5" P_CHI2="1.0" P_Z="0.5591991545902466" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="99.99999999999999" Z="0.584031451883322">
<NAME>Other</NAME>
<DICH_DATA CI_END="2.1596951706862773" CI_START="0.24084274986733545" EFFECT_SIZE="0.7212121212121212" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.33439245715500715" LOG_CI_START="-0.6182664227977582" LOG_EFFECT_SIZE="-0.1419369828213755" ORDER="27" O_E="0.0" SE="0.5595965418217645" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.31314828961887786" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.16111846915855" CI_START="0.1271606052442599" DF="0.0" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.02.06" LOG_CI_END="1.7255941095896157" LOG_CI_START="-0.8956474136479794" LOG_EFFECT_SIZE="0.4149733479708181" NO="6" P_CHI2="1.0" P_Z="0.5348821398492243" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="0.6205706794711787">
<NAME>Not reported</NAME>
<DICH_DATA CI_END="53.16111846915855" CI_START="0.1271606052442599" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7255941095896157" LOG_CI_START="-0.8956474136479794" LOG_EFFECT_SIZE="0.414973347970818" ORDER="28" O_E="0.0" SE="1.5397302461045672" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="2.370769230769231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.375511702832514" CI_START="0.643351891346057" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9407114624505929" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.13846428971222544" LOG_CI_START="-0.19155141795083735" LOG_EFFECT_SIZE="-0.02654356411930596" METHOD="MH" MODIFIED="2008-07-08 09:48:23 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.752545602382161" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="0.3152845666866552">
<NAME>Total Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.375511702832514" CI_START="0.643351891346057" EFFECT_SIZE="0.9407114624505929" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="23" LOG_CI_END="0.13846428971222544" LOG_CI_START="-0.19155141795083735" LOG_EFFECT_SIZE="-0.02654356411930596" ORDER="29" O_E="0.0" SE="0.19385286028538248" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.03757893144082402" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.98698659557351" CI_END="1.4891992323797176" CI_START="1.1360795942000546" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3007109054686141" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="124" I2="8.983232909114063" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.17295280368566518" LOG_CI_START="0.05540875928956572" LOG_EFFECT_SIZE="0.11418078148761542" METHOD="MH" MODIFIED="2008-09-23 08:37:20 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3585328587119947" P_Q="0.0" P_Z="1.4022679196559005E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004860478869835436" TOTALS="SUB" TOTAL_1="1089" TOTAL_2="561" WEIGHT="1100.0" Z="3.8077678982737146">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.731299251355228" CI_START="0.9125937170384146" DF="0.0" EFFECT_SIZE="1.256969696969697" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="25" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.23837214123166162" LOG_CI_START="-0.039722525553429776" LOG_EFFECT_SIZE="0.0993248078391159" NO="1" P_CHI2="1.0" P_Z="0.16149871875634456" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.4000487559617252">
<NAME>Absolute neutrophil count lesser than 500/mm3, patients</NAME>
<DICH_DATA CI_END="1.731299251355228" CI_START="0.9125937170384146" EFFECT_SIZE="1.256969696969697" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="25" LOG_CI_END="0.23837214123166162" LOG_CI_START="-0.039722525553429776" LOG_EFFECT_SIZE="0.0993248078391159" ORDER="13" O_E="0.0" SE="0.16335418386036463" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.026684589384685813" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4823986411205032" CI_START="1.0847213964376048" DF="0.0" EFFECT_SIZE="1.268065268065268" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="39" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.1709650082036248" LOG_CI_START="0.03531820682328647" LOG_EFFECT_SIZE="0.10314160751345562" NO="2" P_CHI2="1.0" P_Z="0.0028769249284382368" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="2.9805912705176483">
<NAME>Absolute neutrophil count lesser than 500 mm3, cycles</NAME>
<DICH_DATA CI_END="1.4823986411205032" CI_START="1.0847213964376048" EFFECT_SIZE="1.268065268065268" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="39" LOG_CI_END="0.1709650082036248" LOG_CI_START="0.03531820682328647" LOG_EFFECT_SIZE="0.10314160751345562" ORDER="14" O_E="0.0" SE="0.07967960259330677" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.006348839069427299" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6608897524052877" CI_START="0.08987764497188971" DF="0.0" EFFECT_SIZE="0.38636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.2203408055332166" LOG_CI_START="-1.0463483157490436" LOG_EFFECT_SIZE="-0.41300375510791354" NO="3" P_CHI2="1.0" P_Z="0.20121708784381043" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.2780917936231864">
<NAME>Thrombocytopenia, grade 4</NAME>
<DICH_DATA CI_END="1.6608897524052877" CI_START="0.08987764497188971" EFFECT_SIZE="0.38636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.2203408055332166" LOG_CI_START="-1.0463483157490436" LOG_EFFECT_SIZE="-0.41300375510791354" ORDER="15" O_E="0.0" SE="0.7440594600534747" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.5536244800950683" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.9565605634398056" CI_START="0.3807386892279169" DF="0.0" EFFECT_SIZE="1.3737373737373737" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="0.6951804171232446" LOG_CI_START="-0.41937298957790947" LOG_EFFECT_SIZE="0.13790371377266758" NO="4" P_CHI2="1.0" P_Z="0.6276672954717204" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="0.48501276063340903">
<NAME>Anemia, grade 4</NAME>
<DICH_DATA CI_END="4.9565605634398056" CI_START="0.3807386892279169" EFFECT_SIZE="1.3737373737373737" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6951804171232446" LOG_CI_START="-0.41937298957790947" LOG_EFFECT_SIZE="0.13790371377266758" ORDER="16" O_E="0.0" SE="0.6546941882246002" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.4286244800950683" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3635576641469074" CI_START="0.7493153963659791" DF="0.0" EFFECT_SIZE="1.3308080808080809" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" I2="0.0" ID="CMP-002.04.05" LOG_CI_END="0.3735662023297772" LOG_CI_START="-0.12533534375570857" LOG_EFFECT_SIZE="0.12411542928703433" NO="5" P_CHI2="1.0" P_Z="0.3294662886388793" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="99.99999999999999" Z="0.9751894867314471">
<NAME>Febrile neutropenia</NAME>
<DICH_DATA CI_END="2.3635576641469074" CI_START="0.7493153963659791" EFFECT_SIZE="1.3308080808080809" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.3735662023297772" LOG_CI_START="-0.12533534375570857" LOG_EFFECT_SIZE="0.12411542928703433" ORDER="17" O_E="0.0" SE="0.2930572377730967" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.08588254461119736" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="182.68662036114347" CI_START="0.6527374569865494" DF="0.0" EFFECT_SIZE="10.919999999999998" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-002.04.06" LOG_CI_END="2.261706741572008" LOG_CI_START="-0.18526146483457137" LOG_EFFECT_SIZE="1.0382226383687183" NO="6" P_CHI2="1.0" P_Z="0.09627564301043931" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.663183831983743">
<NAME>Alkaline phosphatase, grade 3/4</NAME>
<DICH_DATA CI_END="182.68662036114347" CI_START="0.6527374569865494" EFFECT_SIZE="10.92" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.261706741572008" LOG_CI_START="-0.18526146483457137" LOG_EFFECT_SIZE="1.0382226383687185" ORDER="18" O_E="0.0" SE="1.4373612371311975" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="2.0660073260073264" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.4693751644641395" CI_START="0.5515063114852501" DF="0.0" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-002.04.07" LOG_CI_END="0.8108623369701704" LOG_CI_START="-0.2584495130922723" LOG_EFFECT_SIZE="0.27620641193894907" NO="7" P_CHI2="1.0" P_Z="0.3112852102911926" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.01252898238762">
<NAME>Aspartate aminotransferase, grade 3/4</NAME>
<DICH_DATA CI_END="6.4693751644641395" CI_START="0.5515063114852501" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.8108623369701704" LOG_CI_START="-0.2584495130922723" LOG_EFFECT_SIZE="0.27620641193894907" ORDER="19" O_E="0.0" SE="0.628119073905704" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.3945335710041592" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6094770930625577" CI_START="0.018320724904780313" DF="0.0" EFFECT_SIZE="0.17171717171717168" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.04.08" LOG_CI_END="0.20668479995464054" LOG_CI_START="-1.7370573463931926" LOG_EFFECT_SIZE="-0.765186273219276" NO="8" P_CHI2="1.0" P_Z="0.12279571081539091" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.5431445367299543">
<NAME>Alanine aminotransferase</NAME>
<DICH_DATA CI_END="1.6094770930625582" CI_START="0.018320724904780324" EFFECT_SIZE="0.1717171717171717" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.20668479995464062" LOG_CI_START="-1.7370573463931924" LOG_EFFECT_SIZE="-0.765186273219276" ORDER="20" O_E="0.0" SE="1.141763758443518" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="1.3036244800950683" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.16111846915855" CI_START="0.1271606052442599" DF="0.0" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.04.09" LOG_CI_END="1.7255941095896157" LOG_CI_START="-0.8956474136479794" LOG_EFFECT_SIZE="0.4149733479708181" NO="9" P_CHI2="1.0" P_Z="0.5348821398492243" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="0.6205706794711787">
<NAME>Infusion reaction</NAME>
<DICH_DATA CI_END="53.16111846915855" CI_START="0.1271606052442599" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7255941095896157" LOG_CI_START="-0.8956474136479794" LOG_EFFECT_SIZE="0.414973347970818" ORDER="21" O_E="0.0" SE="1.5397302461045672" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="2.370769230769231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="150.15981944725314" CI_START="0.5204161824891531" DF="0.0" EFFECT_SIZE="8.839999999999998" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-002.04.10" LOG_CI_END="2.1765537374162416" LOG_CI_START="-0.2836492073900954" LOG_EFFECT_SIZE="0.946452265013073" NO="10" P_CHI2="1.0" P_Z="0.1315505047823123" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="1.508015715880712">
<NAME>Opportunistic illness</NAME>
<DICH_DATA CI_END="150.15981944725314" CI_START="0.5204161824891531" EFFECT_SIZE="8.84" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.1765537374162416" LOG_CI_START="-0.2836492073900954" LOG_EFFECT_SIZE="0.9464522650130731" ORDER="22" O_E="0.0" SE="1.4451353879802267" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="2.0884162895927605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6588859866678842" CI_START="1.1294921916407903" DF="0.0" EFFECT_SIZE="1.3688311688311687" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="35" I2="0.0" ID="CMP-002.04.11" LOG_CI_END="0.21981653848817667" LOG_CI_START="0.05288323291991509" LOG_EFFECT_SIZE="0.1363498857040459" MODIFIED="2008-09-23 08:37:20 -0700" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.0013658691305346265" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="51" WEIGHT="100.0" Z="3.201768087756508">
<NAME>Grade 3 or higher-grade toxic effects of chemotherapy</NAME>
<DICH_DATA CI_END="1.6588859866678842" CI_START="1.1294921916407903" EFFECT_SIZE="1.3688311688311687" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="35" LOG_CI_END="0.21981653848817667" LOG_CI_START="0.05288323291991509" LOG_EFFECT_SIZE="0.1363498857040459" MODIFIED="2008-09-23 08:35:07 -0700" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.09805745002398633" STUDY_ID="STD-AMCT_x002d_010--2005" TOTAL_1="99" TOTAL_2="51" VAR="0.009615263505206577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-02-17 09:44:30 -0800" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Risk adapted intensive chemotherapy</NAME>
<IV_OUTCOME CHI2="2.319612696342644" CI_END="1.4213002184482963" CI_START="0.9120200288233492" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="1.1385316272268626" ESTIMABLE="YES" I2="13.778709559858017" I2_Q="13.778709559858017" ID="CMP-003.01" LOG_CI_END="0.15268582278615797" LOG_CI_START="-0.03999562404883575" LOG_DATA="YES" LOG_EFFECT_SIZE="0.056345099368661104" MODIFIED="2009-02-17 09:41:04 -0800" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3135469383104901" P_Q="0.3135469383104901" P_Z="0.2516753805116796" Q="2.319612696342644" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.00547392726994598" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="300.0" Z="1.1462895601202208">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.2936047449771797" CI_START="0.7124278135020741" DF="0.0" EFFECT_SIZE="0.9600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.11180159990516794" LOG_CI_START="-0.14725913382603098" LOG_EFFECT_SIZE="-0.01772876696043155" MODIFIED="2008-09-22 06:38:32 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7884996185336213" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.2682594481400926">
<NAME>HIV score O (ACVBP versus CHOP)</NAME>
<IV_DATA CI_END="1.2936047449771797" CI_START="0.7124278135020741" EFFECT_SIZE="0.9600000000000001" ESTIMABLE="YES" ESTIMATE="-0.040821994520255" LOG_CI_END="0.11180159990516794" LOG_CI_START="-0.14725913382603098" LOG_EFFECT_SIZE="-0.01772876696043155" MODIFIED="2008-09-22 06:38:32 -0700" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.15217355736502" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.782757857328896" CI_START="0.8764510522708298" DF="0.0" EFFECT_SIZE="1.2500000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.25109235923406464" LOG_CI_START="-0.05727233321795163" LOG_EFFECT_SIZE="0.09691001300805649" MODIFIED="2008-09-22 06:42:47 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.21797943086858707" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.23191882784476">
<NAME>HIV score 1 (CHOP versus Low-dose CHOP)</NAME>
<IV_DATA CI_END="1.782757857328896" CI_START="0.8764510522708298" EFFECT_SIZE="1.2500000000000002" ESTIMABLE="YES" ESTIMATE="0.22314355131421" LOG_CI_END="0.25109235923406464" LOG_CI_START="-0.05727233321795163" LOG_EFFECT_SIZE="0.09691001300805649" MODIFIED="2008-09-22 06:42:47 -0700" MODIFIED_BY="[Empty name]" ORDER="58" SE="0.18113494677616" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.2011050070961153" CI_START="0.8904618333433293" DF="0.0" EFFECT_SIZE="1.399999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.34264076173307617" LOG_CI_START="-0.05038469037660262" LOG_EFFECT_SIZE="0.14612803567823676" MODIFIED="2008-09-22 06:44:48 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.14499471019843624" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.4574409139334974">
<NAME>HIV score 2-3 (Low dose versus VS)</NAME>
<IV_DATA CI_END="2.2011050070961153" CI_START="0.8904618333433293" EFFECT_SIZE="1.399999999999996" ESTIMABLE="YES" ESTIMATE="0.33647223662121" LOG_CI_END="0.34264076173307617" LOG_CI_START="-0.05038469037660262" LOG_EFFECT_SIZE="0.14612803567823676" MODIFIED="2008-09-22 06:44:48 -0700" MODIFIED_BY="[Empty name]" ORDER="56" SE="0.23086509607659" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.446388607903613" CI_END="1.6254546286473341" CI_START="0.9099782279472046" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="1.2161941960826332" ESTIMABLE="YES" I2="41.968239002026806" I2_Q="41.968239002026806" ID="CMP-003.02" LOG_CI_END="0.2109748515294059" LOG_CI_START="-0.040968998443195764" LOG_DATA="YES" LOG_EFFECT_SIZE="0.08500292654310504" MODIFIED="2009-02-17 09:42:42 -0800" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.178495362804158" P_Q="0.178495362804158" P_Z="0.1859890197268686" Q="3.446388607903613" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.027620459772718695" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="300.0" Z="1.3225381339779272">
<NAME>Disease-free survival</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.3193946298737325" CI_START="0.6697010735025961" DF="0.0" EFFECT_SIZE="0.9399999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.12037471210690837" LOG_CI_START="-0.17411900490751148" LOG_EFFECT_SIZE="-0.02687214640030157" MODIFIED="2008-09-22 07:46:25 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7205767906551236" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.3576880326400977">
<NAME>HIV score 0 (ACVBP versus CHOP)</NAME>
<IV_DATA CI_END="1.3193946298737325" CI_START="0.6697010735025961" EFFECT_SIZE="0.9399999999999995" ESTIMABLE="YES" ESTIMATE="-0.061875403718088" LOG_CI_END="0.12037471210690837" LOG_CI_START="-0.17411900490751148" LOG_EFFECT_SIZE="-0.02687214640030157" MODIFIED="2008-09-22 07:46:25 -0700" MODIFIED_BY="[Empty name]" ORDER="60" SE="0.17298706714168" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.9434578311379416" CI_START="0.9517057537168235" DF="0.0" EFFECT_SIZE="1.359999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.28857512181175" LOG_CI_START="-0.021497305071315476" LOG_EFFECT_SIZE="0.13353890837021717" MODIFIED="2009-02-17 09:42:42 -0800" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09137369058783325" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.6881955843118186">
<NAME>HIV score 1 (CHOP versus Low-dose CHOP)</NAME>
<IV_DATA CI_END="1.9434578311379416" CI_START="0.9517057537168235" EFFECT_SIZE="1.359999999999999" ESTIMABLE="YES" ESTIMATE="0.30748469974796" LOG_CI_END="0.28857512181175" LOG_CI_START="-0.021497305071315476" LOG_EFFECT_SIZE="0.13353890837021717" MODIFIED="2008-09-22 07:48:24 -0700" MODIFIED_BY="[Empty name]" ORDER="61" SE="0.18213807843438" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.425971738800933" CI_START="0.9523606409124812" DF="0.0" EFFECT_SIZE="1.5200000000000076" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.3848857372748669" LOG_CI_START="-0.02119856138531753" LOG_EFFECT_SIZE="0.1818435879447747" MODIFIED="2008-09-22 07:49:59 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07920211403943023" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="1.7553344680757792">
<NAME>HIV score 2-3 (Low-dose versus VS)</NAME>
<IV_DATA CI_END="2.425971738800933" CI_START="0.9523606409124812" EFFECT_SIZE="1.5200000000000076" ESTIMABLE="YES" ESTIMATE="0.41871033485819" LOG_CI_END="0.3848857372748669" LOG_CI_START="-0.02119856138531753" LOG_EFFECT_SIZE="0.1818435879447747" MODIFIED="2008-09-22 07:49:59 -0700" MODIFIED_BY="[Empty name]" ORDER="59" SE="0.23853592718269" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="4.3083564346036685" CI_END="2.085944516704286" CI_START="0.9764329120464253" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4271597243521272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="84" I2="53.578585468544624" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.31930275259980007" LOG_CI_START="-0.010357590501001854" LOG_EFFECT_SIZE="0.15447258104939915" METHOD="MH" MODIFIED="2009-02-17 09:44:30 -0800" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.11599854887257588" P_Q="0.0" P_Z="0.06623885579694394" Q="0.0" RANDOM="YES" SCALE="116.7206561626616" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.055597412008694766" TOTALS="SUB" TOTAL_1="253" TOTAL_2="232" WEIGHT="300.0" Z="1.836803860652357">
<NAME>Tumor response rate (complete response/unconfirmed complete response)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4942326559269663" CI_START="0.9295946027783706" DF="0.0" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="56" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.1744182235293579" LOG_CI_START="-0.03170640645802141" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2008-09-10 12:22:02 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17478290813277128" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="1.35699465728678">
<NAME>HIV score 0 (ACVBP versus CHOP).</NAME>
<DICH_DATA CI_END="1.4942326559269663" CI_START="0.9295946027783706" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="56" LOG_CI_END="0.1744182235293579" LOG_CI_START="-0.03170640645802141" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2008-09-10 12:08:56 -0700" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.12107862798796078" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="109" TOTAL_2="109" VAR="0.014660034155446998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.275011421584447" CI_START="1.0701531465379386" DF="0.0" EFFECT_SIZE="1.560323886639676" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="26" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.35698358135297664" LOG_CI_START="0.02944593276656018" LOG_EFFECT_SIZE="0.1932147570597684" MODIFIED="2008-09-19 11:04:07 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.020757352937946724" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="100.0" Z="2.3123690772841883">
<NAME>HIV score 1 (CHOP versus Low-dose CHOP)</NAME>
<DICH_DATA CI_END="2.275011421584447" CI_START="1.0701531465379386" EFFECT_SIZE="1.560323886639676" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="26" LOG_CI_END="0.35698358135297664" LOG_CI_START="0.02944593276656018" LOG_EFFECT_SIZE="0.1932147570597684" MODIFIED="2008-09-19 11:04:07 -0700" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.19239723611717013" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="95" TOTAL_2="82" VAR="0.03701669646552612" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.022034053792392" CI_START="0.9712068929742022" DF="0.0" EFFECT_SIZE="4.183673469387755" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="1.255803805981828" LOG_CI_START="-0.012688243927346615" LOG_EFFECT_SIZE="0.6215577810272407" MODIFIED="2008-09-10 12:22:48 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.054762673400216566" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="41" WEIGHT="100.0" Z="1.9207544347026089">
<NAME>HIV score 2-3 (Low-dose CHOP versus VS).</NAME>
<DICH_DATA CI_END="18.022034053792392" CI_START="0.9712068929742022" EFFECT_SIZE="4.183673469387755" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.255803805981828" LOG_CI_START="-0.012688243927346615" LOG_EFFECT_SIZE="0.6215577810272407" MODIFIED="2008-09-10 12:13:59 -0700" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.7451185092535648" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="49" TOTAL_2="41" VAR="0.5552015928322548" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.236087745108463" CI_END="1.3277507911176603" CI_START="0.5430765893597364" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8491586254404243" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.12311656885821078" LOG_CI_START="-0.2651389181262092" LOG_EFFECT_SIZE="-0.07101117463399917" METHOD="MH" MODIFIED="2008-09-22 07:51:08 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5389980607628613" P_Q="0.0" P_Z="0.4734066733979293" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="232" WEIGHT="300.0" Z="0.7169472136171392">
<NAME>Tumor response rate (partial response).</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9928609080231185" CI_START="0.5664751842213887" DF="0.0" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.2994769881204372" LOG_CI_START="-0.24681911067573895" LOG_EFFECT_SIZE="0.026328938722349145" MODIFIED="2008-09-10 12:26:42 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8501536755954044" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="0.18892235094001575">
<NAME>HIV score 0 (ACVBP versus CHOP).</NAME>
<DICH_DATA CI_END="1.9928609080231185" CI_START="0.5664751842213887" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2994769881204372" LOG_CI_START="-0.24681911067573895" LOG_EFFECT_SIZE="0.026328938722349145" MODIFIED="2008-09-10 12:26:42 -0700" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.3208970326421759" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="109" TOTAL_2="109" VAR="0.1029749055585537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9824563736783576E-31" CI_END="1.3257957932278397" CI_START="0.26934081616163913" DF="0.0" EFFECT_SIZE="0.5975708502024292" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="100.0" ID="CMP-003.04.02" LOG_CI_END="0.1224766366600645" LOG_CI_START="-0.5696978282053503" LOG_EFFECT_SIZE="-0.22361059577264294" MODIFIED="2008-09-10 12:27:13 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.20538664196649192" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="100.0" Z="1.2663533155940412">
<NAME>HIV score 1 (CHOP versus Low-dose CHOP).</NAME>
<DICH_DATA CI_END="1.3257957932278397" CI_START="0.26934081616163913" EFFECT_SIZE="0.5975708502024292" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.1224766366600645" LOG_CI_START="-0.5696978282053503" LOG_EFFECT_SIZE="-0.22361059577264294" MODIFIED="2008-09-10 12:27:13 -0700" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.4065867069808048" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="95" TOTAL_2="82" VAR="0.16531275029349482" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3978084796391586" CI_START="0.2919853499073952" DF="0.0" EFFECT_SIZE="0.8367346938775511" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.379814491707964" LOG_CI_START="-0.5346389383255203" LOG_EFFECT_SIZE="-0.07741222330877814" MODIFIED="2008-09-10 12:27:43 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7400116371769294" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="41" WEIGHT="100.0" Z="0.33183793655368893">
<NAME>HIV score 2-3 (Low-dose versus VS).</NAME>
<DICH_DATA CI_END="2.3978084796391586" CI_START="0.2919853499073952" EFFECT_SIZE="0.8367346938775511" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.379814491707964" LOG_CI_START="-0.5346389383255203" LOG_EFFECT_SIZE="-0.07741222330877814" MODIFIED="2008-09-10 12:27:43 -0700" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.5371544714191516" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="49" TOTAL_2="41" VAR="0.2885349261655881" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.691292568390185" CI_END="2.7709662169463756" CI_START="1.5994126380416902" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.105212195236054" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="132" I2="44.13774534203024" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.4426312309849714" LOG_CI_START="0.20396052334942175" LOG_EFFECT_SIZE="0.3232958771671966" METHOD="MH" MODIFIED="2008-09-22 07:51:03 -0700" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04975845119435107" P_Q="0.0" P_Z="1.0973846465084133E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08420898961757177" TOTALS="SUB" TOTAL_1="1012" TOTAL_2="936" WEIGHT="1200.0" Z="5.309811848092995">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.662360151532512" CI_START="2.2203692192895463" DF="0.0" EFFECT_SIZE="3.8461538461538467" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="13" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.8236281059287869" LOG_CI_START="0.3464251981295774" LOG_EFFECT_SIZE="0.585026652029182" MODIFIED="2008-09-10 12:37:38 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.542621713910346E-6" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="4.805633617202125">
<NAME>Thrombocytopenia - HIV score 0 (ACVBP versus CHOP).</NAME>
<DICH_DATA CI_END="6.662360151532512" CI_START="2.2203692192895463" EFFECT_SIZE="3.8461538461538463" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="13" LOG_CI_END="0.8236281059287869" LOG_CI_START="0.3464251981295774" LOG_EFFECT_SIZE="0.585026652029182" MODIFIED="2008-09-10 12:37:38 -0700" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.2803113502337462" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="109" TOTAL_2="109" VAR="0.07857445306986592" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.474295367709501" CI_START="0.9375275930494538" DF="0.0" EFFECT_SIZE="1.8047846889952153" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.5408667372870986" LOG_CI_START="-0.028015941378625103" LOG_EFFECT_SIZE="0.25642539795423674" MODIFIED="2008-09-10 12:38:01 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07724194891386747" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="100.00000000000001" Z="1.7669180784003948">
<NAME>Thrombocytopenia - HIV score 1 (CHOP versus Low-dose CHOP).</NAME>
<DICH_DATA CI_END="3.474295367709501" CI_START="0.9375275930494538" EFFECT_SIZE="1.8047846889952153" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" LOG_CI_END="0.5408667372870986" LOG_CI_START="-0.028015941378625103" LOG_EFFECT_SIZE="0.25642539795423674" MODIFIED="2008-09-10 12:38:01 -0700" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.3341645014629216" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="95" TOTAL_2="82" VAR="0.11166591403796293" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3755987920935286" CI_START="0.02035840542932832" DF="0.0" EFFECT_SIZE="0.16734693877551024" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.13849178579831442" LOG_CI_START="-1.6912562410879082" LOG_EFFECT_SIZE="-0.7763822276447969" MODIFIED="2008-09-10 12:39:19 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.09625868446979885" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="41" WEIGHT="100.0" Z="1.6632685835003234">
<NAME>Thrombocytopenia - HIV score 2-3 (Low-dose versus VS).</NAME>
<DICH_DATA CI_END="1.3755987920935286" CI_START="0.02035840542932832" EFFECT_SIZE="0.1673469387755102" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13849178579831442" LOG_CI_START="-1.6912562410879082" LOG_EFFECT_SIZE="-0.7763822276447969" MODIFIED="2008-09-10 12:38:42 -0700" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="1.074803048391776" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="49" TOTAL_2="41" VAR="1.1552015928322548" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.764235505397904" CI_START="1.5992761097086161" DF="0.0" EFFECT_SIZE="2.1025641025641026" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="39" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="0.44157504099510947" LOG_CI_START="0.2039234497193255" LOG_EFFECT_SIZE="0.3227492453572175" MODIFIED="2008-09-10 12:49:34 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0175283352085832E-7" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="5.323565422320699">
<NAME>Leukopenia - HIV score 0 (ACVBP versus CHOP).</NAME>
<DICH_DATA CI_END="2.764235505397904" CI_START="1.5992761097086161" EFFECT_SIZE="2.1025641025641026" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="39" LOG_CI_END="0.44157504099510947" LOG_CI_START="0.2039234497193255" LOG_EFFECT_SIZE="0.3227492453572175" MODIFIED="2008-09-10 12:49:34 -0700" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.139597721109745" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="109" TOTAL_2="109" VAR="0.019487523739034146" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4750881047319466" CI_START="1.156383733490841" DF="0.0" EFFECT_SIZE="1.6917894736842105" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="25" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="0.3935906629535804" LOG_CI_START="0.0631019739491095" LOG_EFFECT_SIZE="0.22834631845134498" MODIFIED="2008-09-10 12:49:54 -0700" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.006760505868183715" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="100.0" Z="2.7084168085455764">
<NAME>Leukopenia - HIV score 1 (CHOP versus Low-dose CHOP).</NAME>
<DICH_DATA CI_END="2.4750881047319466" CI_START="1.156383733490841" EFFECT_SIZE="1.6917894736842105" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="25" LOG_CI_END="0.3935906629535804" LOG_CI_START="0.0631019739491095" LOG_EFFECT_SIZE="0.22834631845134498" MODIFIED="2008-09-10 12:49:54 -0700" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.19413069186662094" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="95" TOTAL_2="82" VAR="0.03768672552461293" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.402700968145865E-31" CI_END="8.13270665887053" CI_START="1.3774011084975588" DF="0.0" EFFECT_SIZE="3.3469387755102042" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" I2="100.0" ID="CMP-003.05.06" LOG_CI_END="0.9102351078797167" LOG_CI_START="0.13906042815865174" LOG_EFFECT_SIZE="0.5246477680191842" MODIFIED="2008-09-10 12:51:00 -0700" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.007657343880025373" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="41" WEIGHT="100.0" Z="2.66681662903886">
<NAME>Leukopenia - HIV score 2-3 (Low-dose CHOP versus VS).</NAME>
<DICH_DATA CI_END="8.13270665887053" CI_START="1.3774011084975588" EFFECT_SIZE="3.3469387755102042" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.9102351078797167" LOG_CI_START="0.13906042815865174" LOG_EFFECT_SIZE="0.5246477680191842" MODIFIED="2008-09-10 12:51:00 -0700" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.452991824244384" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="49" TOTAL_2="41" VAR="0.20520159283225486" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.818415073404825" CI_START="2.0130284916978867" DF="0.0" EFFECT_SIZE="4.666666666666669" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="6" I2="0.0" ID="CMP-003.05.07" LOG_CI_END="1.0341636401335121" LOG_CI_START="0.30384992178363945" LOG_EFFECT_SIZE="0.6690067809585758" MODIFIED="2008-09-10 12:53:26 -0700" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="3.295815939769902E-4" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="3.590865577753567">
<NAME>Infection - HIV score 0 (ACVBP versus CHOP).</NAME>
<DICH_DATA CI_END="10.81841507340482" CI_START="2.0130284916978862" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="6" LOG_CI_END="1.034163640133512" LOG_CI_START="0.30384992178363934" LOG_EFFECT_SIZE="0.6690067809585756" MODIFIED="2008-09-10 12:53:26 -0700" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.4289898932699247" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="109" TOTAL_2="109" VAR="0.18403232852774137" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.417527627276805" CI_START="0.5730680500175331" DF="0.0" EFFECT_SIZE="1.1770334928229664" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" ID="CMP-003.05.08" LOG_CI_END="0.3833714458596134" LOG_CI_START="-0.2417938038749632" LOG_EFFECT_SIZE="0.07078882099232509" MODIFIED="2008-09-10 12:54:07 -0700" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.657142382669509" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="100.0" Z="0.4438619699732696">
<NAME>Infection - HIV score 1 (CHOP versus Low-dose CHOP).</NAME>
<DICH_DATA CI_END="2.417527627276805" CI_START="0.5730680500175331" EFFECT_SIZE="1.1770334928229664" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.3833714458596134" LOG_CI_START="-0.2417938038749632" LOG_EFFECT_SIZE="0.07078882099232509" MODIFIED="2008-09-10 12:54:07 -0700" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.3672251623119859" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="95" TOTAL_2="82" VAR="0.13485431983506438" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.305209391614368" CI_START="0.6225052053598349" DF="0.0" EFFECT_SIZE="1.434402332361516" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-003.05.09" LOG_CI_END="0.519198978115782" LOG_CI_START="-0.20585701266660225" LOG_EFFECT_SIZE="0.15667098272458985" MODIFIED="2008-09-10 12:54:41 -0700" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.3969824126632886" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="41" WEIGHT="100.0" Z="0.8470228160761613">
<NAME>Infection - HIV score 2-3 (Low dose CHOP versus VS).</NAME>
<DICH_DATA CI_END="3.305209391614368" CI_START="0.6225052053598349" EFFECT_SIZE="1.434402332361516" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.519198978115782" LOG_CI_START="-0.20585701266660225" LOG_EFFECT_SIZE="0.15667098272458985" MODIFIED="2008-09-10 12:54:41 -0700" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.42590147807061085" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="49" TOTAL_2="41" VAR="0.18139206902273103" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.862962573113779" CI_START="1.1195735855639828" DF="0.0" EFFECT_SIZE="2.333333333333334" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" I2="0.0" ID="CMP-003.05.10" LOG_CI_END="0.6869009271144021" LOG_CI_START="0.04905264347478682" LOG_EFFECT_SIZE="0.3679767852945945" MODIFIED="2008-09-10 12:54:58 -0700" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.023733297613857198" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="2.261419415315771">
<NAME>Mucositis - HIV score 0 (ACVBP versus CHOP).</NAME>
<DICH_DATA CI_END="4.862962573113778" CI_START="1.1195735855639828" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.686900927114402" LOG_CI_START="0.04905264347478682" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-09-10 12:54:58 -0700" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.37467523920983586" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="109" TOTAL_2="109" VAR="0.1403815348769477" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.69386503623334" CI_START="0.1594194779522506" DF="0.0" EFFECT_SIZE="1.7263157894736842" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.05.11" LOG_CI_END="1.2716991028968319" LOG_CI_START="-0.7974586173791317" LOG_EFFECT_SIZE="0.23712024275885013" MODIFIED="2008-09-10 12:55:20 -0700" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.6532774106116928" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="100.0" Z="0.4492138334923618">
<NAME>Mucositis - HIV score 1 (CHOP - Low dose CHOP).</NAME>
<DICH_DATA CI_END="18.69386503623334" CI_START="0.1594194779522506" EFFECT_SIZE="1.7263157894736842" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2716991028968319" LOG_CI_START="-0.7974586173791317" LOG_EFFECT_SIZE="0.23712024275885013" MODIFIED="2008-09-10 12:55:20 -0700" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.2154334873860053" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="95" TOTAL_2="82" VAR="1.4772785622593068" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.8891116541987" CI_START="0.1251928114412074" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.12" LOG_CI_END="1.8566631169949925" LOG_CI_START="-0.9024206075556676" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2008-09-10 12:55:44 -0700" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.4978585246623114" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="0.6778630653271641">
<NAME>Mucositis - HIV score 2-3 (Low dose CHOP versus VS).</NAME>
<DICH_DATA CI_END="71.8891116541987" CI_START="0.1251928114412074" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8566631169949925" LOG_CI_START="-0.9024206075556676" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-09-10 12:55:44 -0700" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="1.6206994374857624" STUDY_ID="STD-NHL_x002d_HIV_x002d_93-2006" TOTAL_1="49" TOTAL_2="49" VAR="2.6266666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-03-16 09:52:12 -0700" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Modified CHOP plus GM-CSF versus CHOP</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7938216794284925" CI_START="0.5574690123706152" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2537792684241523" LOG_CI_START="-0.2537792684241524" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-03-12 15:06:10 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="9" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Complete response (Per-protocol)</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mCHOP-GM-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHOP</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7938216794284925" CI_START="0.5574690123706152" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.2537792684241523" LOG_CI_START="-0.2537792684241524" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-12 14:54:56 -0700" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.29814239699997197" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="9" VAR="0.0888888888888889" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.978359384943037" CI_START="0.7140629575674211" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.4739771008978899" LOG_CI_START="-0.14626349562055085" LOG_EFFECT_SIZE="0.16385680263866959" METHOD="MH" MODIFIED="2009-03-12 15:00:46 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.30039956597322903" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="1.0355769473858736">
<NAME>Complete response (Intention-to treat analysis)</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.978359384943037" CI_START="0.7140629575674211" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.4739771008978899" LOG_CI_START="-0.14626349562055085" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2009-03-12 15:00:46 -0700" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.3643323966354011" STUDY_ID="STD-Kaplan-1991" TOTAL_1="16" TOTAL_2="14" VAR="0.13273809523809524" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0650522896615193" CI_START="0.5978385668078773" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.314931053001594" LOG_CI_START="-0.22341607188024365" LOG_EFFECT_SIZE="0.04575749056067514" METHOD="MH" MODIFIED="2009-03-13 12:30:24 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7389990148657457" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.33317920492856506">
<NAME>Total death (Per protocol analysis)</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0650522896615193" CI_START="0.5978385668078773" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.314931053001594" LOG_CI_START="-0.22341607188024365" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2009-03-12 15:50:40 -0700" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="0.1" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.978359384943037" CI_START="0.7140629575674211" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.4739771008978899" LOG_CI_START="-0.14626349562055085" LOG_EFFECT_SIZE="0.16385680263866959" METHOD="MH" MODIFIED="2009-03-13 12:30:33 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.30039956597322903" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="1.0355769473858736">
<NAME>Total death (Intention-to treat analysis)</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mCHOP plus GM-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mCHOP</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.978359384943037" CI_START="0.7140629575674211" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.4739771008978899" LOG_CI_START="-0.14626349562055085" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2009-03-13 11:59:55 -0700" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.3643323966354011" STUDY_ID="STD-Kaplan-1991" TOTAL_1="16" TOTAL_2="14" VAR="0.13273809523809524" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9431668215711175" CI_END="2.3496394124987203" CI_START="0.42872606102285327" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0036690939471173" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.37100121836627414" LOG_CI_START="-0.36782011617583377" LOG_EFFECT_SIZE="0.001590551095220165" METHOD="MH" MODIFIED="2009-03-13 12:18:02 -0700" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8159455267639839" P_Q="0.0" P_Z="0.9932668050237231" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="70" WEIGHT="700.0" Z="0.008438908614176038">
<NAME>Cause of Death</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mCHOP plus GM-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mCHOP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6407060987886215" CI_START="0.3391012258982805" DF="0.0" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.5611856213052331" LOG_CI_START="-0.4696706401838829" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2009-03-13 12:14:43 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8618676903062437" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.17399716502144305">
<NAME>Lymphoma</NAME>
<DICH_DATA CI_END="3.6407060987886215" CI_START="0.3391012258982805" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5611856213052331" LOG_CI_START="-0.4696706401838829" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2009-03-13 12:14:43 -0700" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="0.3666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.471986683336928" CI_START="0.046921987889437036" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.9764410788047995" LOG_CI_START="-1.3286235969161622" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-03-13 12:10:01 -0700" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7645922708955076" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.29945582818278177">
<NAME>P carinii pneumonia</NAME>
<DICH_DATA CI_END="9.471986683336928" CI_START="0.046921987889437036" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9764410788047995" LOG_CI_START="-1.3286235969161622" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-03-13 12:10:01 -0700" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="1.35400640077266" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="1.8333333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1236933584781585" CI_START="0.010249903231271793" DF="0.0" EFFECT_SIZE="0.22916666666666663" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="0.7095831303025818" LOG_CI_START="-1.9892802347373062" LOG_EFFECT_SIZE="-0.6398485522173623" MODIFIED="2009-03-13 12:10:55 -0700" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.35271319980965277" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.9293394650140737">
<NAME>Staphylococcus aureus sepsis</NAME>
<DICH_DATA CI_END="5.1236933584781585" CI_START="0.010249903231271793" EFFECT_SIZE="0.22916666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7095831303025818" LOG_CI_START="-1.9892802347373062" LOG_EFFECT_SIZE="-0.6398485522173621" MODIFIED="2009-03-13 12:10:55 -0700" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="64.87500144203905" CI_START="0.1821411327529152" DF="0.0" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.05.04" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.536242706838319" MODIFIED="2009-03-13 12:11:43 -0700" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4100604366971322" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.8237872931848573">
<NAME>Severe wasting syndrome</NAME>
<DICH_DATA CI_END="64.87500144203905" CI_START="0.1821411327529152" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.5362427068383191" MODIFIED="2009-03-13 12:11:42 -0700" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="1.4988632055964644" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="2.246590909090909" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="46.11324022630342" CI_START="0.09224912908144611" DF="0.0" EFFECT_SIZE="2.0624999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.05.05" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.3143939572219626" MODIFIED="2009-03-13 12:12:51 -0700" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6479317695865698" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.4566372948657711">
<NAME>Cytomegalovirus encephalitis</NAME>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2009-03-13 12:12:51 -0700" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1236933584781585" CI_START="0.010249903231271793" DF="0.0" EFFECT_SIZE="0.22916666666666663" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.05.06" LOG_CI_END="0.7095831303025818" LOG_CI_START="-1.9892802347373062" LOG_EFFECT_SIZE="-0.6398485522173623" MODIFIED="2009-03-13 12:16:37 -0700" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.35271319980965277" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.9293394650140737">
<NAME>Suicide</NAME>
<DICH_DATA CI_END="5.1236933584781585" CI_START="0.010249903231271793" EFFECT_SIZE="0.22916666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7095831303025818" LOG_CI_START="-1.9892802347373062" LOG_EFFECT_SIZE="-0.6398485522173621" MODIFIED="2009-03-13 12:16:37 -0700" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="46.11324022630342" CI_START="0.09224912908144611" DF="0.0" EFFECT_SIZE="2.0624999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.05.07" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.3143939572219626" MODIFIED="2009-03-13 12:18:02 -0700" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.6479317695865698" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.4566372948657711">
<NAME>Undetermined</NAME>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2009-03-13 12:18:02 -0700" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Kaplan-1991" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3417303583388644" CI_START="0.9164413856306268" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.5239714040822359" LOG_CI_START="-0.037895306709646984" LOG_EFFECT_SIZE="0.24303804868629442" METHOD="MH" MODIFIED="2009-03-16 09:47:20 -0700" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.08996487896882142" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="10" WEIGHT="100.0" Z="1.6955830026900074">
<NAME>Adverse effects (Toxicity = or &gt; grade ii/ By patients)</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3417303583388644" CI_START="0.9164413856306268" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5239714040822359" LOG_CI_START="-0.037895306709646984" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2009-03-16 09:47:20 -0700" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.3300432872042264" STUDY_ID="STD-Kaplan-1991" TOTAL_1="16" TOTAL_2="10" VAR="0.10892857142857146" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.629486476492626" CI_START="1.1290938281901777" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7230603448275863" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.41987094156904964" LOG_CI_START="0.052730033485695646" LOG_EFFECT_SIZE="0.23630048752737265" METHOD="MH" MODIFIED="2009-03-16 09:52:12 -0700" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.01163724802907632" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="41" WEIGHT="100.0" Z="2.5229574524980873">
<NAME>Adverse effects (Toxicity = or &gt; grade II / By cycles</NAME>
<GROUP_LABEL_1>mCHOP plus GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>CHOP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.629486476492626" CI_START="1.1290938281901777" EFFECT_SIZE="1.7230603448275863" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" LOG_CI_END="0.41987094156904964" LOG_CI_START="0.052730033485695646" LOG_EFFECT_SIZE="0.23630048752737265" MODIFIED="2009-03-16 09:52:12 -0700" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.21566038678496746" STUDY_ID="STD-Kaplan-1991" TOTAL_1="58" TOTAL_2="41" VAR="0.046509402428241774" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-04-06 12:06:13 -0700" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Figure 1a.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-04-06 12:06:13 -0700" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uzda7Ac53nYeX5IJfjg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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 1b.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-04-06 12:06:13 -0700" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uzdbbAc13nYeX5wJfyQ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</FILE>
</FIGURE>
<FIGURE FILENAME="Organigrama chop.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Low dose versus standard-dose m-BACOD for treating HIV-associated Non-Hodgkin's Lymphoma.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uzdfbAl6X3Q9/tPh1PV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</FILE>
</FIGURE>
<FIGURE FILENAME="Organigrama CHOP vs. R-CHOP.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AABqxUlEQVR42uzdW4wfWV7geT/6AdF+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</FILE>
</FIGURE>
<FIGURE FILENAME="ACVBP versus CHOP.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uzdfbAdZ53Yef6L/kgF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</FILE>
</FIGURE>
<FIGURE FILENAME="CHOP versus Low-dose CHOP.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uzdfbBdZ33Ye//V0R+d
opnbPzxz21gz7QRP2hjN5Rbrj2Drn2DN3NrXM7ehmmnT8fQW0Nw2t5qSpE5iKkJSTG+UEYUYBcNF
Ir7JaRMXgR2QwRhhUyJsQwUmsbAFHL9yLGT52Jat4xfIunq2vKTnrLPe91p7r7335zvzm/229np/
eb7r9zzPuiQBAAAAAGABuMQqAAAAAAAQYAAAAAAACDAAAAAAAAQYAAAAAAACDAAAAAAAAQYAAAAA
gAADAAAAAECAAQAAAAAgwAAAAAAAAgwAAAAAAAEGAAAAAIAAAwAAAABAgAEAAAAAIMAAAAAAABBg
AAAAAAAIMAAAAAAABBgAAAAAAAIMAAAAACDAAAAAAAAQYAAAAAAACDAAAAAAAAQYAAAAAAACDAAA
AAAAAQYAAAAAgAADAAAAAECAAQAAAAAgwAAAAAAAAgwAAAAAAAEGAAAAAIAAAwAAAABAgAEAAAAA
IMAAAAAAABBgAAAAAAAIMAAAAAAABBgAAAAAAAI85I1xySVjxa5du5K9e/cmd9xxR/Ltb3+7k2kP
bV3A+rId7Ruw3a132P4ACDAB3hDXXnttcs899xBgF92F4fHHHx/dBLIdZ2/fmPVt55wA6921xfYH
CDCmLMBpLC0tEWCFroUonMz6ci+iAM/LtnNOgPXu2mL7AwQYAxHgEFWZYAKs0DUPhRMCPDv7xrxt
O+cEWO+uLbY/QIAxIAEO1aGff/55AqzQZbkJ8CDWkWPc+rXeMW/b0fYHCDAmfOF85JFHcu9YpnH0
6FGFCPuO5bY8lhWwX4MAAwQY83PhLJLgWepgxkXE+iLABBiwX4MAAyDATriVnDx5cqIn4ZB5Do9e
yhPvUPU6fTRTmK95KkSE5Sla7vSRVCHrXlb1vIrQDunWW28djS8d90033bShTfc462sSy5EljCt0
zpZdrjAfTabT1X4S9uHs/KTzFL4P22EcJrEdJ0nYH7L7S7qfzNu262v5+z6HDplpbLMywmMDs8dn
ev4L3zd5rGCd/Tosfxhv2LZl54Mhr9O8c3h4H74rOoeH78N+nPefceYvjDc9JuN1mh47ba5ffQrw
PGz/MK/xtKrOf7NczgABxowIcJtxtZl2OKFlT7ZVEU5ydQpxbeYnnNiK2j93XXAMF68uOyHLo6w6
e7pcacGs7b7T13KUzUu4yFVNJ1ygmu4bZVG2DxftN2333Wlsx77PBbEoxIW2quWZxW3X5/IP7Rwa
Cs1tnxwQCMPl/T+Md1rHW1NpqLv+627XqvXe5HxQdx+a9HEQrgNV08ouQ51jp+y833QfbDP+Ls5P
i7D9y6YXjqd5KGcUjT9v+cooOr+AAGNGBTicRKsuZmUn+KqTcNP5Kbqo9CG/dS82bQuVTacRLpZd
3jDo67FaTQsrRVX2u5KosvXWpGA37e04KQEOhYVx19MsbLs+l3+I59C8eQjf1aHJfydxvDWh6fas
e/4r+l/IODW52VFnuadxHDQ5h6fTabKu68pP2+MnnJOLjp0+BXhetn+VwGePj1ktZ5SJe90yZVFt
zDBeEGD0IMBFd/XL7lw1nXbbglvdu2hN5qfo4tqH/LYtNKVRpxpS2wtGk+3X93IUdcLWxUWwi/VQ
dIzM2naclAC3KWjlidAsbLs+l3+I59Cic0HVubOocJd3zE7ieGtCnQxmW4EoE68u959pHAdNrxth
Gdqs66rqqePcPCp7KkafAjwP27/Otoxrf8xyOaNsHdetqVC0/EU1ZECACfCYhd+iE23ZHbUm0x63
8FCnV+q681NWMO2jzdO4y1x1V7OrdVu2/SaxHF0uQ3Y7jrsewvKPKx9VhZNJbMdJ1wbp4hifhW3X
5/IP8RxaJLJV7ZmLCppZcZ7ENmtCWR8ZXcxPl/tPkWjP2nHQNKoEo4ubi2EckxTgRdn+81LOKLtR
WbcadF7Gv8tzGQgwAU7Od7ITTpZlVWzKhLDJtIsuPqFaR7bwU9buZ9yMdFlBpo9qc0V387JVtsLd
vaJlruqJu+yiFnfcEF7rFKKntRx1CjjxspTdKc4WVMYtpBRVj0qzFXFmIBTyi9ZBWVW9SWzHaQlw
vI7STkbqVi+bhW3X5/IP7RxaVlCrOsaLOrPJMolt1oSy5jKx9Fedl4rmp+n+U3b8F1WVnPZxkG2n
WnatKFq/Zft12b5Xtr7CcRVn15o+GnISAjwP27/O/M56OaOvGjJt2rmDAC+sAHcRbU8kXRSog3jH
PZmGE3Kbqi3Zu4tFJ82+2ozlFRKbVp0pu/tXVqWpKBtTVTVzGstRtS8XLUtZ1aWmbbbazFvRNIqq
2xWtg0ltx2kIcNGxVVTI7LLZxSS23aSWfwjn0DrHXtPx5+3fk9hmXdTiKZqfogJw021bVvWxSGiK
CuXTPg7yplN1Iy9vfy36T9l8Fd3kL2tXWdSWs83yj1OOm5ftn72ZER9f81bOaCuybcUZBJgAdxhF
7V26FuAuxbNqfooyKG0fQ1K38BRO1OGinT5uoWy9dtUut00mpqoKdJ/LUfafqmUp2q5Nsy1FFIlm
26rpeQWaSW3HSQtwWQGzTPq7mq9JbLtJLf8QzqF1xLBoHRUtb/Y8MqltVpeiwm/Z/KQ3W+vefGiz
/4TxjdvsZ1LHQdF0ypahzX+6FKVA0Q3zpsvf9ribl+1f9zicp3JG3vBV1aDzbgAU3dAAAbYxepDf
sh4P2558ytrfpM+yG7f9bdn8FN3NbdLL8jS3Z1MBqioUl93RnMZyjFPAL1qWpj1CF1F0p71qfy26
C5x3wRzaduxKTMsKPW2ePT7EbTep5Z/2OTSPvPNqUZYj7yZP3jE6qW1Wl6JrR5ed0rQ999XdXkM+
DrrsNKzJOaBOtdKiG5NF5YauBXhetn9fEjfkckbd/g6q1nVftRNBgAlw5iTV5GDrqxOscEJpU5gr
az8z5G7lw4kvnCzLCrhN7hjWqTLT9C5638tRtv3aLktXVUmL5LSqhkTRtPIumEPajl0KcJdVboe6
7Sa1/NM8hxaRl1kqOu7y9vG8682ktlldis5ndeZn3PXe1WOrpn0clC3HtPofqXNsFJ1fu7q5uijb
v6u2+LNUziiaVpMbhJ79S4AxAQFukzmYxGOQwn/C3cu2J+pxHgnSF9kqPuP06DuO/IwrTl0uxySX
ZZo9HDftSXQS23EaYjqp6Uxi201y+ad1Di0jb56y0yqqLj3NbdZnlmlS05hGL8NdHwd9/2fc7TeJ
ac379h+nZsqsljMCebVHmtwgHFoNRRDgmRDgvLtXVQ/6blrVounJYNzn8FVVWWozzrp3Jsft5TGs
26KqdLMkwH0txyIJcJMCCgEe/rab5PJP6xxaRt51JXstycsUN61GOiuPBFsEAe7yOCDA87/9mwrw
PJQzUnmvk20uqv7s2b8EGB0ekGnPoF1IcNsTSZWIt+2Zus9nRY5zAi7rqGiWBLjP5SDABJgAD/cc
WkZe4S3bvCSvMNumIx0CTIAJ8Hxt/3ktZ6TkZXazNyLzqj9Pq4YiCPDcCnDZ3aamd53GPdmld/ma
ZjSKJL2O7LbtCKvtCbisnUpalShMP7RpKXvcxrRP5n0vBwEmwAR4uOfQKvIKeTHZ+Wv7KBUCTIAJ
8PwK8DyVM5rIbR1JBgFGRwdz2TNEx82KtiHt2CAU5oo6BGrbAUN6wil7DnDbzibK1kHROg7z0FUB
tG0HH108QqHL5Sj7T9tl6aqdWtE67pJJbMdFFOBJbLtpCvCkzqFV5HXQlZ4b8vbRssLdpLZZ38fm
kPafIR8Hff+nKKM4C51gLcL2n9dyRkqRqKdlzqKEVJed7IEAE+AMZdXo6vSQ3Oed8XDwl7UBaTI/
4QSanmyadmU/jgC3ufB20clCnWcbN3l8ziSWo+w/VXdCiy6cXRVSitZxlw+nn8R2XEQBnsS2G4oA
93kOrTOtomtI3nWmbP1PapuNe2yWNRfq6jnAXe0/Qz4O+v5PH49BKvrvUAV46OfBeSxnVN2ASKeX
t4959i8BRs8nnLI7g3WqQjeZdjiJhUJAONjrPOC8zTTqdm8/iTv6bbZNm2xekQBVnUDLMkTTWI6y
6VS1hSm6cDZ9VmHTddxlD42T2I6LKMCT2HaTWv5pnkPbFmDzOu2q2qcntc3GPTbLCr5FheWuHs3W
9H9DPg76/k9ZZrGKohpjTduvT/v8MfTz4DyWM6r2wXR6dR8PBwKMjgW4rFpw1Qmh7rSLCulVd86K
qoYUXbia9Ig9icciNa1q0+a5dmXtYIqyh1XPE53GcpRNp+xCXVaVv+judpfruOxCFQpJdbNAk9iO
iyjAk9h2k1j+oZ1DmxTymtZqmNQ2a3KNbHqTuGh7Ne35uqv9Z8jHwST+U1TGKavpVpQ1bfrc1yEI
8NDPg/NYzqgz3aLxggBjAgJcVZAuu7tVd9pl4w8n1mwhIpysw4mh6UWrybpoW+W0CUXzH76Plzm8
r+r8oc2dybSaTZolCq9FVbrKpjWp5aiar7DN4otN2X5VlmWqEs0wjexFt6wqabhoxvMV1nOYt6L1
ViQtfW/HeRbgaW+7vpd/iOfQJue8pm3bJrHNmlB0bIZpxteMMF9lx3FXN+W6vOZN+ziYxH+qrhXZ
61jZNiwTxjbnp0Xf/vNazshSt+d+z/4lwJigAFfdTevioj3Osyvr3hFsMj9Fd0TrdgBWh3GeY9fk
LmNZVaAuenec1HJ0uQxld6mrLp55F6GyO+hdzVvf23EeBHio224Syz+0c2ibQl6dviUmtc2a0MWx
2fXjp7q65k17/5nUf7o4fqpuprQ5Py369p/XckZeNr3OOD37lwBjwgJc9mikLu72dVW4L7s71tVd
4TptOvosNOVdqKtOinUygm3FaVLL0dX8V91BrXOhzdvny6pB1Y2qjjb63I7zIMBD3XaTagM8tHNo
00Jek7ZtkzjemlDV5KDqXFiW+Z7U8TPE42BS/8lrj94k6mT72p6fFnn7z2s5I4+q3vk9+5cAYwoC
XHWBz6sa3ObkO84FqOqE09VDyrvsgr5utZe4gJgnQXVOtm2mNW5Pml0uR9P5bFtIqTO+ops+4xQg
6l4w+9yOsy7AQ912k1z+oZ1D655T29SumcTx1uf5PPsUgmnvP0M8Dib5LNe2Ely3qmvb89Mib/95
LWe0ucHt2b8EGFMS4KrCS1YK20w7jKOsfU2ddlaTuBh0WXiqk9UL6z2tTlM0T3WkvE6WIn6uXpP1
1fdylG2/MM6qgkuTbVbnQlt2p7rqTm52nTSt1tTndpxlAR7qtpvk8g/tHFr3PNH2nDqJ460JacdA
davM1ukkZ9KdJw3pOJikALcRraY1wtqcnxZ5+89zOSPv3D1u/wggwOhJgMuqoWTbb40z7bSThVBA
yDsRh+/DiaZJlbm289Pm+XNNCYWgsDxxG6Fwog3rNLuMRSfJJu3nwkUkO62wnNlCcJtqZH0tR53t
F/aZeNph3wnz02ZbhfnNVlkL4w7jq3OxD8Okj6Qp2n/HKYj3uR1nWYCHuO2m8RzgIZ1D6xz3455P
+z7e2p4/sus+nZcmyzut50gP4TiYhgCn+2k4j6aPFMs7x7YVkqbnp0Xe/vNezshS1E7cs38JMAA3
czwSAAAAzFU5o0iAPfuXAANwYSLAAABgbsoZZVWgQYABuDC5MAAAgLkpZxT1Eu7ZvwQYgAsTAQYA
ADNbzog7vwuZ37JHZHXZ3wwIMAAXJgAAgImWM5r0sA0CDMCFiQADAIC5F+BJ9lwPAgyAAAMAAOWM
qQiwtr8EGAAIMAAAmHsBDs9fBgEGAAIMAABmvpyxd+/eUfveeBrhGcBBfOMOskCAAQAAAAAgwAAA
AAAAEGAAAAAAAAgwAAAAAAAEGAAAAAAAAgwAAAAAAAEGAAAAABBgAAAAAAAIMAAAAAAABHh4vPWt
H18Xk+Suu07Y0wa83e0bs3d8TXObTZIHHniq1jqY9WUBAAAgwHNQYD59+mzysY89MNcFdAJs3yDA
3fPII88mu3cfLl22WVn+OssCAABAgGe8wBwX+hT8CPC87xsEuL/lm3UBXoRMPQAAIMAK6AtSRdN2
t29Yh6SRAAMAAAJMgBX8iJJ9wzokwPZ1AABAgAkwCLB9wzokwAAAAAR4KgXmot9De83bbvvOhe9D
283PfObhZGXlTK3p5EURYVph3HH70A9+8L5RT8FF06tahnvvfezC+MK4wueqZQ69taYdNIUI77M9
uIb5CfMVz2tYT2EZ6jDusgbOnHl1tDzxvIZxxPPadRvgdJrxPhGvp7L5n+a+Me6xUrYfNV2H6b4T
xtNk/TWdXrxfpMdu6HysqayF/Sld9qrjP7vNwvJk56NsuzXZP+qu7+w5LD1WH3romVbrIl6esvXR
dF/PO57jeQ2/j0uYz3i8bdZn3etI3n7Y5PwYHxfohvg4qPq96/MqAIAAD16A4156iyLvETZtJSdP
qLKRLbBVTTsUVrPfxYXevGWOBStP8FIZarpeul7WbEdS2Uhlp0sBjgulVTG0fWOcY6VqP2qyDvPG
lRdZwW66zYKUNZXfPIEpOwcUCWSdc0fRftKlAIf5yN5kyDtO6tywqTo3jLssdY6tMP26Alnn3JNd
7r4EOF62usdpG2lG/ZsKRdu47AYJAIAAz70AVxX26hSi6kpO3cJyVTagahnKMh51l7nuennssdXK
gl3bZQ3jrvP/vHltK8B1pxlHtuA6zX1jnGOlaj/qax0W7UNV0wti2kZ+s+OtutFTJCd1j5G8cXQl
wHWENSu4Zeuizfmw7rI03S/qbssyuQk3BpqI7TgCnN0nquY/vnEX/ofu5bdsG8c3jaaZBc6r9VNW
+yTUkKi7z5QNF8afnW64tjSpMVJ0fSo7p6OcJtvXMjlOHacEuLUA5+0IeVnHsAO2lapANruXnWbY
ybPDFGVYm2SpioYPy5NWNQyvRQJWNVyeJHW1rNltEAos8XjC+6LMV9ttla32mRWfMO911sG09o1x
jpWq/ajNOsxmefP2oTxJqZpeLDlN5bdI/uNtHdZ/vP9lL05xhjv9b7bqbvgu3j/zblyM+xikbLON
7P6anYcqIUyHiccTliuuHl50PmyyX4T/Z7dX9nhuu4+H/5Xtz30KcHwzpWr+4/msqgmBpPJmQlEN
miLiG2hdnE/bUFXrJ+/GW3ojqSpznZ4j84bL1pype5M1e95te2MTxdTdvpbJceo4JcBjCXDRDpS9
k1x0d6bOxTa7M5Zl8LIHWl57uKZVketUo807YPKGy2Zxsuulq2Wtu/7zRHkcAQ4FqVAYDQXxqjt7
XUyv631jnGOlTiGwi+UO8522j80Tx6pxheGz27xptrBOtjE7nfgiVzd7lN1XuhTg+FgM81m2HuP5
LauxUHYzIj4m847HJvtFmciMmxWtevZ2nwIcb++q+Y/ns86xXNV2uux/2bb4YRxVVa7TjEf2hmjZ
/7LHVDrN7Lklnae4zX343Dbrnz2HNt3GTfe1Ljp8S+czTDvcYMpe/9J1kz2/pDffsv11ZCkarmq6
6TbLuxZVTTvdrtq0t6fu9rVMk8FxSoDnVoCL7n50KTnxnf6qOy5ZwczbgZvewak7fNvh+ljWbMGr
rICXrQrbRSdYkxDBPvaNcZahzp3ANss9TtvGvOllC7htxl9X/ONMb1EtkHEKy+MIcLzv1JGZouVo
si7HWZYmbb/bEh8jdWpm9LGs8Y2qovUZn7PqZEXqVHXPK8hU/a9o369qklFn3RbVfqiapzYZiex8
1d3G8bZqMt1xryNpTYGymivpMZs9XtN5rprf9BoaD1dnuvENs+x1N2+cZesHzam7fS1T/zhOCfBc
C3DT7FObYZrckc6Os047zKr2S3XFr+66KRtfV8uardpctp267gSr6IZIOJnkZWCGtG+Mc6z01Stz
3KN007Z2eQX2LkSq7nLH+1ZZdjQmjC9cFNOaBH0JcLyemyxzdjma1CoYZ1my2y7uEbyrDqDiGxZF
N4j6FuD4ZkPRPlOWkS8rJGULO9kmBdllrtOmOzv9Op3x1b025c1z1Ty1yfxnM9p1t3Gd/aVrAY5v
rte5dmfXR7r+qo7VdB+LmzDVrTGT7sPZbZwdZ5P5zpIuR9E5NG/62VoJaU2iqnmImybE275OrYiy
+SzaFnXH3WScVdsrPm7z1kvecsT7RB0xq3P+TZc7bkpTdH2pM99t12uTfcVxSoAXUoDHLey3GaZJ
VFU1bCpNTQS4zXBdLWsfy9hknOHEE062dQuDQ9g3ms5nmxsCXXWCVVWVsu4y1ZXScQqwVcOGwn3Y
T+rIRpcCPM6+08e6qBpPXtX1PCGuaodeJ9NQVmgZd33VWdayKvJxs4e6hY+y6vpxgSk+HrLt1NP5
yEpz/J9s05O46l1aBbtuB4BhGnlikPd7eC2S/D6P72n0Bp2uwzbtjsfpWKfpdIvOFVXTTm901X1K
RN5xmh4/8b5edi3ONgGJBTq+8ZbOU1nHh/GNkHR9511nirZF3XGPu33rrpey9R3XRMnr6LXJ9bWo
1kiczWwz323Wa5N9xXE6nf4PCDABHrvwNU8CHI9rWgLc5NE2Q9s3hiLAaUG6bm/jddsUti1U9CXA
dZeRAK8vGFR17JHuF20kKBbPorvnkxDgWPSyBYy4QF53383rlLHqBlJZVey0HX4obMXrKd42RfMW
z3/T6vTxPJX1b9Fl7ZaqG53j3kxre5OmTXXQpj2px+uxTDjrFKzLOutJf4/3n6rsVVrQz+4nqZTF
x026z4Vpx+stPp/Ew6fHX9im4Xpe9BSPPBmMxaGoemu8LYqeulE17rLtW3f/T5c9ex2NO+tM10u6
TuLzatq7cLYfgXS5656f0n0r23dKfB6Ml6nJfDddr033Fcfp2WTeIcAEmABXDFPUNi29QISTeTix
ddk+fF4FOL5A1bmhULe9ebZtYZM7ul1KX161+zSrFfaVULhLO/iahABPQha6EOC4MBL2jSoZblr4
aHP+6kOAy7Z7m47syrIfRTLcZv+oM2/Zfb/J/8ep+TSNfbrPMkob6j5fPe8mRtt9oc2069TuSeUl
r9p+fE5PC/RlfTAUSVDRfpRe56v6dUiPuzwRLOpoqO64y7ZvHfFM10tRO9H49yKpTWUwLd9kBbUO
2elkSa//6fibzneT9dpmX3Gczj8EeIoC3LSdZ9cSMkkB7mpZs+Mpu0vVVRvgbGE8zEPdLNIQ9o0h
CnBMONlme6Ot6v26aLi83mnbrquyfSuuIhnPYzz9sv2kC2ksGqar55hOQ4Dz1nOeEDfNyo37WKku
lzUvmzpOp2p5bajLHgU2rgC3Ga7LG34EeCN1s1J5wzWZbl4msupmVXrjr+5NnTxZyRPOOjVGssuW
la68acc9kBcNV5aNK9oWdcc9zvaN10udR2DG5aR0m6bbOLymEpwV46rjts58ZJep6Xw3Wa9t9hXH
KQEmwD1KTpOefmddgLta1ux4yk6WeXe8+tw3ptVD+KSPlTb/CesmFt2ik2xeFaE604sL+NlsfRMJ
bLNvFRUI6lyg+hDg+EI3TjueSQlw3cf+lGUYZ0mA45snqcjHNy3aHOtp5ryoVkV8k2YSGeCyfgiq
9oFJndvmSYDrdqyTN1yT6abXpVgy6nas03RdpIX3ova2dZuZ5PUhUjWvRW3S66yzqm1RNe5xtm+d
YfPaocbrN+2kMZ3X9H2aKY6vp2USWdZJWHwzIp3PNvNdd7222VccpwSYAPcowE2e9TrrAtzVstZ9
DnBRxzpd7BtFJ5C8TMxQ9o1pC3A2u1vWS/O46zD7+Ksm2cI6+1a2SnzeXdoqUcjum10KW/YYKavO
VPcxSH0KcF5nNFU3mPp4PuukBDh7PMTL31V707xn9WYLnk3aAMdtdMdtA5xHnUdEzbsAp/tE2Q2Q
9LoQXw/qdqxTNFy67qvWe3xNyhbMu+4xNl7vRfPXdNukN2jqXkvjTuHiTFreNsje2KyzLfLG3Ub8
mgpaKorxMZrOS7ofptfndNj0xmqba2kTCW8633XXa5fHseOUABPgBne047tm2UJxtle6uIv4+MSd
Zs7SR4PUaUc1JAHuclmzMhU+xyej8L7ojl+b+c5mVbKdZ4TpFfUuOJR9Y9oCnJWyVILjeQ3Lki20
lz3Kosm+VrfjpLx2xfG+le3gKlsIyj6KId5PwrKGi3jevlmUYSi74DW54RD32hvvN2W1DPoQ4Lxl
yd7sCftAtup4mLesNDYhPobrNF/oW4DznlHepuO2eJ2UXRPigs+0e4GuWh9hnuJ9Mf6ty5vEdWRp
kr1Ax530VO3H2etdnfksGi7dtmVyE9+0i/fRqo512hJXMS7a7un8FB3PYXnqdlxVp3yQ3R/zzkHp
8VhXvprUFqq7jsvWS7wd42M03ffSdZT+N13/6Tw06YCw7LyUJ6lN57vJem26rzhOCTABHkMQiurb
Z0++dR4Bkhd5J9+hC3BXy1rUKVVedZYuBDhP3upG3gl3GvvGtAU4T0rrbL82z5zOW3dtHitT1UlX
XmcdTTu5KKqmndceuuw5vWUXwi7OJ+OIRZ1ladJGq03nZvH463Ss1rcA5+3DbTIU8bkp2+Y8ltKi
Z3826UW9bi/4ZYJRtox15qnLZkJ1CqFN22R39Rzg7E2gsJ3T4yi7Let2kFQ2XLptszdZszft2k67
7c2AdJnzmrGkw2RvNMbrKha2Ossf1nt8bkllN+8xYvG6yN6gi6fRZNxNt1vZustbL+l2zIpQOo3w
n3h+YnFqmj1Mz7lxdeSwTxfVJmk6303Wa9N9xXFKgAnwGIX9ou7O8+5kNn3ETlH10aELcJfLWlXA
T+WkqyrJZb2txifDrADlZbymsW8MQYDjC1Gd5/jW7UCqziNn6t4YyN68KNrH4sxZ3Rsc2Uc8xQWm
7MW3aH9rUtgO858nn3VvmHQlwHWWpe4Nkqr9oqpQUVYImLQAZ4+Ftjeuqo6poqqaZefPonmpOhcV
yWLdR6T1eWOvyfaps790LcBt18E4Hes0uc7kXVvSc13XfVQUPSanyU2T7PyWdVyVrYVSduOlaBul
Pf1nh28y7nFuHNe9cZ63PuN5jNdbXIZqevwVLXeYt7xqxE3nu+l6bbKvOE4JMAEes7AfdrZslbKy
k0ja615eFd/0eWxlmY9ZEOCuljUuXGerncZVa7sS4PSEmz4fL7tN04tqVrqLLt6T3jeGIsDpegzL
kj2Rh2Wp8xzTJtPLTqOqQ6zsOMM6jQUjjK9OgTgsQ7bgkn2mYnwjJE9S0g5IioZpUt02vYNftN/2
KcB1liVeJ2lbs+zjxsZpGxoXloqOyUkLcLYAN06P3Xltfqv21XTfjveLOus5nVb8v6rjtu56Secp
3v7jbvs28xEfu2070RtnX81bv0XzMU7HOnnnirzrUtG0++pYp6gdY9ENoHh/KVpXVcufNgups97j
bFt8nBWtjybjbiL5VTcemxxHRbXWxnkubPz83rAcYR2k/QwUbYsm8910vdbdVxynBBgAFopJd3yD
yTGpnoYxP+cBncYAAAEGAAKMmSTO5PfZ0zBmm7h6YxfVrgEABBgACDAmTtw8YZKPFcNsEVd/blPt
EwBAgAGAAGNwcjNOm1vMJ3XaigMACDAAEGAQHMw8bpAAAAEGAAIMAAAAAgwAAAAAAAEGAAAAAIAA
AwAAAABAgAEAAAAAIMAAAAAAABBgAAAAAAAIMAAAAACAAAMAAAAAQIABAAAAACDAAAAAAAAQYAAA
AAAACDAAAAAAAAQYAAAAAAACDAAAAAAAAQYAAAAAgAADAAAAAAgwAAAAAAAEGAAAAAAAAgwAAAAA
AAEGAAAAAIAAAwAAAABAgAEAAAAAIMAAAAAAABBgAAAAAAAIMAAAAACAAAMAAAAAQIABAAAAACDA
AAAAAAAQYAAAAAAACDAAAAAAAAQYAAAAAAACDAAAAAAAAQYAAAAAgAADAAAAAAgwAAAAAORzww03
JNu3b0/27duXrK2tWSEgwAAAAADmk+Xl5eTIkSPJ7t27k8svvzw5fvy4lQICDAAAAGD+ZXjbtm3J
sWPHrAwQYABocyEFAACzw8rKyigTvLq6amWAAKds/QdXJJdccokQYooRjsOhs2fPnmTLli3JgQMH
nJkBAJgRlpaWkp07d1oRIMAXJnCu8J18/JtCiCnG6DicAQFOhZ0IAwAwO1x66aWjbDBAgAmwEAS4
hQB3KcKhx0oAANAfN954Y3LzzTdbESDABFiIAQnwaz8ZL16NXgvi6quu7qUK95bLLkuOf+cvk5XH
n0ySV14vjrU4XhvFaNnfeD9WnI1eu4yXXx0vXopei+JMFKPvXsmPMy3ixeh1XawVRGa4F96IDd+v
1Y/nq+JsjXhj2NWz7eO56HVdvJyJs/lx+uXzkQ53OnptGs8WxUsFkRnu1EvjxY8zUfR9UZw8cz5+
/EacjF7HjWeaxIvnYyV6Hb2Phll5sZv4UQfxdBovZOLFnHghP56Kouj7PuPJnuOJ5yvihSie7yYe
j6Lo+2lFR4R+PMJNa4AAE2AhFkqAR9PJ++2VKDb8/voo9tz0vlz5vf66/z05dv83kyNfvifZ+c5/
mhz609sJMAEmwASYABNgAjwgAQ7s2LEjOXz4MLsCASbAQhDgNgKciu/o93NyGwQ4ZIAvf/Obk9Vn
ThFgAkyACTABJsAEeEACHJoyhQAIMAEWggA3EOCR+D5wUXzT1+VHvz96PfCJ/ze54Zf/BQEmwASY
ABNgAkyAByTAoc8O/W6AABNgIQhwTQE+fOefXxTfV1/fIMAHP3XggujueMc1yeE7/pwAE2ACTIAJ
MAEmwAMR4CNHjiTbt29nVyDABFgIAlxHgHMjJwMcIlSFDh1jrT1/hgA3FODR+mgowEe/ct8oCDAB
JsAEmAAT4CJ0hAUCTIALRaSPddLXeGdxXupMv8957GPc445zHgQ4zgCH2P/RW5Jd73r3YAQ4rwOv
su+zvw1VgE/+8Mnknj+/K9n7Hz+U3PrRjxFgAkyACTABJsC5rK2tJZs2bWJXIMCzJsC5hVUCTIDH
mHbZ/lQ0H02GXcQMcBrbr7o6OfKlLw8uA5wnwIXDvPzqeBLcQIDPy2+7KtB3/Ol/S5YO/BEBJsAE
mAATYAJcXu4HCPAlM52d7VqUCPD8ZuLLxtlEdNt8v4gZ4BDh2cBb3/KWi1WhByDAZVnevO+rBHjD
/7PDRwK8YdgSAd447MXv8qpA3/Trv6EKNAEmwASYABNgAgwCPC8CXEc46gpyWRa56fBF89BmmLoZ
7rrz3/e8VI2nSVY1b1pNtwMBHl4GOMTNv/Mfkxt/7dcHK8CVmeGaAlz4/qVXN3zOE+DzYvvqBgHO
im9WgoP8hs+hCnQIAkyACTABJsAEmACDAM+xADfNENcVuTbjLPtfk2Gazn+RJI4zL3XWb13p7Wu5
m8hm3fXWZLm7zF7PawY4jZAFHj0zeMoCXCa/0xTgC/LbQoD1Ak2ACTABJsAEmACDABPgzuSlKznr
epgmmcy2MlmVlW06HgK8mBngEEF+Q6/QoU1wNqYtwLnVngkwASbABJgAE2ACDBDgWWgT2qZK9CwJ
cJtOm4Yyv12Jf5tq0ONKa5NpygDnR2gPfOSLX47i7lFMuhfoqh6iC78v6OSqrgAXtQFeJ78EmAAT
YAJMgAkwAQYBJsBN2lwuggA3rco8TwLc1w0UAtxvBthzgNf3+lxHgJv2Ak2ACTABJsAEmAATYBDg
ORLgthnSpuOYJQGetYx1089DqQI9Ti0EGWACXJQBLnoOMAEmwASYABNgAkyAQYAJcOtekpuOY5xe
oMetmtx2WpOclz4EOG+bTbIX6Lrj7PP5xTLAi5UBLnoOMAEmwASYABNgAkyAQYAJ8OCfdesZv/YJ
AiwDTIAJMAEmwASYABNggAAvhAQSYPvGuOOWASbABJgAE2ACTIAJMAEGCDABJsAzsY666KRrUTPA
4fFIBJgAE2ACTIAJMAEmwAABFmKBpHxRM8CdBQEmwASYABNgAkyACTAIMAEWggCHOPbAt0bTCa9D
ygATYAJMgAkwASbABJgAAwRYCALciQCvnnw22fGOa9b1dL3tyiuT4w/9pQwwASbABJgAE2ACTIAB
AiyEmB8B3n7V1bmPkNpy2ZZk7YWXZIAJMAEmwASYABNgAgwQYCHE7Avw0fu+Xvg85xD7P3qLDDAB
JsAEmAATYAJMgAECLISYfQEOglsmwLve/R4ZYAJMgAkwASbABJgAAwRYCDH7Anz4zs+XCvC+vb8v
A0yACTABJsAEmAATYGBxBHjz33pTaQFZCNF/hOOwD9bW1pItW7bkTnPTpk3J8vJyZ9M6ePCgMzYA
AEMWCwIMAgxg3jly5EiyefPmDfK7tLTU6XS6lGkAAECAQYABoBUrKyvJnj17kp07d45ejx8/3vk0
ZIABACDAAAEGsBDIAAMAQIABAgxgIZABBgCAAAMEGMBCIAMMAAABBggwgIVABhgAAAIMEGAAC4EM
MAAABBggwAAWAhlgAAAIMECAASwEMsAAABBggAADWAjBlQEGAIAAAwQYwFywZ8+eZMuWLcmBAwda
CTIAACDAAAEGMDMCHC6cIfJEWAYYAAACDAxegLde8Q8uFGqFENOJrT//c0ny+qvn4ychXtkYr1fF
WvSaH3ve91sXP7/WLMJ/s/O95bLLkgOf/Pi5388myye+N3pNXg3xcvRaFi/lRJ1h0jgTvUbxSvRa
K15cH2tF8cL5yA7/yosXv0+HuRDPR69RnK0bqzXjuej1XLxcFadbxLMX46WyOBW91ogzcfz43HcF
cSYbJ6PXGvFi9PriMzVjpWb86OLrCz+6+Fo7nm4Wzz9VM56MXuvEE1Gc+7yaxhMXI/199fGLr7Xj
sSjyvsvEc3mxPEb8MIqi79+I0z/oKL4/Rpx4I869fzaNExfjdEFcGObR6LWreCSKou8bxqnvRfFI
FN/rII4PKB6Oos4wDxNgEODe7gR98+NCiCnG6DicgAD3JfBBhH/3Ax8454jPjS3AN/yLf06ACTAB
JsAEmAATYAIMAkyAhSDA4wtwlxngENdfd21y7MFvJIdu/9PR+7UXnhtLgEfzSIAJMAEmwASYABNg
AgwCTICFIMBDEeBUfEfVns/FwU99Kjl85+fekODTBJgAE2ACTIAJMAEmwAABFkLMtgBnxTeNtA3w
RQl+jgATYAJMgAkwASbABBggwEKI2RPgILZ54htngNNOsJZuO5jsfOcvEWACTIAJMAEmwASYAAME
WAgxewJ8Ps4WRrYX6AOf+HhOh1YEmAATYAJMgAkwASbAAAEWggDPuADHGeC0E6xqCSbAeTFaBw0F
+OhXv3Qu7ibABJgAE2ACTIAJMAgwARaCAE86A1wvEzwcAc7r4ToV3/XfDU+ATz7+aHLPFz6b7L35
d5Jbb/kwASbABJgAE2ACTIBBgAmw6FvgqvalOsOMM/w0xzvuOOc1A5xKbLEED0+AsxngWIbXDdOT
AK+X32ZVoO+4fSlZ+vQnCTABJsAEmAATYAIMAkyAhyWKGzJNBHhqolq2LYrmocmwi54BLpfg4WaA
mwjwxv++EL1fL8Abhi0R4I3Drq57n60CfdONv6oKNAEmwASYABNgAgwCTICHLYrzIMGzsAxl89hE
dNt8v+gZ4DT2f/Q/J1vfckWy/aq3F8YQ2gDnSm8NAV7/3xfWV5uO5Hfd+5Lsb5H4ZiU4tP0Nn0MV
6BAEmAATYAJMgAkwAQYBJsCDlrCq75tkKOtkOcv+k/29zjTy/j/ufLWZBgEebgY4jaP3HUmO3H3X
G3F4QyyqABdlg+sIsF6gCTABJsAEmAATYBBgAjzzAtxUPLsYpo6IVv2/7ny0FfGqcbTJUDeR43HG
tegZ4KG3ASbABJgAE2ACTIAJMECAxYAFuEoax5HkvkW8qUiOU32cAA8nAzzkxyDltQGu0wt0XQEu
agOcJ78EmAATYAJMgAkwAQYBJsAEuEZV6a4ElgDX6yiLAM9HBnjSzwGuI8BNe4EmwASYABNgAkyA
CTAIMAGWASbABFgGeDACXNYDNAEmwASYABNgAkyAQYAJ8ML2Aj2NNsBNRLQPAR63M66+BLjLackA
ywCXPQeYABNgAkyACTABJsAgwAR4YZ8DPI1eoKvmo24nWn32At1GNuv2tD3JZx3LABNgAkyACTAB
JsAEeFICvGnTpmRtbY1hgQATU7HI1c+HMA0ZYAJMgAkwASbABJgA9y3Al19+eXL8+HGGBQJMjgQJ
nu64JyHAx755/2g64XXIGeAtl11GgAkwASbABJgAE+AeBHjHjh3J4cOHGRYIMDESJHi64+xTgFdP
PZPsuOYd66p5b7vybcnx7357kBngesMQYAJMgAkwASbABLgpu3btSvbv38+wQIBJkRDTl/K+BHj7
1VfltrUOmda1F1cHlwEmwASYABNgAkyACXA/AnzzzTcnN954I8MCASYgQsynAB/97/cWdlAWYv8f
fEQGmAATYAJMgAkwAV4QAT5w4EByww03MCwQYAIixHwK8P5bPlIqwLve/S4ZYAJMgAkwASbABHhB
BHhlZSXZsmWLnqBBgAmIEAMQ4B4IHV2UCfC+ffs6m9bBgwedsQEAGDg7d+5MlpaWrAgQYCHE/Alw
uMMb7vTmyW94FuDy8nJn0+pyXAAAoB+OHDmSbN++3YoAARZCzJ8Apxe6zZs3b5Dfru/+ygADADAb
dPU84Lwb7Nnfyv7XZHxlw/RZjsIcCvDmN/2t0iqSQoj+IxyHfRLa/OzZs2dU7Sm8dnHRyyIDDADA
bHDo0KHk+uuv70R+i75rKsBdfwcCDAC9IgMMAMDsEHqDbvtM4KrsbFMBHndYAkyAAWDiyAADADA7
hH5CggS36RCzjnASYBBgAHMtuDLAAADMHrt37x61CQ5NpELV6K4FuCwIMAgwgMESLoyhR+kDBw60
EmQAADA8gvQGAQ49QwcZ7lqA20pt1bA6wSLAANC7AKcXmTwRlgEGAGC2CNfy0BlW05vYQ2sDDAI8
p/x19DpP8dMpxk+mFK/3FK9Fr0OIV8eIV1rEWvSaH3v2/Fbp71X/zd5t/Tt/538+d/H8+Lnfz567
eH5v9Ho+Xo5ey+KlnKgzTBpnotdx4sWa8cIbUfRbPEwaz0evbWI1OXLk8Oi1PJ6LXuvE6RbxbM04
Fb02jR83iJPRa9N4pmas1IwfRa9t4umG8VTNeDJ6rRNPRFH0fRqPR69147Eo8r6rE8tjxA+jKPo+
jR90FN8fI068EXnf1YlHo9eu4pEoir5vGt+Louj7tnF8QPFwFHWGebjXknXoACs8HaK1pAyoF2gQ
YAJMgAkwAc6Nvh7jtGXLZcnNN//HTgT40KH/MgoCfFGADx78JAEmwASYABNgAtwZ4XGIW7duHXWE
NZaoTPE5wCDABJgAE2ACXEuAu8wAh7j88p9NrrnmF5Pvfe87nQjwnj2/OQoCfFGAl5e/S4AJMAEm
wASYAHfGjh07ksOHD9MLEGACTIAJMAGuK8DXX39tcuzYN0aiu7T06eTv/b2/d07UjhNgGWACTIAJ
MAEmwAMW4NDeN/TlASy0AG/d+g96qxophKgfW7f+3OAFOBbfOD7/+UPn5v+K5OjRrxJgGWACTIAJ
MAEmwAMV4BtvvDG5+eabWRYWW4DPF4o/LoSYcpw/FocpwIcPfy5XfNM4ePBTyerqSrJ9+1XJ/v3/
mQDLABNgAkyACTABHpgAhza/Ifu7srLCskCAyYcQBLg6zhZG2gv02tpzya5d/yrZvfvfEOAxBfj8
9mqWAT569EujIMAEmAATYAJMgLOEdr+h/S9AgAmwEAR4TAEOGeC4E6x9+/6fZPv2tyerqz+aCQG+
2KtkuQAXD9efANfNAJ88+Whyzz2fTfbu/Z3k1ls/TIAJMAEmwASYAK9j3759ye7duxkWCDABFoIA
d5UBjjvBOnLkrmTbtrclx48fG7QAr3/cQrEAlw/XrQCfn0a7NsB33PEnydLSJwkwASbABJgAE+B1
BPkNEgwQYAIsBAHuOAOcvgb5DRJ8443vvSC3ZXH11W9P/u2//deDywCf/608A7zx2YXx8BsFd/2w
xQK8cdjVde+zVaBvuulXE1WgCTABJsAEmABnuf7665NDhw4xLBBgAiwEAe4jA5xKbKgGffPNH6gt
wO95z/85KAG++H09Ac6Kb1Zyy35bL7/Pb5DdYgl+7pz83j36HKpAhyDABJgAE2ACTIBjtm3bdu5a
cZRhgQATYCEIcF8Z4FnpBKtKgPOiDwHemA2uL8B6gSbABJgAE2ACXMall16qB2gQYAIsBAHuOwM8
iwJcLbn9ZIAJMAEmwASYABPgvgT4/DVjfM6ceTV561s/PvZ4uhgHCDABXnB5muS27Gp6k57vPqc7
7jhlgKffCVYqt30KcFEb4Ly2wASYABNgAkyACfDQBPiRR57dIK8rK2eSD37wvmT37sOj19Onz46+
D68f+9gD634P/08FOB1X+l36+bbbvsMECTABJrbl3w9dgOsux7TmfaOQtJv3cZZHBnjxngNcR4Cb
9gJNgAkwASbABJgA9ynAd911YoMAB7kNkhuEN7wPw6TDBqnN/p4KcHgfMsrpd0GW0/+CABNgAjyI
zOmsZXqbzEfTdd31tpEBXhwBLusBOivAdZ8DTIAJMAEmwASYAE9CgIOsZgU4+zlkemOxzavuHL6L
I80YxxlkEGACTIBrZ4Djz0WZzbzMZ9U4mmRR86Y/ifkmwDLAs5IBrg4ZYAJMgAkwASbAwxLgrLTm
ZYDvvfexUTXmNJtblAEOopwV5/Df7PcgwAR4wSW4TtXbprJZJaBtxjWOyI8z322z0E3keJxxyQAT
4CYCLANMgAkwASbABHhIApyX0X3ssdWRtKZtfNOOstJMbvb3dBxpm99UlB966Jl1bYJBgAkwAW4s
wH1JXB1x7aotMwGWAZYBJsAEmAATYAJMgIcjwHWQxQUBFp1IcN8iOU514S46kmqa3W5SDXpcae1y
WjLA+XK7b99/GgUBlgEmwASYABNgAjzbAvyZzzycAARYzLUAN6nG3Od8E+CNcezY/aPxh9chZ4Dr
DSMDTIAJMAEmwASYAA9dgAECLJK+OsTqqypxWwFuIq2zUgW6qdgORYBXV59Jdux4xzpx37btbcnx
498eZAaYAMsAE2ACTIAJMAEmwCDABFj0IsBNO7pqWi25TWa4i/kep1ftSUryJAR4+/arctfVli2X
JWtrqzLAMsAEmAATYAJMgAkwQICFWMSbCNOeRtcCfPTovaXtpffv/4gMsAwwASbABJgAE2ACDBBg
IUjw5MfdtQAHwS0T4F273iUDLANMgAkwASbABJgAAwRYCBI8+XF2LcCHD3+uVID37fs9GWAZYAJM
gAkwASbABBggwEKI6Uh5lwIc2viGtr558rtp06Y3srYywDLABJgAE2ACTIAJcH3e+taPr4suuPfe
xy6ML7zvYh6b8sgjzyYf/OB9o+cXhwifU8L3XU7vrrtOrBs/CLAQBLijTrCOHPlisnnzmzbI79LS
HyV6gZYBJsAEmAATYAJMgMeVy/Rz+hrELryPBS98/tjHHkhOnz47+hxew+cs4fsgn/H/VlbOrHvN
m0b2czr8bbd9Z93v6ecs6bBh2mEeQqTTCrKaJ7hhnGH49PdY4tPxxMuanYfwGqYLAizEggtw96ys
rCR79uxJdu7cOXo9fvx459NYXl52xu4J6xYAMDQBjiNkR9PsaSC8njnz6rqsaSqnQRZTqcxmQFNB
jDPAQRIfeOCpC9+n8pidRvZzOl+pYAYBTaedx2c+83Dy2GOr60Q8luU8AU7HH4t5PHx2WbPzEKYX
pgsCLAQBnkEOHjzojG3dAgAWRIBjUklNhTGvenT6PmRGs3IcE36L/xcEMYw3zSCnwpidRt7nuBpz
ENowzTQrW7VMWVnOE+Ds8gWhDfMappNOP17WvHnoqgo5ASbAQhDgCSNLad0CABZXgIOcpgIcV2HO
/ifN4mYFM/5P/D6IdfgcxDeMI3zOm0b2cxj2oYeeuTCd8HuYdt68xfMXhDmvmnSdDHAqwSHijHXZ
PBBgAiwEAZ5RZCmtWwDA4ghwHGnb17TqclqVOZbcVPTSDG82E5u2p812PhUkNhXfVGrzppH9HN7H
2dd0PEUdT6VVoMP0yzLYMenwaRvgVNLT9ZFd1uw8qAI9RQHevPlvlT4qRQgxmQjH4qwiS2ndAgAW
Q4DHpSgLO03iDrMmtaw6wZqiAAPAuMhSWrcAAAJch6FmPUOWuayjrC6XNUwnzWaDAAOYQWQp++H1
119PnnzySSsCADA3AgwQYAAzjyxlP5w5cya5/fbbrQgAAAEGAQaAoSAD3A8ywAAAAgwCDAADQwa4
H2SAAQAEGAQYAAaGDHA/yAADAAgwCDAADAwZ4H6QAQYAEGAQYAAYGDLA/SADDAAgwCDAADAwZID7
QQYYAECAQYABYGDIAPeDDDAAgACDAAPAwJAB7gcZYAAAAQYBRi3+eijx12Xx153GTwcYP4lex46f
lsVPo9efJq8PJX4SvdaM137yk07j1ZbxSoN49Ac/aDT8KF7Pj7XCeH1dnI1eC+O16LV2vHYhXs6L
c+MbxWvRa4146dx/8+KvTpy4+PnV9fH8y2eTR3+4vOH7EGei1zOvvhq91o3z/31xXby6Pl4pjhei
1/XxSvSajY3DP18Wa3G8cj7OjWf1jXg+J1aj19W16LVGPBfF+u/XyuPs2vn/nX0lOX324uvpc99f
fD0Xa/nx7NmLcTqKZ1vF2ej1Ypx6+fz3p17OibNpnF0fL+fHj9+IvO/GjZN146WXL76WRfSfZ9J4
KRsv146VKIp+zw7XSZzJiXPf/+hCvFQQ0TBn6sRLpfF0FHWGGVI8NY14sSBq/p8AgwCDABNgAjxQ
Af7UgQMEuKUA/+b73pdcdtllyR9+8pMbJPfkc88l/+VP/5QAE2ACTIAJMAEmwCDAIMAEmADLAM+H
AIdCSYiRCH/ikzLABJgAE2ACTIAJMAgwCDABJsDjCPBN/+E/yAAPXICzIiwDTIAJMAEmwASYAIMA
d8zPX/GWDYUvIcTk4x9ecUWvAmwdz178zDkRvvMLh9dlhSctwH/yp382CgJMgAkwASbABBiYCwEO
B8Pdjz0phJhyhGOxbwGWAZ6NDHCIa6+7Lrnn3ntHGeD3/tqvJz/75jcnh+68c+IC/Bs33TQKAkyA
CTABJsAEGCDAQggCrA1wpwIcxPcvHnhwQxvg//HQd5NffMc1o99/8MQTBJgAE2ACTIAJMAEGASbA
QhBgGeDZFOBYfMt6gV76s9tHbYR/46b3Jc++8CIBJsAEmAATYAJMgEGACbAQBFgGeDYEOFRr/osH
H2z0HOAgvkGAQ7XoIMQEmAATYAJMgAkwAQYBJsBCEGAZ4MEL8Lpo+Bzgv3r0RPKPr7su+cV3vCP5
1kPfJcAEmAATYAJMgAkwCDABFoIAywDPpgDXfQ7wZ+68M7niLW9J/t2v/Vry1MmTBLgHAQ7HT1MB
/uJX7z0X9xFgAkyACTABBgiwEEIGmACPmwGOO8E69cKLyW//7u+OqkUfuO22uRHguIOwWIDXfT9A
AX7k8SeTz37hcPKBmz+U7LvlFgJMgAkwASbAAAEWQsgAE+AuMsBxG+DvP/FE8k/e+c7kH115ZfL1
Bx6YaQG+KL7rM8Cx+GYluA8BLpXfiirQf3z7f0s+8ek/IsAEmAATYAIMEGDRp0g13a5t/jOry9rX
tMedFxlgAjxOBjjbCdZX7rtvVC36X//KrxRUi54dAc5mgOsIcPa/qcim77OCG0eZAG8c9uJ3eVWg
33vjb6gCTYAJMAEmwAABXhwJzQYBnsxyTmLd5413nGnJABPgLjLA2fjQ3r3Jz1x2WfL2q67KxNU5
cdWGCP/9l+9619QzwEXSWyXAcXXpPAnO++25kuxvvvhefJ8KcGj7Gz6HKtAhCDABJsAEmAADBHjh
srCTksxZzeZ2Lb99r5OicbadlgwwAe4yAxxHyAB/4e67c+PzZfGlu5N/9su/PIgq0NMQ4PT7NgKs
F2gCTIAJMAEGCDABrviu7PeyTGZVtjlvGk3mreo/dcbZdP77kM8666Xt8i26AMsADzcDPC9tgAkw
ASbABJgAE2AQYAI8RwJcJa5N2p0WDVP2v6btWfuabttpjyPAdcW7yTpqWw1dBpgA95EBXsReoOsK
cFEb4HgYAkyACTABJsAAARY9ZIDHkcyuh6mSwknOW98C3LYdNwGWAZYBnq/nANcR4Ka9QBNgAkyA
CTABBgiwTrDG6MhpUgKcN/0+BbhJNnYSAtx2+WSACbAM8OwJcDb7m/ccYAJMgAkwAZ5lAV5ZWUku
vfRSdgUCTICn3xHVuBLVpwA3qcrcx3QJsAywDLAM8CQzwEXPASbABJgAE+BZF+CjR48m27ZtY1cg
wAR49gS4TdXlLkR0Gpnntut2mtXPZYAJsAwwASbABJgAE+ChCfDS0lKyc+dOdgUCTICHLcBteoHu
ow1w296bu+ptuu/11nUbYL1AE2AZYAJMgAkwASbAQxLgm2++ObnxxhvZFQgwARbzfoNhluatTwF+
4FvfGo0/vMoAywA3EeAP/d7eURBgAkyACTABnl0BvuGGG5ID567VAAEmwIIED2ae+hDgHz/7bPKO
a65Zl8G+8sork4f+8i9lgGdAgE+/8OLUM8BFQYAJMAEmwAR4NgR47dx5ZvPmzaNXgAATYEGCBzMv
fQjw1VdfnVuN+7ItW5IXzhWOZICHLcA/fOLJqWeACTABJsAEmADPtgDv378/2bVrF7MCASbAQgxP
5rsU4K99/eulj5n66C23yADPQAY4SDABJsAEmAATYALcltD7c+gFGiDABFiIuRbgPzgnuGUC/O73
vEcGeAYywHd+/gsEmAATYAJMgAlwK44dO5Zs3bqVVYEAE2Ah5l+A7/z850sFeO/v/74MsAwwASbA
BJgAE+A5FeDQ5jdkf4MEAwSYAAsxSAHuknDh27JlS678btq0KVleXu5sWgcPHnTG7oGVlZXkrrvu
siIAAI3LAOG5v3p+BgEmwEIsjAAHjhw5Mur5MSu/S0tLnU6nS5nG+gJMkGAAAOpy6NChUea362s9
QICFEIMX4EAQqD179ozuBIfX48ePdz4NGeCkt20nAwwAqMP27dtHZYnrr79etWcQ4DLe9KbNpe0E
hRCTiXAszioywP0gAwwAAAgwAAwMGeB+kAEGAAAEGAAGhgxwP8gAAwAAAgwAA0MGuB9kgAEAAAEG
gIEhA9wPMsAAAIAAA8DAkAHuBxlgAABAgAFgYMgA94MMMAAAIMAAMDDBlQHuBxlgAABAgAFgwuzZ
syfZsmVLcuDAgVaCjHbIAAMAAAIMAFMQ4EsuuWQUsQin4isD3A8ywAAAgAB3yNYr3nKhUCuEmE5s
/YdXJMkrrzePtWax57fed+71tY1xtjrCf7Pz/TN/9+8ml7/5zcmxbzyYLH/vxLnhXj0fLzeMl87H
nt+8KVn+q0cvfF4fr1yMMx3Eiw3ihbWLr2XxfNM4uzFW18faM6vJyqOPXfzuuei1LE7H8XKzeDYv
XqqOUzXix2eieCk/Tp5pFs/kxYsXY2WM+FGdeOFiPF0RTxXF8+Xx5PPnh3syjeer44mqWM2Px2vE
Y2PE8nPt4ocdxQ/iOJ0f359QnKgTz16MR1vGI1HUGaaP+F4ap7qJ43MYD5dEA2644YZk+/btyf79
+0e1iAACnJ3AuUJs8s2nxRDjwVmLp7qNBwYe90evreLJCzE6DicgwH0J/KZNm5L3/dZNYwvw9rdf
lRw5fDcBjiLI712f+3MCTIAJMAEmwAS4FqFm1pEjR5Jdu3Yll19+uSZKIMAEmAAT4MUW4C4zwCGu
v/a65L4vfyW5/rrrkmPfeIAAywATYAJMgAkwAZ6iAGdlOGSDSTAIMAEmwASYAI8pwEF8Q9Xn9PdP
3nprsv2qq85LMAGWASbABJgAE2ACPHUBDhw/fjzZunWr6tAgwASYABNgAtxGgLPim0ZoA7yy/ESy
7W1XJssPP0qAZYAJMAEmwASYAA9AgAP79u1Ldu/ezaxAgAkwASbABLiuAB/+3J254pvGwU99alT9
efn4oyORbSTBBFgGmAATYAJMgAlwbwIcnigQnuAgCwwCTIAJMAEmwDUFuCriXqCD/DaSYAJcKMCh
g7GmGeCjX/pqcvSLXyXABJgAE2ACTIAvEDrFCj1DAwSYABNgAkyAOxDgNAOcdoLVSIKnLMBpu+bs
5wvfvSHA676fkABfeumljTLAJx95PLnns19I9n7g5uTWfbcQYAJMgAkwASbAI44dOzZqCwwQYAJM
gAkwAe44A5yKbZDf8Kzx1R+dHKwAZ2U39/05uS1636cAh2m0bQN8xx/fnix94tMEmAATYAJMgAnw
BTZv3pysrq4yLBBgsnkxLhRshzDenkT1wrxMSYAvTr/GMD2Ia2fjjgT4wjhlgDc8BunY0QdGYlsq
wVMS4FLpbSnA2cdExd9lBXjjsBsFOG0DvGHY586ue5+tAn3Te29UBZoAE2ACTIAJ8DpCBjhkggEC
PIOCuq4gSIAJ8Bjyu2F/qiHL676/v60Ez38GOJbgkAkOglsWm9+0Oflvf/JfJyLAeVWeuxTgsvfr
P5/NFeDR56gX6CLxzUpwkN/wOVSBDkGACTABJsAEmACnXH/99cmhQ4cYFgjwLGdnuxZWAjyMKtB9
CHDZOGuJboUAN5fgxcgAx9Whj9x1d34cPh//y9atE8sA591MK6wOPWEBTuU37gW6rgDrBZoAE2AC
TIAJcBHhUUjhkUgAAZ7hqsnx93UFuSyL3HT4onloM0zhtAoENm+Y+HPROOoMUzWd8vGsl9hstrfs
uzrZ2KLfCfBwM8Cz1AnW0AS4aQaYABNgAkyACTABLmLPnj2jAAjwnLTNrSPAdeW0zTjL/tdkmDgD
XCa4Zdndsv/UGaZO5njjeJ4qFeG6n/MywE2qJ7dp99tEjtdJbk4nWPUleLEywIvSC3RdAS5qAxzL
rwwwASbABJgAE2ACDAJMgDsX4HGEuddhasprVfXmOrJb9l2dbHNWgMsyvgRYBthzgNf3Al0mwG17
gSbABJgAE2ACTIAJMAjwnAtw2yrRsyTAeWLahwC3G6Z/AW5bDXocAS7sKIsAz00GeFoCvKEH6Jzn
AKcZYAJMgAkwASbABJgAgwAT4FKJnFcBblqVeZ4EuK9HHxFgGeBpZoCLngMsA0yACTABJsAEmACD
AC+oALft5KrpOGZJgCcrt5MT4Lzs7jSrQBcOQ4BlgCcgwDLABJgAE2ACTIAJMAjwggpw3ecAVz0j
uK9eoOv2FN14Wi16Zh63mvQk2wDndZ41yV6g646zjgDrBZoAdy3AZ54+lZz64ZMEmAATYAJMgAkw
AQYBXkQBnvbzfCc6rUE943eyzwEexQNPTew5wK2CAHeeAb7+2uuSY3/xAAGO4sS3/yr52t1fIcAE
mAATYAJMgAkwCDABnr78EuDZEeDOJTgjwM3kd/ICfOz+b46mc+z+BwebAS4PGWACTIAJMAEmwASY
AIMAE2ACTICnI8GRADeX38kJ8Oozp5Id77hmXTXvbW+7Mjn+7e8OLgNMgGWACTABJsAEmAATYBBg
Aryo8eCsxWwIcJ9VoIcowNuvujq3/fSWyy5L1lZflAGWASbABJgAE2ACTIABAiwIMAGefQE+eu9/
L32G8v6P/IEMsAwwASbABJgAE2ACDBBgQYAJ8OwL8P6P3FIqwLve9W4ZYBlgAkyACTABJsAEGCDA
ggAT4NkX4MOf+/NSAd73e3tlgGWACTABJsAEmAATYIAACyEm23FbH6ytrSVbtmzJld9NmzYly8vL
nU2ry3HhImfOnElOnTplRQAACDAIMAEWggBXceTIkWTz5s0b5HdpaanT6Rw8eNAZuwdOnDiRfO1r
X7MiAAAEGAS4Cza/aXNpFUkhRP8RjsM+WVlZGV3wdu7cOXo9fvx459OQAe4HGWAAAAEGAQaAgSED
3A8ywAAAAgwCDAADQwa4H2SAAQAEGAQYAAaGDHA/yAADAAgwCDAADAwZ4H6QAQYAEGAQYAAYGDLA
/SADDAAgwCDAADBhqjK8MsD9IAMMACDAIMAAMIWL5pYtW5IDBw7k/i4D3A8ywAAAAgwCDABTuGim
zy3OE2EZ4H6QAQYAEGAQYABoeeHrQoBjEf7t3/7t0e8ywP0gAwwAIMAgwB2x9S1XbCjQCiEmG1uv
+Pkkef2VlrHWKPpahr/9t/+n5Mtf/EKSvHr2jXi5YbxUHa/EcaaDeLF+rL1w8bU0nm8WZ/NidV2c
OfV0curJH0bfPRe9lsXpi/Fy03h2Y7xUJ05Vx5kfX4yXCuLMyYbxzMZ4MY6VMeJH1fFCHE9XxFP5
8XxVPPnGsE+ej+frxBPlsVoUj9eIx9rHc8st44cdxQ8uxumi+P6E4kR1PBvHoy3jkSjqDNNHfO98
nOoqjs9hPFwcBBgEuKORnyu4Jk9/Uww2HpyteKrreGDgcX/02iKePB+j43CCApy8tpYTZytjz/t+
K1d+r7/u2uS6f/y/JR+6+YOdCPDR+76S7P/ohwnwG3Hir76dfO0rdxNgAkyACTABJsAEGASYABNg
AkyApyXAQXyPPfiNC7/veve7kwOf+PjYAnzgE3+Y3PAv/jkBlgEmwASYABNgAkyAQYAJMAEmwAR4
ugKcFd80Dn7qU8nOd/5SsnTbpwmwDDABJsAEmAATYAIMEGBBgAnw7Arw4Ts/lyu+aSyf+N45B3xu
JMiH7/wsAZYBJsAEmAATYAJMgAECLAgwAZ5NAa6KkAEO1Z/bSTABlgEmwASYABNgAkyAAQJMgAkw
AZ4RAQ4Z4LQTrLUXTjeUYAIcC/BoOzXMAB/96pdGQYAJMAEmwASYABNgEGACTIAJMAGeUAY47QSr
mQQPQ4DjTr7yvrvw2wQFuE4G+OTjjyT3fOGzyd6bfye59ZYPE2ACTIAJMAEmwAQYBJgAE2ACTIAn
lQFOxba+BE9fgPOkN/t+EhngWH6btgG+4/Y/SZY+/UkCTIAJMAEmwASYAIMAE2AC3FdcEIQSma0z
TP7w3Uprt+O9PzNOGeC85wDXk+BhVYHOE+Cy7O/GYZ5f9z6ODcOWCHB4//f//t9PfuEXfuHC9xf/
t7EK9E03/qoq0ASYABNgAkyACTAIMAEeRuRVpSzfBgS4b/ndsC1qyPJ64T0vwq0keAEywFkJDs8J
PnL3XTlx+EL8+1/9d8k//aX/Y2oCnK0CHbcBLpLgIvHNSnDubyXZ3/D5b/7NvznKAMfim5XgIL/h
c6gCHYIAE2ACTIAJMAEmwCDABHgwAlz13TwK8LSrQJcJdbXoVgtwKwlekAxwVoK3X/X20rj8zT+b
XH3VL0y1DXBRJ1h9CvDF96sbMsChDXCZAOsFmgATYAJMgAkwAQYBJsAzIcB1vl+fLc4Rz5rf1RlP
9vc604gFeH02tTwDnDtfBRng+HNRxpYADzcDPAudYBXJ7wXhnZIA18kAE2ACTIAJMAEmwAQYBJgA
z7QANxLPjobJE+Sm/y8S3qrP2e+KBLhIisdp99tEjtd/3tgJViMJXrAM8KwIcFVP0GVtgKsEuKgN
8Pqq0DLABJgAE2ACTIAJMAgwASbAjbO340hy2wzwOAJc1ga4SRtdAiwDPAvPAa4jwCFWVx4fRZ1e
oAkwASbABJgAE2ACDAJMgOdagDdkYMcRWAJc+vvG4QjwPGWAJyXAZT1A5wnwsfu/PgoCTIAJMAEm
wASYAIMAE2AZYBlgAiwDPJMZ4KLnAMsAE2ACTIAJMAEmwCDABHjheoGeRhvgOgJc2k54TAGu0wZ4
GgJcPAwBlgHuX4BlgAkwASbABJgAE2AQYAK8EM8BnkYv0GUSXNVTdFGPzl33At1UgOv06NxOkvUC
LQMsA0yACTABJsAEmAADBFh0FA/OVszoc4Dbx2wJ8LFvnp/WsQfvH3QG+NCfLSW7f+VfE2AZYAJM
gAkwASbABBgEmAATYAI8HAm+KMCN5XeCArx66plkxzXvWJfp3nbl25Lj3/32IDPAhSEDTIAJMAEm
wASYABNgEGACTIAJ8LQk+P7MOO8fpABvv/qq3OrmWy67LFl7cXVwGWACLANMgAkwASbABJgAgwAT
YAJMgAcXGzvBGpoAH/3v9xa20Q6x/w8+IgMsA0yACTABJsAEmAADBFgQYAI8+wK8/5aPlArwrne/
SwZYBpgAE2ACTIAJ8III8P79+5Ndu3YxLBBgQYAJ8HwK8OE//1ypAO/b+3sywDLABJgAE2ACTIAX
RIAPHz6c7Nixg2GBAAsCTIDnU4DXzqyO2vrmye+mTZvOS6sMsAwwASbABJgAE+CFEODjx48nl19+
OcMCARZCTPf50H1y5MiRZPPmzRvkd2lpqdPpLC8vO2P3wOrq6igAABiXtbW1URkAIMBCiLkV4MDK
ysqo04udO3eOXsMd4K45ePCgM3YPHDt2bBQAAHTBpZdeOioXzL1EpU/pAAGO2bz5TaXtA4UQ/Uc4
DpPk1XPxSstY6yjOjhXLy9/LfPdyw3ipYZzpIF5sEC9Er2XxfAexeiFWVx8fRfxdkjwXvZbF6THi
2ZZxqkb8uEacbBjPVMTKGPGjhvF0RTzVMp6MXuvGEy3j8Rrx2Bix3DJ+2FH8oEZ8f0JxomE82jIe
iaLOMH3E9zqO43MYD5dEN4ROsEJnWPMul0Ocx7xyYJ35LfqtbHxlwwx+282Hx/91jzGkeekjfjqg
+MkU4vUe4rUO49XoddyYbQE+ePBTBLgHAT527OujIMAEmAATYAJMgLsg1CraunUrAR7A/MTfNRXg
rr8jwASYABNgAiwDLANMgAkwASbABHjuBDiwffv2UR8hfcplVdaxKgPaVNLqZDrbZkybjqNpBrep
AI87LAEmwASYABNgGWAZYAJMgAkwASbACyPAhw4dSq6//vreBLgL4W0iaW2m12aabWVy3GEIMAEm
wASYAMsAywATYAJMgAkwASbAY3DDDTckBw4cmCkBLsq+di3A41ZF7ipj3kV7YQJMgAkwASbAMsAy
wASYABNgAkyAF16AwyORQha4TYdYXQtw9vtpZYDzRLSupA49A6wTLAJMgAkwAW4owMvLx2WAZYAJ
MAEmwASYAM+JAKcSHHqFDp1ihcckHj16dGICXJRxbSNpXQpwnXnr6obBtNoADx0CTIAJMAEehADv
2fNbyZYtlyUHDnxcBlgGmAATYAJMgAnwHAhwIHSGtWXLluTyyy8fVYuehgC3yZjWzXq2FeAuJLrJ
8k+yF2gCTIAJMAEmwDUFOD2J5omwDLAMMAEmwASYABPg2RLg0AZ4x44do0cjtclo1mmnWqfH5XEF
OE962/Tg3EUv0U3XW5usbhfrmAATYAJMgAlwAwHOE+GQAV5ZWSbAMsAEmAATYAJMgGdAgNOeoEM1
aGBhBHjr1itq9TgmhOgvtm79+YkJ8NVXv72XZQgi/OUvfyFZWvr0uYvptecups91JsBHj34l2b//
wzLABJgAE2ACTIAJcEccP3482bZt27nryyrbwmIJ8Pl0+DfFoOPBBY8HBh73R6/t4vxxOBkBPj+t
7jLAIYLwHjv2jQttgA8d+q/nLqpvO3dR/VEnAnzgwB8mN9zwz2WACTABJsAEmAAT4I7YvXt3sm/f
PqYFAiwIMAEmwHUFOBXfvDbA4ftQw+T48WMEWAaYABNgAkyACfCABDhkfS+99FJVn0GABQEmwAS4
jgBnxbeoF+jl5YdHmeCjR48QYBlgAkyACTABJsADEeCQ+Q0ZYIAACwJMgAlwSRw+/Llc8S3rBTpU
g96+/e3J0tJBAiwDTIAJMAEmwAR4AAIcHncU2gADBFgQYAJMgMeIoucAr62dTnbu/KVk377/RIBl
gAkwASbABJgAT1mAZ+2ROCDABJgAE2ACPEgBrnoO8O7d/2YUBLhdBvj8tmsmwEePfnEUBJgAE2AC
TIAJcGB5eTnZsmULwwIBFgSYABPgvjLAcYQs8PnHJJ0etABffGh8uQBfHK7/DHBTAT558pHknns+
m+zd+4Hk1lv3EWACTIAJMAEmwMmRI0eS7du3MywQYEGACTAB7jsDnMahQ/9l1C5442OShiHAcU/X
ZQK8frh+M8Dr5bdZFeg77vjjZGnpEwSYABNgAkyACfC5a+qBc9fUGxgWCLCYXQG+WACfjJB2Nb36
4+lWWC9OtzsBvjhOGeA6Ahwi9Ay9efObcp8rnBdve9v/OqgMcCq9ZQKcXYb4u6zwbhx2fQY4/m7j
sM+te5+tAn3TTe9NVIEmwASYABNgAhzYs2fPKMblzJlXk7e+9eNjj6eLcYAAE+A5iSJBzH4/dAGu
uxyTEOA8+d0oE9WyvP77+zPfyQDXEeChtwEuE+BYeOsIcNn74t9W1wnvmTNPbxDg9e83SvDRo18a
fQ5VoEMQYAJMgAkwASbAXQnwI488u0FeV1bOJB/84H3J7t2HR6+nT58dfR9eP/axB9b9Hv6fCnA6
rvS79PNtt32HCRJgAkyAJy+8088Y95/5rSe65QI8TiZ4ETPAsy7AedGHAIf3X/va3cmJE99uLMB6
gSbABJgAE2AC3JcA33XXiQ0CHOQ2SG4Q3vA+DJMOG6Q2+3sqwOF9yCin3wVZTv8LAkyACXBlBjj+
vL5wnj+evGHyxlEmtEXjqjuN8vl+oDRjW7c6MwGWAR5HgNd/rtcJVlcCfOrUD1tlgAkwASbABJgA
E+C+BDjIalaAs59DpjcW27zqzuG7ONKMcZxBBgEmwAsswWXymSejTapNdyGu41SBLp9WdRXmcdr9
NpHjjcOu7wSrjQTLAA+3E6xUevsU4KI2wOmrDDABJsAEmAAT4KEJcFZa8zLA99772Kgac5rNLcoA
B1HOinP4b/Z7EGACTIBbye040lpXXMcR4PxhCLAM8GI8BzhPgLMZ4Ka9QBNgAkyACTABJsBdC3Be
Rvexx1ZH0pq28U07ykozudnf03GkbX5TUX7ooWfWtQkGASbACyrB3Yhk9wKclzHuW4CbVoMeR4Cr
OsoiwPPZBnjSApztLTqW3WwGmAATYAJMgAkwAR6CANdBFhcEWHQgwEVZ4vzPdYcpG77pb3Wm1cd8
t1meJr/XmX6beTw//IROKD1Oa3l5uZfxLvozC0+dOpWcOXPG1RAAMHMC/JnPPGylgwCLcapCV//W
ViTj79oKcBNp7WO++xLgJmK7yAL8/ve/nwD3wNe+9rXkxAm9YQIAZk+AAQIsBiHAeVnNupnWomHr
ZKnLptHFfLdZh3XH1Vf2d54EuC9kgGWAAQAEGASYAAvRYTXoaU5DBricQ4cOJbt3717Yi4AMMACA
AIMAE2AhBiXB44x7UgJ87Nix0bTCK2YHGWAAAAEGASbAQgxGgscdZ98CvLq6muzYsWNdVe9t27Yl
x48f73Q6fWWAFx0ZYAAAAQYBJsBCzJWU98n27dtz205v2bIlWVtbc5YdODLAAAACDAJMgIUgwDU4
evRo6fOT9+/f39m0ZID7QQYYADA0AX7rWz++Lrrg3nsfuzC+8L6LeWzKI488m3zwg/eNnl8cInxO
Cd93Ob277jqxbvwgwEIQ4A4IglsmwLt27XKWHTgywACAIQpw3uf0NYhdeB8LXvj8sY89kJw+fXb0
ObyGz1nC90E+4/+trJxZ95o3jezndPjbbvvOut/Tz1nSYcO0wzyESKcVZDVPcMM4w/Dp77HEp+OJ
lzU7D+E1TBcEWAgC3BGHDx8uFeB9+/Z1Ni0Z4H6QAQYADFGA4wjZ0TR7GgivZ868ui5rmsppkMVU
KrMZ0FQQ4wxwkMQHHnjqwvepPGankf2czlcqmEFA02nn8ZnPPJw89tjqOhGPZTlPgNPxx2IeD59d
1uw8hOmF6YIAC0GAOyK08Q1tffPkd9OmTcny8rKz7MCRAQYADFGAY1JJTYUxr3p0+j5kRrNyHBN+
i/8XBDGMN80gp8KYnUbe57gacxDaMM00K1u1TFlZzhPg7PIFoQ3zGqaTTj9e1rx56KoKOQEmwEIQ
4Dc4cuRIsnnz5g3yu7S01Ol0ZID7QQYYADALAhzkNBXguApz9j9pFjcrmPF/4vdBrMPnIL5hHOFz
3jSyn8OwDz30zIXphN/DtPPmLZ6/IMx51aTrZIBTCQ4RZ6zL5oEAT1iAN29+U2n1SCFE/xGOw75Z
WVkZXfB27tw5eu36EUjoDxlgAMAQBTiOtO1rWnU5rcocS24qemmGN5uJTdvTZjufChKbim8qtXnT
yH4O7+Psazqeoo6n0irQYfplGeyYdPi0DXAq6en6yC5rdh5UgZ6CAANAV8gA94MMMABgaAI8LkVZ
2GkSd5g1qWXVCRYBBgBkkAEGAMybAA816xmyzGUdZXW5rGE6aTYbBBjADCID3A8ywACAeRNggAAD
AHKRAQYAEGAQYAAYGDLA7Sl7HJUMMACAAIMAAwDmqkASntd84MCBDb/JAAMACDAIMAAMDBng8Qok
6WOxsiIsAwwAIMAgwADQ8sKHYQtwVoRlgAEABBgEuGOueMtbNhS+hBCTjXAcvvbTn44XP7kYr+aE
9Tx7cemllya3HzqU/OEnP5m89NprF+LMq/XjxVrxamH8yZ/92ShefOXVC/HCGPH8unhl7FgtirX8
eK7jOL22djHOdhPPdhyn6sTL5+PHL5+98NpHnBwrXq6MZ9J4KbyePffaJF6uHSsDiB/lxkvVcabf
eHoK8VTD6Hp8kw4CDAI87kTOFbJ+sPqCWND4/qLGc9VxYl0832uE43ASAnzx808axStdxesXY61R
vN46zhbFa9Xxcm68VhkvNYjffN/7cuX32uuuSw5/+cvJyeeeS97767+e/Oyb35wcuvPOiQvwb9x0
0ygIMAEmwASYABNggAALAkyACfC5CG2ACXA3AhzE9y8efHD02z1f/Wry3ePHR+//x3e/m/ziNdeM
fv/+E08QYAJMgAkwASbABBgEmAALAkyAZYBnU4Bj8U3jiZWVUQY4/m7p9tuTn7nssnNS+r7k1Asv
EmACTIAJMAEmwAQYBJgACwJMgGWAZ0OAQ7XmrPimEWeA4wjiGwQ4VIte+rPbCTABJsAEmAATYAIM
AkyABQEmwDLAwxfgssjLAMdtgP/q0RPJP77uuuQX33FN8q2HvkuACTABJsAEmAATYBBgAiwIMAGW
AZ5NAS7KAGcl9zN33jnqSfzf/dqvJ0+d/DEB7kGAw/HTVIC/+NV7R0GACTABJsAEGCDAggATYBlg
AlwRP3zyydIMcByhWvRv/+7vjqpFH7jt/5sbAY47CCv6fogC/MjjTySf/cLh5AM3fyjZd8stBJgA
E2ACTIABAiwIMAGWASbAZXHnF75QKwMcR+gh+p+8853JP7ryyuTrDzw40wKcJ77Z7wsluEMBLpLf
OlWg//j225NPfPqPCDABJsAEmAADBFj0EWlhsIkAp/+ZNYkda77HFOB02kWfZYAJcFcZ4NMvvthI
gNP4yn1fG1WL/r9+5f9Onjz545kW4KwI1xHg7H9X1y5+lye4cZQJcHbYIL4X3udUgX7vjTeqAk2A
CTABJsAAAV4MCc0GAZ6M/Oat+74FeFwJlgEmwEUZ4CDBbQQ4jQ/t3Tt6bNLbr7q6JK4qjPDff/mu
d009A1z1vkiAY/HNk+D4c54A533ODp8nwUF+w+dQBToEASbABJgAE2CAAC9UFnZSEtxGgOcp85v3
W+7wPQjwOBIsA0yAu84Ax22AQwb483ff3Sr+2S//8iCqQE9DgMuyxVUCrBdoAkyACTABBggwAS75
ruz3sixyVbY5bxrx71XSWJRFrft7dthW2dqaAtxEjC98fm79+zTy5osAywDPYgZ4XtoAE2ACTIAJ
MAEmwCDABHhOBLhKXIu+azJM0f9K5bCBgBaNo2y8tbO1Y2R/68xfngBnM8BN2vy2kWAZYALcZwZ4
EXuBrivARW2Aizq+IsAEmAATYAIMEGDRQQa4zTi6GKauvLYV4HGH6VuAi6o/F2XWCbAMsAzw/D4H
uI4AN+0FmgATYAJMgAkwQIB1gtVAgPvOEtetAt2nADepBj0JAb4osDLAMsAywIsgwGU9QBNgAkyA
CTABBgiw6KgjqqYZ4D6yxE16VJ5EBrjrDrAIsAywDDABHvc5wASYABNgAkyAAQIspiDAVXLbJkvc
ptrxUKtANxknAZYBlgEmwASYABNgAkyAAQIsBiLAbXqB7qMNcNvem5t+10Uv0G3mv+s2wHqBJsAy
wASYABNgAkyACTBAgMVAY96eA1w7xnwOcJnIDlGAH/jWt0bTCK8ywDLATQT4Q3v3joIAE2ACTIAJ
MAEGCLAgwLMqwT0IcFv57VOATz57OnnHNdesy2JfeeW25KG//EsZYBngWgJ8IQgwASbABJgAz7QA
33jjjcnNN9/MsECACTABXkgJ7liAx5HfPgX4qquvzq3KfdmWLckL5wpCMsAywASYABNgAkyAF0OA
d+7cmSwtLTEsEGACTIAXMnqqAj0kAb7v618vfdTUR2+5RQZYBpgAE2ACTIAJ8III8LZt25KjR48y
LBBgAkyACfB8CvBHb/lYqQC/+z3vkQGWASbABJgAE2ACvCACfOmllyYrKysMCwSYABNgAjyfAnzn
579QKsB7f//3ZYBlgAkwASbABJgAL4AAB/ENAgwQYAJMgAnw3ArwC+cKQ6Gtb578btq0KXn0+9+X
AZYBJsAEmAATYAK8AAIcOr8KnWABBJgAE2ACPLcCHOLue76SbN68eYP83vbHf6wXaBlgAkyACTAB
JsALIMBr585PW7ZsUf0ZBJgACzGcCMdhX4QLXnjuX+j9MbweP37c2XVGCNsuFFwAAGhL6Pk5lAEA
AkyAhVgIAZ4EIQOM7rnrrrvcsQcAtGZ1dTXZunVrsry8bGWAAKe8KVM9Uggx+QjHIZBFBhgA0JZw
/dixY0dy6NAhKwMEGAC6RAa4H2SAAQBtCNWew3N/wytAgAEAM4EMMACgCdu3bx/VLAttfo8dO2aF
gAADQB/IAPeDDDAAACDAAICFQAYYAAAQYAAYGDLA/SADDAAACDAAYCGQAQYAAAQYAAaGDHA/yAAD
AAACDABYCGSAAQAAAQaAgSED3A8ywAAAgAADABYCGWAAAECAAWBgyAD3gwwwAAAgwACAhUAGGAAA
EGAAGBgywP0gAwwAqMPJkyeTSy65ZF3s2rUrOXr0qJUDAgwAmA2efPLJ5PXXX7ciAGABOHbgwCja
EEQ3SO8dd9xx4bulpaXRdyQYBBgAOkYGuB9uv/325MyZM1YEACwAR/bsSd5/Tlg/vGVLYxG+9dZb
R7L7yCOPrJeJNzLBgeeff/7CcOn36fDpd+lw4f211147+hyyy/H/brrpptF3AAEGAHSKDDAALJ4A
p9FEhIPMpgKbFeD0+zQjHOQ1rTKdSu7evXtHn4P8BikO7++5554N43788cdH/wlCDBBgAIPlm0/v
SW7/46uT33/3Jesurl3EV0Ns3z56ff8CRlinaXS+Xn/u55Kv/o2/sZDrVQghxHoRPufHFyImzdiG
zGyZAOf9lgpwmuENghuqUacyHI8jfJ9+BxBgAIPm49+85EJ0fWFOoljEgklf63bR16sQQoj1EV8a
YrIZ2+z3abY2CGzI9IYI4ht+C1nhQPhvKsDh9zjD++1vf/vC8CHCZ4AAAyDABNh6FUII0Ut89oYb
CgU4zdgGeY1JqzUHEQ7Z4VSSQ/XntDp02gY4SG36e15b4liSizLKAAEGMEgB7v5MVXBFtm6tVwBA
bbJtgFPxXV1eLr0spKIbkwpumuGNxTUIcJrRTQnyHHeOlR1P+D1tNxz/DhBgAATYurVeAQBjCXAs
vlWXhezzf9P2wHFV5bQac4j0kUlxO994PPFjk4L0poIdIrzXAzQIMAACTIAJMABgbAHOE99JXBbS
KtBpp1gAAQZA0ogaAQYATE8Meros5D0XGCDAAEgaUSPAAIC5E2CAAAMgaa7IBBgAQIABAgyApLki
E2AAAAEGCDAAAmzdWq8AAAIMEGAABNi6tV4BAC4LAAEGQICtW+sVAOCyAAIMAASYAAMACLDLAggw
ABBgAgwAIMAAAQYAAkyAAQAEGCDAAEiaKzIBBgAQYIAAAyBprsgEGABAgAECDICkuSITYAAAAQYI
MAACbN1arwAAl1uAAAMgwNat9QoAcFkACDAAAmzdWq8AAJcFEGAAGItvPr3nQnTOnj3JV7dvH71a
t92u12/s2JGs/ft/bwcGAIwus2kABBgAAAAAAAIMAP3y/ve/30rogQ9/+MPJ6uqqFQEAAAgwAAAA
AAAEGAAmiAxwP8gAAwAAAgwAAAAAAAEGgMkjA9wPMsAAsMAicMkllQEQYADAIAotZYUYAADaXE8A
AgwAA0AGuLjAkld4qVugkQEGAJBgEGAAwEIIMAAAAAEGgI4kTduiftctAQYAACDAAAYkauhfhKsy
wgAA1L2OuJ6AAAMACQYAYK6vz26oggADAAAAWAgBzn5PgEGAAQAAAMy1AKe/EWAQYAAAAAALI8EA
AQYADKrgooACAABAgAGQtIVbx9bz/9/eHbxIVt17AHeZpX+Cf0LATXZxmSwGssxbZRNklm4DAyNI
3ETj4oFBF/EFEbMSM5tx8URMeAyRgGZ4OAwSdEAZJ2pmyASNIaQe33r8Or8+3ltd1dPVXd39+cDh
3rp1zr23bldX17fPvecCAAjAgJDmOAMACMAAQtpZPZ6OLwCAAAwIaWfqmAKAvyUgAAP+sAIAG/y9
9jcbARiAU/GFxZcXAIRhEIABIe3MHtdx3nEF4ChDr78rCMAAQtrOHlvHF4DDBF8QgAGENMcWAEAA
BhDSdvH4Oq4AHOZviUuVEIABhDQAOFd/o8dlIAADAABnNgALwQjAAOzklxanqwEgAIMADAhp5+YL
yzrLAWDdEOxvCQIwgJC288fV8QUAEIABIc2xBQAQgAGENMcWgPP8N8WlSgjAAEKaYwvAufx74u8I
AjCAkLZTx/agAgD+ToMADAhpAODvtACMAAwAAAjAAjACMAAAIACDAAwAAJyuAOxSJQRgAAAAEIAB
AABAAAYAAAABGAAAAARgAAAAEIABAABAAAYAAAABGAAAAARgAAAABGAAAAAQgAEAAEAABgAAAAEY
AAAABGAAAAAQgAEAAEAABgAAAAEYAAAABGAAAAAEYAAAABCAAQAAQAAGAAAAARgAAAAEYAAAABCA
AQAAQAAGAAAAARgAAAAEYAAAAARgAAAAEIABAABAAAYAAAABGAAAAARgAAAAEIABAABAAAYAAAAB
GAAAAAHYIQAAAEAABgAAAAEYAAAAzlEA/va3v7146KGHFEVRdqbkcwkAAI48APuyrSjKLhYAANhK
AP7zn/+sKIqyM0UABgBAAFYURQAGAEAAFoAVRRGAAQAQgAVgRVEEYAAABGABWFEUARgAAAFYURRF
AAYAQABWFEURgAEAOHMBuO7N+de//nWnviSn/OUvfxEaFEUABgBAAD7aAPz111/vXADepVCuKIoA
DADAGQnA//jHPyaff+GFF/bqPPfcc8tl77///uLJJ59cLvvlL3+59/znn38+26Yev/LKK8vp97//
/cXbb7+9t74f/ehHy+W//vWv9wXgmr97964AoSgCMAAAAvB2AnAF2Tt37iw+/vjj5fxPf/rTxbPP
Prucv3Xr1jK89sA616bqpP4nn3yynL9w4cLyNOcK01nfn/70p8kA/K9//UuAUBQBGAAAAXg7Abie
mytfffXVN05ZPqjNP//5z8Vnn3022WZqfXn8xRdf6AFWFAEYAAABePsBeGrdKffv358NwHNt6lrj
qTZT6xMaFEUABgBAAN56AP75z3++fO6tt95a3LhxYzn/1FNP7Z0CndOVr169ui+wzrVZ1ctb67t+
/fri2rVrrgFWFAEYAAABeHsBeCzVU/urX/1qb9nPfvazxd/+9rfldbw//vGPl8t+85vffKPHdqrN
qgDc1/f666+7BlhRBGAAAATg4wvAu1qECEURgAEAEIAPFYBTMihVSm5jtE75/e9/v3j88cf3QulP
fvKTxaeffro8TXnddTxIqf0VKBRFAAYAQABeOwBX8M1Iy7klUULsOuXevXuLL7/8cnnt8N///vfl
AFbrtn2Qkn3MvlYQFioURQAGAEAA3igAJ1gm1J6Gkn0VgBVFAAYAQAA+VADetAf4pIoeYEURgAEA
EIAPFYAPcw3wSRfXACuKAAwAgAB8qACsKIoiAAMAIAAriqIIwAAA7HoAVhRF2bUCAABbCcAAO/XB
5nMJAAABGBCAAQAQgH3RBARgAAAEYF80AQEYAAAB2FEEBGAAAARgAAEYAAABGEAABgBAAP63Dz/8
0E8KEIABADj7Afjy5cuLRx55ZPHSSy/5iQECMAAAZzsAZzspgvDZcPPmzcWlS5eWP9NMb926tbhz
587imWeeWU7jvffeWz6ea1P1ql2VV199de39SP2s7+LFi3vrO8r3/UkGsXHb5ykUCsAAAJyJALyt
IJzwk+D05ptvLl588cVl2DoO2W6C3rbbbCqBNMdiW+vOzzDHO/PXrl1bllqeaWT79f4a2+RndOHC
hX3P1Xpq/iBZR73G/LwTgsdgXeE8z2V7ddyzjbTJspTM1/6N9fq+jG1SL3Uq6Nf8lStXltvuP+cs
q/d/9n1V3VpXlmVb2a96XFMBGAAAAXhLXzS/+93vfiPEHkVJEL5x48aRB74EjApiCTB5rgej7t69
e8tpQkWv1wNr1tFDR9pk/ZlW+9qH3r7XK1lPBcG5dlOvrepPvaZeL8Es8wlW434fhR5sp4JxwlyC
XUJn1RvbVN3sWw/OeT3rBuCpfahjG5nmcfaj1p35alvLKyDXPtTjqte3M7bJa+091qlbr2HuOPX1
rqo77mM9znup9k8ABgBAAN7CF80H+UI61QOc8oMf/GDx7rvvHsmBGANwgkVCcAXQlOqlSyiqUJjw
kjq9F7MHxmqXaQWqWlbzFU5772Ztt9ebCsBT7cbX1Z/P65p6Tb1e7U/td/9nwHEE4OqJr9OT1w3A
Vfpp05u8J+ufAekx7SFxal/HYDv1eNXyHnb76de93Vg//5jo/xhYVXfVPo7LBWAAAATgHQ7ARxl8
5wJwAlCCX4XcPNd7zSpkVZ0KJ6nXQ2hfbw+X47LeQ5t1VZieOg25L59qN4bN6lHtp8mOr2nsIe7b
mFrvg6jTcPsxGHtyx9BbbWo/6pTeCvO93br6KdBZf45PpOe7X0u8zR7ghO1sr07nXhVq67TrOt16
nQA89gDXds78B5sADADAaQ/A2wi+cwE483VKc10P3J9PaJnqGa0gvCpIzgXg2k71MK8bgMd2YwAe
r2eeek1jval9PEr9eta6ZnZVAJ5rU/t3mACc8Dw1CFaWV+9s/dzqut2DrgGua5PrWI4BeGxT1yz3
9c6F2rrutx+HgwJwbW+8Bng87VoABgBAAN6RAHz16tWtBd8e+BKCEojGwZH6QEM9PPUe4TotOfV6
WMx6065O6Z0LlxXG5upNBbdsa6rdqOrWKdBTr2lcz7YD8K47TE/paQ1d/X0tAAMAIACfcADeRVO9
rXPB+ryFx7OgTm0XugRgAAAE4HMfgNe9TVJdo8o33b59f9/jL774clnWsW7dcRvshm3/TgjAAACc
WADO6cupt+3TmDk93njjg2Upzz//zuKJJ64up6+99v4yuD766At7z2e+wmzqPP30b5cl8xV0UyeP
M71+/dO9ujV/3IFpbvTo0xjYDrt/B73ebb1uARgAgGMPwHfv3l1873vf2zeC83e+850juW8vp9f9
+1/vC7cJqAmzJT27FWgz7fNj3YTmLOuB+e23P1q8/PIfl/MffXR3X/0up7D3AaLGAapq1Ox+jezU
rYXmnq/BpsbBs/oI0FODXx3liNsP8ju96vZNtY9zr6WOSR94q65Rn7odU19n1X+Q+08LwAAAHHsA
fuyxxybv3/vII48svvrqq50+MNu8djcDUfURjE/LNcJHta8Jq9VzG+nxrcDa6yTQZnlKBeCxbubf
eefjvfoJvwnFmZYsT+gejbcIGm9RNBXEpgJwv+3VGOqmbos0d1ulqfWfhHrtfZC3uXsez72WOiYV
hvuo01Mhe1znOMicAAwAwE4H4Lq9y1z5xS9+sbMBL71/mc8oyXkdPQD1e/n2QJt6aZcv7nP31K3b
6tSI0RWO1t1OXU+caer3dfb9qPX056r93Oudqzsek6l7Gh8mAPcQmx7chNb+/Nwp0Af1AGc6Xhs8
F4DnQl0PcasC7tT7f+r2ROsE3F0KwFOjis8dq4NO867bSfXbTB0UgMfeYQEYAICdD8AJuKsC8IP0
7mwr/FYorWBXtwOq+/32OnVLobFewmzd+mhcb55PmBoD8Cbbqfvl9ra1nVpP2tYo1RWGs6wHufH1
TtWdOiY1HfdvE+Mp0FG9vCm5NnjVNcCpm+CbUkF6rN/DdA/X3VH1AK8KwKexBzjvo7x/1wnAq15L
zef06Pxe9FtLrQrAh7kFlQAMAMCJBuDcu3dVAH7uued26kDM9dpGej+rx7WCQV0f2uv1dVR46Mtq
PXP32F13OxVS87hCx9w6az/G2/pM9d6OdeeOydT+bSqnMvfTlLelTpGeUtf8bnINcJ3ZMPf+78/3
a4Br1PBxO1PXAK9a/3FIWM12Mz0oAK96LTVfx6S/T3JMp3p9o/7x0E+b3vQ4CMAAABxrAM41vrnW
dyr8futb31p8+OGHOxeA+62NpgLlWGesNxeAq031ss6F1U22U8+vCtIVZqpnedXrnao7d0ym2rId
PXw7DgIwAAA7GoDjrbfeWjz88MPfCL/jgDi7IKf89msfV/WoVlCsU5NXBeBxvX1ZnS696XYSPuv5
fqp15sdrN+cGE5rbr1531TEZ90/oYKc+2LwXAQA47gAct2/fXly+fHnxwx/+cDl1C6TtmBuhuV/b
e5BN6oIADACAAMyJqEGrRpucquy0ZgRgAAAEYF804cD3/Lq/C35nBGAAAARgOPaQVKM09xGMa/Tn
PnJxpn3E6Kpbg43V42pX11WPI0tXvbnltb6pWzDhcwkAAAEYDv3enbpPbw0G1gcFG+8ZXHXHW/4k
PPdB3sZ7C1e9ueX9/rpzA5jhcwkAAAEYDv3e7aG2h9Fx+VSdvjwjYie0To2MfdC9fqfui+v3y+cS
AAAC8Fak5y639UnJiMoJMeuegjpXd9U6Nln/g+jbOa5tnpaQNNULGzk1uVu3Bzjtcnuoan/YHuBx
+wjAAAAIwEcm11726zlz+mmCYkJxja6c5ysY93p5fqzbpU6Fz6yjX1fa29StjPo6av3jemudU20O
2s7Ytr+ese1ZD0n5Z8d4HW4ds7pGOOqa3fEa4DEA59j1a3c3vQZ4bvtCnQAMAIAAfGQSBmvwowqE
PTj2IFoDHNV86iVITgXgHlBTN9OErjE0p9R8ns8+jOuvUJV6tT9zbVZtp/ant631jW2FJPxsAQAQ
gM/gF82EwPTgJRhWEExYLFmex3XKan9+rDsVgOv59PhlO31Zpgng2W4F8XGdCaV9elCbqe3UfO81
nqpXy4Qk/GwBABCAD/FF8w+fXF688IeHDlXS9jglUI4BtU5VnQq9mwTgqWV9/WPbMYBXT/BBbVZt
u7fN+sbwPPd6QAAGAEAAPuUBOAEwPakJfXXacXqEM59BjRIWaz7heAyJve66AXhsU/P9dOYeQrNs
HBxpVZup7YzL6vWuCvTCBAIwAAAC8OLs9gADAjAAAAKwL5qAAAwAgAAMIAADACAAAwjAAAAIwAAC
MAAAAjCAzyUAAARgAJ9LAAAIwIAADAAAAjAgAAMAIACfsy+ad+7cWTzzzDN75b333juwzZtvvrm4
devWvnXMtVv13FG/jtrOcW0TBGAAAATgUyRBNoF2KlBeu3ZtX5Csuq+++uq+ABz37t2bbJdpr1/r
6O3TNo/n1jnV5qDtjG1Tf9VrAwEYAAAB+BwE4PT8JiRWyKxlmb744ot7yypgjgG4B9SxXQ+mvW2e
TxCtNqmXdVQoTb0KxnNtVm2n9qe3rfWNbUEABgBAAD4nAbgHxwqJ1St88+bNZW9p74Ede2N74Bzb
9WWZXrp0aRlAM01oHXugE0r79KA2U9up+b6fU/VqGQjAAAAIwEf1RfPy5TQ4XEnbLQfg8RTog8Lk
OgF4almmCZ2rtp8w3nuCD2qzatu9bdY3hue507+3pa637qdjn5TsR97DFy9e3Gh/1n3fn2QQG7d9
nkKhAAwAgAB8QABOCOqDYE2FxPQMpwf2ypUry+m6ATjtst60q+CV+X46cw+hWXbhwoVvhLW5NlPb
GZdlPtO58HxcwSHby3bG065rP3pvdAX2mu9BfvyHwKZyHHsveH7++ZlWEM60fsZ5Lj+P2pfsf9pk
WUrmsyz/uBjr9dcztkm91KmfS83X+6tfn51leT4l+76qbq0ry7Kt7Fc9rqkADACAAHxOAzDHZyoA
V4CsMJdSoS/hMxLkav4oQtzUe7euoY5M8zjbzL4mEPft1/IKyPWa6nHV69sZ2+R11vaqfraTacL5
3O9XrXdV3XEf63H+IVL7JwADACAA+6LJMQfg9GhW6K0wXL3cFXbzfPWuHsX7blxH9fxmGz0kTm1r
DLZTj1ct72G3n37d2431c1zS41the1XdVfs4LheAAQAQgH3RZMsBuAbjSuk9vWPArZ7f1K9TjCss
P4h+CnQF7Mi+JGhWz+w2e4DzWrK9Ot19Vait067rHwTrBOCxB3g8rV4ABgBAAPZFk2MIwL1Uj2sF
yXFAsOotrXB8FKNW17XR4yBYWV7bi37d7kHXACdU1+OpADy2yevop3OvCrV13W+/FvigAFzbG68B
Hk+7FoABABCAfdHkmCV87oLD9JSe1t+Fo+hNF4ABABCA4ZSq+y/7XRCAAQAQgH3RBA5tvAWWAAwA
gAAMx/WLsIX38dzo0afx9+iw+3fQ693W6/a5BACAAMzOWXWv223LgFB9gKhxgKpcG9tHh673+zgy
89zzNdjUOHhWHwF6avCroxjg6yh+p1fdvqn2ce611DHpA29lwLF+jMZjVeus+g9yn2efSwAACMDs
jASnhN8a2XhcPobAhKFx+VzddY23CBpvUTQVxKYCcB+4awx1U7dFmrut0tT6T0K99tq3qQBcj+de
Sx2TCsN91OmpkD2us9+H2ecSAAAC8BHLF/j0UFVZp/cp4etBr2WsEHee1C2D6n679R7qyxOaqhcx
ATc9jDlOCVI5ZtVbm59T/cwe5L07F2xXBdyp9//U7YnWCbi7FIBzLHOs+zGdO1YHneZdt5Pqt5k6
KACPvcMCMAAAAvARmwui+dKeANYDcdWtMDa1ngS0/oU/Kkj1On27Nd/XWT2f47pOsxy3Crf9FOj0
BtfyCsN1/MeexDq1OCGt7h28qaPqAV4VgE9jD3COaY71OgF41Wup+fyc8k+NfmupVQH4MLegEoAB
ABCANwzA1fNVIbSWZZpwVssq+I4BuC/LOhKcKjxleQLwWKdPa3m2VcEvJcse5HrIXZMwVGGpB+C+
vMJnHdccj6qbaa9bdTZVvcibXANcYXzu/d+f79cAZ321rG9n6hrgVes/rp9P9cQfFIBXvZaar2PS
38M5plO9vv1n30+b3vQ4CMAAAJx4AP6f/10sHn/2/8uT/7VYvHDl3+WtdxeLP9z8dzmJAFwBNKXC
avXO5ot+vsj3Htqxt3bqlOjqRav7yo51ahsp1etWwSvbrFDeT8M97RJmE5iqN7TeQ3XdZy2rY18h
Mseln0pbp0/Xes6iHr7Ps02PgwAMAMCJB+Ar/7NYPPr45uWxJxaLl65uPwCPp0BPnZ58UACunr69
13zlyl7v8VSdvt6xbakgfF6cpbDPCX2wCcAAAJx0AE6IPY7UnmEAAASdSURBVEwATkmP8bYDcHoR
+yBYUwE44Sy9UTVQUw/AeW4cQGgczXas07eRxxWY08uZfUjvZ5ZVHV/sQQAGAOAUBOBPPt9/mvMr
/73/NOg6PTrlP57aH4D/87XTeYD7dcCAAAwAwDkJwOfR3GnNjsvNvYGQqie9bkVV1/jWLY7m2lS9
8RZW4z1njytcrfu74HdGAAYAQADmnKjbDtWgY32067p1UPQRosc2OU28bpdTz9V6an6d924NsNVH
MK5ByPrIxZn2EaOrbt9O1c+0gvs4snTVm1te65u6BRM+lwAAEIA5ZXqwnQrGNRp2HyF6bFN161rt
Cs7pDd4kAE/dp7eu2+7Xb4/3DK664y1/+r2Kx3ZT9wIel/f7647Xj+NzCQAAAZgzFoATIGuQsE0C
cJV1R8yeut/uGG7H5VN1+vIE8H6rpnXbjcvH7eNzCQAAAZhTqE7v7SNsjz25Y+itNtWzW6ci1/2a
e7tN3rtTvbBRp1eXdXuA0y6jdlf7w/YAj9vH5xIAAAIwp1RCYgW+ugZ3VQCea1MB+rABuK4l7tfh
9sBdpzPXNbvjNcBjAK5rkGvfNr0GeG77ftd8LgEAIACD9y5+tgAACMDgvetnCwAAAjAn7vbt+/se
f/HFl8uyjnXrjttAAAYAQAD2RZNj9cYbHyxLef75dxZPPHF1OX3ttfeXwfXRR1/Yez7zFWZT5+mn
f7ssma+gmzp5nOn165/u1a15BGAAAARgXzQ5Vvfvf70v3CagJsyW9OxWoM20z491E5qzrAfmt9/+
aPHyy39czn/00d199RGAAQAQgM/9F83ctzX3j61So/iuklGK+8jDmc+yrGud9udVwmr13EZ6fCuw
9joJtFmeUgF4rJv5d975eK9+wm9CcaYlyxO6EYABABCAj+WL5gcffLD43e9+tze9ffv24saNG3vT
+/fvLz777LO96XGr8DoVjHNrmx5oq25uUTMVgCP3pz2o/aa37TlLAbiH2PTgJrT25+dOgT6oBzjT
8dpgAVgABgCAYw3Ad+/e3RdwxwA8BuR333138frrr+9NjyMAp+c3wbTCaS3LNPeLrWUVfOcCcJ+u
ap9lCcjnzXgKdFQvb0quDV51DXDqJvimVJAe6/cw3cM1AjAAAALwuf+i2YNpSnpwe4/uzZs3lz25
ved27hTocTq2v3Tp0jIYZ3peT5XOqcz9NOVtqVOkEYABAEAAHsLr3LKaP2wA7u0ThgEBGAAAAfjE
AvDFixf3DYI1FWDTM5ye2ytXriynmwbgyPrTvp8C7Qs7CMAAAAjAAD6XAAAQgAF8LgEAIAADAjAA
AAjAgAAMAIAA7IsmIAADACAA+6IJCMAAAAjAAAIwAAACMIAADACAAAwgAAMAIAAD+FwCAOCEA/DD
Dz+8/LKpKIqyKyWfSwAAcOQBGAAAAARgAAAAEIABAABAAAYAAAABGAAAAARgAAAAEIABAAAQgAEA
AEAABgAAAAEYAAAABGAAAAAQgAEAAEAABgAAAAEYAAAABGAAAAAQgAEAABCAAQAAQAAGAAAAARgA
AAAEYAAAABCAAQAAQAAGAAAAARgAAADW93/wlmgGJmsXEgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Low-dose versus VS.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AAB2TUlEQVR42uzde7Bd1X3gef5Jl/6K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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAk0AAAGvCAMAAABxQBF+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-04-06 12:05:50 -0700" MODIFIED_BY="[Empty name]" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAh4AAAG8CAIAAAAenTtlAAAiN0lEQVR42u3dvW4cR9bG8QGcOGCg
wFfga2BkEA4MZ74nO2QgwA55F4IvYWHthrIiRQa8Sy0kBQqo3WztFfodisCCL6d72DNTp7pO9e8B
YRBD8WG7Ps6/TnV9bDZERETFNRARERUStBAREbQQERG0EBERtBAREUELERFBCxERQQsRERG0EBER
tBAREbQQESUPfw4lgRYiolKBb86HBC1ERLOi3tE/JWghIiJoISKqGfiEPmghIioV9Ua/J2ghIiqA
luHe23uREFqIiMqghaCFiKhY4FMO0EJERNBCRETQQkS0tvB3Pw4qEGghIirGlQffELQQEUELtBAR
QQu0EBF1HP5wBVqIiAhaiIgIWoiI1hX+XDQJLUREpWKfQoAWIiJogRYiooJBqvSclbgHLUS03vA0
58PTiSUSQgsRrSI2yTmghYiICFqIKEV4CgtQZsOghYhWF5tGv4/wj/sr0EJE1Chahntv70vFK2iB
FiJaO1pkLdBCRFQsPIWHP+9aoIWIiKCFiIighYiowSBV9B3+/5zv/wlFDS1EtJYINfVNs84ELUQE
LdACLUQELdACLUREBYJUwBLh+4bCILQQERG0EJHcgqCFiOigIDLnwyLQOt32f+uYXQUGLUTUaAQ5
+qen+xO0EBE1hBZxD1qIqPkgEhNGoAVaiGjVWUUcXSLeiHjXAi1ElAAtQ5ULuwhaiGhdaEnnT9BC
RO0GkYx0MSEGLUS04ggV867l/jfCILQQ0boSl9BkyDFi0EJECTIMaCFoobXEO009KWNCTz7Om3VB
C9GSjXvOhxRElIiDXlQftBAt2bKP/ikVoXhQPao7aCEiahctJkuhhej4wKEoKhRy3B6ROFv5ELQQ
HR84tHAFDi3QQlQ+cBQ/24o6CNPGH9BCdGqwo6RoCQJAhak8aFGU1G3jVg5VQ4k3IgQtRLTmfIig
hYjkQ+V345sKgxaik4a9mnq16J+iqDUGaCEqwBUBJWPUjpsQ0xKghQhaVkeX6BVcWgK0EEHLShOX
6PsrvWuBFqLjmziu1IgjqWK0xgAtRARaJsSghcjIdN3lXO2Mfc0DWoigZRVZRWhUCbq8UiSEFiLh
Y70IV4PQQkRUeHCgTKCFiFaXuCQKKaAFLUTCRw6uPPim/Wfe8wlBC5Hw0SdaHNcPLUTQAi0ly7nm
GWLaBrQQCR8thpKIlCWuBk2WQguR8GFwYHAALUREBgfQQkS02pRIGIQWomPCh6ZOU1xBF2ghOpIr
wgdBC7QQQUueCJLzrDZvcaCFCFrSJAE2NhK00CqauKhUjSulijp1PkSqilpqiGIHtMhRoIWobFax
/0MyOCBoITp1TFqkZVp83Bm0VCK0ELWCLq9buhx8lGIVaEELdTsmhZZu6jF0hVgQtzQMaKE+x6RB
41NoyZ4dRg870AVaqGe0DPdehxQ/OL1s7DB/UgEt0dNW0AIttBa0yLSgZYHwZ6AALdRrE5RpdRJK
hGmCFlpVyBtKr2am+sSCLmghaijDKDtRo9fUxO3oDGTBekQsaKFVMCBicZEVYknRMvWyvcgygbKG
BC20itwCWmrHkYrruIqjRduAFmolgqTILYo/s73cLbQ6aIEW6qehzPlwPZ3cKuSe0mU1CC20ZAw9
9KdHoCsdV9BlCDvohaCFaEUjU2iJzjv/RykTj9BCqxiTrjzk7ZaJTpR9N75MC1poycAxRJ4VGLq+
yKvapGipsKxZ24AWWh4tQ8DRJnE7DISP+hlA9MSjtgEt1CdacnXyuAUCplPqE0tGCy3UYUMxfhSY
6jePdJkWQQu1GKlzLT6GltE0jjQGTYFAC1okMQQtJLdoAACmU7JnLXbMQAv1Gaajt8XJLaQpj7YN
ghbqNgPwzLKWObYpljUTtFD/YTp08XHeMXuWJCZ6SlNlQQt1HqZzTXnLh+pkLUHTsK5FgBZaUT6U
aDgJLUFpinKGFqIEaLFAoJtkSLCCFlpFJw+a9Y7bfRIxiYcr2QGg7qCFmuiBBcN09Ky33KKDvBNa
oIVWhJbBGxGqgpbol+2aBLSQMH3SY1t8nA4tohO00LroIpjKh/bkFilSCgsEoKXPTqgooIWWokvq
90PQQvsatJKHFpqZUsQt8dAfoaXDIViKawqjD5Ecck61WXy8hwQZkyGVCC2yexkArSJM11x7ph6h
pYdCVw510GLpQVK0OOkLWmhlzSVyNixozBt6FZg0a4g/TyFRpkXQQm1NTYSmLImglX3M0XiGIR+C
lnX1xjWjJfqZoYXkKNCiWSd47Fzb4hLlQ9ozQQutoivW32GQsVi0Zw9P0KI1t44uxaIGd/PCiIah
sUGLrkjHF/XgWvXMg7C4iUdVCS1ErQQmvaYbtBC0kNyiIbTIO5PWoMXH0LKKrqgKLBFWg4/2lIjq
c1YstHTbFXO17KAXqnX2zGvqSdGiD0IL9dys5RajrMItaCFo0azlFiGVqBMVr8E6VzkYGUCLrmhk
WibJMOYlghZqrrkEpSx1ssM1551E0ELrTeNSoGUwnTKRFEZPW6VwJgW6QIkPOXdFVBunO50sb8OO
yGijH9iNO9BC3Y5Mg7IWI9Psw45qaCn1tzQzaFlFBhD6zA2mKRWe2eLjyu05um2U3ecvY4aWnjMA
qtC9xZE9DTtFTym+BfiByZrvtxbUOgx5NblYpBzqhA95J+nX0EK6TVSOCC2pW13j5SyiQktvGQC0
LFuDSqN4RlttWfOQ5GVnrrMq9Iolw3Siqdjo1/hePsloF3HOcnJdrkGePtwEWnINmqLfiAQtBtXU
ZbTV+mDxfCjdAgH9DVpaDEyluk30oljcgpY6zulKGFqaaNmWwKdDS9CUZlJKJZ3PrLCmuXj+DS3U
JwOCMvHRTp4ILYMNd2ROAlpMIKynwyQamdpw101+b6YUWqDFWKyVkGfnUDWE512UmAW00NJnh0yH
llw7DKIbhpFTtQFNrtJONLyDFlo+zY+GVuq0YOV0SYqW6CsGoIVoyQ7jOJY+Epe4SBp0NnZS0EJL
VxmAeActe1LDvMuRV/ucFXZTtV/I0NJbMI172pqX1MZF6nTxLuOiCY+a7jVqVL8T66GFTk8vQse8
bbaQ0LOlgxI4dyY9Oo6BFmhZcnyX6JLauGcuHvdzoYWyD2iCdlNBSytNJFdrjh6nJ3rm0KXY7U+s
73+qU545o3O1jDbu4EtZC7UVRJqdVJF31hl5zPlwDc4ZW10EBaCFqEA/14kyLsTIdWf2YPExLZUy
R0+vZTxBoIMTefVQ+X26AY2G20/ji952HnozZp1gWuFle+OBiQxo6kALWvpEyxBwbm61q5PqDPrK
Bo4U74eIqvVuaOkWLe03vgrOcaWU8TZ4yh4xEq14hJauUubo2gya5w2FVgcvWvTQDjq4rIVo4Zad
9LqnlS8+Dt2clMh5qDvBW7xMSo3toKXbGL3nE1pt+Ahtb3HH3Wdxjs7ChzxbraGlibFe0AbgRIdI
VsstWg4fFY4BjR7KFGzSGZ2j0ZJo4AgtTYx5h3WfxzXEX51U3Nxu/PrtrX3n0eaRoj0PpSd4oaU3
tNQMIu2PxergMFH4iBufcq7fDeOycO9aoCV89NFHbpEiTDvsnZZqG1aIddtWUkwjxDVuV4FlyVGo
y8EBtJDAtJbxY95EPGhBVyJnNQgt0EIFijpF3plozJvamaCluZFvkLMCr4Dw0It7oSUXWvRBoaet
MW/GmwTX5hyNltSNGVqGbNtpg3ZTQUtbY96W0RK3bzmX89TIVJMOGiGlc655Jl6zbU+v6BAtxff5
D9Vn8Bp3rtQtQUsOl3a2Q9ttK3wUPMQi9T7/9p3rDzsoKV0q7ABrcAMAtBgx0SrQkvdy64zO6WY7
irc6aIGWxcY12Z0ToSXv5dYZnVPPdkAL1Q6mzhDLW4PdXG495Fx8nC5dNiFG6SdqhszHUxaP0dXq
LkuunNo5xYAm6HQJaCFoaW7MGxdB6tBl5Qe9JDr6PpxY4uaCg4UhZrV+rqvA0jmbTqGZdFnnIUDa
7sItL9ESYTKdQoeO6lZ7dCm0QAs1mg+FDnvLLhCICKYZnWsmQ9BC0ELHV2KWSTxaKisq6AwtxryH
tT+lnT18FBytQ8silZjrsaGFZC3CRxNoscSjpz54eplAC7ScOpperXPekBHBlaDy6cO5lGf0+6Fd
z6P9oaUJBgSt1q/zzMUjdQrnOsf1D3mOD4CW1MMO71q6zS3av6Ow/tF4uZyLt41cb0TqDJUSObtl
Elq6Qkv9Z14nWuLCR66LdUMXHaRzrpnRNr78B1qWpnrOBSTFp+zTOWfMWpKe9dvBwDHFbIeshZYZ
i1H2kanFx9mbB7QQCR/tPjC01B/kRbS6lhdMQ0tD7W/Nz5zOOe9M/f3n1w3NTAS1Z2jpcMCbLuRl
dJYMEUHLisJHhQtfoaX+yDRXk17t4uO8B19CC7QchpYhw0awpGhJFDuiQ54tk0uNPJqd7YCW3kam
oWjJ+N4iXTDtY6gELUnLueCWMmjptp+r3IydvI/R0sqds6PldGdoITKdQikbXst7nrSw5Tt5+1HJ
TYLGvNTgyCDoMO+Sq5nV2VKdPPScKLHDsCMaLYYd+iC0rAItdlxrG/WnU0gfhBZoaSgNz3u67ZDq
Bnvny/U3J9H4ogbNa/lJj0RHENoWt8dq5XmnQ4BqDhzjWl0pZ2gBrQ6bdWrnoYsFAmt21gehhQBg
RQCAlmpoSdcHi+f3ekUrswcOmbAt7v4DQwu0VM6Hyr6Ng5YOe6ZVQNnHj8P/X72adLTE2fGUok8/
dLEtbpGMM64f5XpxLWsZcl5gDC3QsmTjM36s1qWD5gaF6aTOdRbTO/m4w5FvnLlOnrFtpCsNzUNR
QAvpMCGjyDXXoAsXtA1oIWhp8Q9VuLDL6+VuumHjcxKa15KTHnEnmBrl1Q+m+hHV5ErxVuddS4dJ
QIo3IlSn5LPfBDNErsNu3LnaRdHtX08OLa2EoSwrlyguNay/Cqj90bQzwqGFukWLOzkyZj+LtDpo
qTOmiXjgkIxQrF982Bs3mla/BC11nPNeXlD8mYUeorYGB0PCiwAG58sRtFA7Y7G8V4E5rZkIWpqO
10PYuheVG1p9GdFC2Xt3lixc9Fk4MCW6h47kFjLaxXt3tcNpvGuBlhoh78EoLGJXYyLnjAAYgpd4
uNy6Qu/ebdjQQonRMtUD1+lMNXO41M7Ry5rL7qmCln56Y5Z1L9CyVNsYkqwQ41wzo921jdixW8ZN
oCdo6TijzbvPf7D4eOeBMw2dRU+Clo7Rkihjo65mZRTEshGk8ZeTVgH1gRbK27vr5J1lx3bQ0vnI
VP3Gjssy7Eyqs0KMc97Bgdf40LIAWvY7nOKf0Vlu8WhpxC3kzeg8ZJjShBZoWWDMO5XXF5y5yuXc
zcg0UTDlHN3GrBDrajol14DXKqDQ8FH/3DNoCR3eRY8aW47e0ELUHA7rPHAca4OWpSRyJmghIiJo
IWqj5zz6yenpxZDnvhbanyC27wwtRG1FjfaXrqbbFZHaOeOqNmihfsY1nWUtQeFjWOXS1T6ccy1q
KDvyEHqWB0D0pEfxp+VcB1qJttNyzo6WqRzuaH9o6T98mOuogNv2d+M7nrKy8/0/0b7zFGihBVoq
oeV+my6+zz+Fc4XxY3SrI4IWaCkwPm02JGV0zosWokNzOGjppCIbf1rOddASOp3iEMn6zhE1OFgh
RmRw0EhGW2Sug/OhGfMKp2GhZbFyD2p8Q8IDSGgRtHCOdk6EluIT6aLPwkPdCkcQNrvyPbUztHCe
2Q1TZLTFgwa0tJK1ZMmH9rTylThXW8gb0VQcIhnqnHqRd9m4AS39Qys6H4pYgda+M5HhL7Q0WnO5
xjXQQiQcQUuOEUGuSFd25XuXzkQELa2gxTi6g+kCW1M5d7AFGFqgZdwz3YIoaNmtwaCn5cwZWtZF
l6QTYnZcF++ZVnhzru882NdCi4ymTSPM7+emxTjnnRaTtVDVYKcrEhG0ZMUAAEDLaPPgzDnOOWhI
Ci2thJKV4zCd8xD2FseNjZzrOw+l3x1CS4d0sUIs9WhAyOPcgbPQ01uoSroZE1oEJs7QQu0mFrl2
zGR0jkbL4B0A5/zO0NLtaNo+/7zjA6JOeoeC6JUuKje6kIkIWtod8LY88g3dHpjOGVqIoCXHsDfR
QS9Bz5zdmYigpa0YXTxORV+eWtw8qbN3LUTQsha0cK6G8PBuGbB8nDPnOs7Qsnz4qHMXZMvPnNQ5
ethRfI0fZ87VnKEFtKjRwYGQxxlaiFbHlaDsUGDiDC1UYMw7pFoh5iqwaLQMJh4553eGloXHvBF7
5qu9xeFc528RZR06K4hu0OKWyWrh3jstImiBFmjJ1i0tiuWc1hlalg8fWRYfuwqsm2EHZ87RztAC
WlSA4hYfc+YMLURNZ4cCE2dooQJTNI3XgqvAaqJlsHSVc35naOlnOiUjtHoaJSgQImjpdjqF+msb
nDmnc4YWaFkyH8p7FRi0cOYMLQnidcsAoJkFHgdyzpxzOQs9RG2NH4n6GXgpiBaqoWXnBzt1I4ZL
iZyhhQhami/9gPKPW2hbdmFbRuc4tJij59yNM7QsTJQU5wtBy56iLr4XJ6LDc+Zc2RlaFuBK0JCh
jjO01GkbQh5naCFZC7QITJw5Q0t7jGnZ2b4Wzpw5Q0tWxuRyJiKCFiIighYiIoIWIiIiaCEiImgh
IiJoWW+ZEhH1LmipihbOnDlzXrMztGginDlz5gwt0MKZM2fO0AItnDlz5gwtpIlw5syZM7RAC2fO
nDlDy5rRcvPnzeX15cXLiyd/fbL5y+bs+dn5i/Mf/v7D+z/en+j88ePNhw+X795dvH795B//2Fxf
n719e35z88PHj5xLOsfVYMa28efNzfXl5cuLi78+efKXzeb52dmL8/O///DDH+/XWM6coWUZtFy9
ufrib19s62/3a1uvP/3zp6Od//3vq9evv9hGjd2vbTT51784l3GOq8GMbePN1dXfvvhi7JE3W9L8
86d1lTNnaFkGLduBwGgV3v/a/psjnLfDz9HAcf9r+284n+gcV4MZ28Y2NXnskTfbf7OScuYMLcug
ZTs6eLQW776mRgpTztsx6aOx4+5ranzKedkazNg2tvnKvEfeTOUuPZUz55JoefQy9t1/8ODPzTw5
YOpHo5/M+T8a/WdHfDj1tKOzmVNZ52ge+u4/72Y6f/x4c3+u45dfNl9/vfn889uv777b/Prrw9mP
//6X8zHOcTWYsW38eXMzNQ82OjP2n3c9lzPnkmjZvYB9FBujDzEHEo/+4mjEP9pw/oePzl2O/vTy
+nJmLe5JQkedP3y4vB8gvvzytlh+/nnz7NntN199NWvqg/OCNZixbVxfXh7yyOPTYt2UM+fF0DIn
oTmCBMehZfRXjuPNfLRcvLwYqbA7jVXk+Yvzmc7v3l2Mzm/89tut93Z8+uDzt285H+McV4MZ28bL
i4uD0PLivOdy5hyOltH/Hh2OHwXGUmjZP+02+vndqr75FXn2/Gym891a0gdfr15tvvlm89lnmx9/
fPij62vOxzjH1WDGtnG3znj+1/OznsuZczG0PJpJpEDLo/NdB82SPfLhaBXe105dznQeHZZ+++2t
5fffj7+w5XyEc1wNZmwbU0Fp+pF7LmfOJdGyO3gvhZZR23bQ8nidNTAy3Y5Jt/r995HYcWIGsFrn
brKWIqUha+HcaNZy4ruW09Ey53cLoqX+fPrU1+nvLdbp3NO7ltNLw7sWzuXRMsWJ3YgcukLsFLTs
f4CICbFqq4Duvu40f3Mc5y7X6sSVhhVinFtBy7B308mjJCi4r2VqG82Jm132/79U27uwP3ycskdk
5c4d7GspWBr2tXAe7MavLLvxe3W2G/++7MbnDC1NoGVwhlh+Z2eI3ZczxDhDSxNouRspjK/N+JR1
Pn399GjnT6fbPpk+3ZZzGee4GszYNra5y9Rqse3nr5+uq5w5Q8tiaBmmb0cYnc08yHnqTo7ROXTO
DdZgxrYxdV/L6PuV7suZM7QshhbOnDlz7tsZWjQRzpw5c4YWaOHMmTNnaIEWzpw5c4YW0kQ4c+bM
GVqghTNnzpyhpW+0EBGtQdAia+HMmTNnWQu0cObMmTO0kMbHmTNnztCiiXDmzJkztEALZ86cOUML
tHDmzJkztFB4RU6dQfvx43vOKZynzvr94/0anzljaUyd9fv+jzWWRoQztNRGy6ebM76YvjnjJ86N
O7+5upq6u3cbTaZuVOz1mTOWxtWbq6m7e7ekmbpRsdfSCHKGlqpocWNjdue4exUzPnPG0oi7VzFj
acQ5Q0s9tLhnPrtz3G3wGZ85Y2nE3QafsTTinBdDy+5fPPQZTn/m0WfYLY2p8wz2l+nobOb9rPOX
XzZff735/PPbr+++2/z668M8dPTuP84LOv95czM11zE6+zF6x2I3z5yxNG7+vJmaBxudGRu9Y7Gb
0ohzbggtRzzAic88ipDd70c/HP31R5/tw4fL+1X15Ze3Dj//vHn27Pabr76alYRyXtD5+vJyZuzY
M/XRzTNnLI3L68vNIQ89Oi3WTWnEObeClkezhLvvRz886Fd2f3ocWkZ//dHifvfuYjTT/O2324fc
jhQefP727TnnppxfXlwcFD5enPf8zBlL4+LlxciT3Wnsoc9f9Fwacc5NoGVmfN/9949G/6k/MSdz
ejRrOQItd6v6Hny9erX55pvNZ59tfvzx4Y+ur884N+V8t5Z0/tfzs56fOWNp3K0zno+Ws+c9l0ac
8/Jo2f9356QOB/3KTLRMkexEtIwOEL799tb2++/HX51xbsp5KihtpqNTx8+csTQeeeKxh+64NOKc
F0bLFF12bwKYk0/M+ZWZr/GnXqtEZC3b0cFWv/8+Uosnjj44F3euPDJt/JkzlkY3WUvjPaXFdy2H
vvA4YiLraDaciJapmc2pr9PnTDmXda4/n97yM2csjZ7etbTcU1pByxQwDn3XcmLWEv2u5cF6jLuv
O83fpsR5Qedqq4BSPHPG0uhghViKntIQWkYJsbsi69GlwEUmxOrsa9lfkaesT+cc5Fxt70KKZ85Y
Gh3sa0nRU5ZEy4kcalx2tvfqbDd+9tKwG7+OM7TUfmDncWV3doZY9tJwhlgdZ2eI1Wbhp3NGn0yf
M/qUc+PO2/Hp1Iqg7eevn67rmTOWxjZ3GV8t9mke7OnrdZVGkDO0LJBmTd2OMDqbyblB56k7OUbn
0Lt/5oylMXVfy+j7le5LI8IZWjLN4HHmzJlzCmdo0UQ4c+bMGVqghTNnzpyhBVo4c+bMGVpIE+HM
mTNnaIEWzpw5c4aWvtFCRLQGQYushTNnzpxlLdDCmTNnztBCGh9nzpw5Q4smwpkzZ87QAi2cOXPm
DC3QwpkzZ87QQuEVOXXO6MeP7zmncJ46N/f9H+06x5XG1Fm/f7xfYzlzhpZl0PLpdoQvpm9H+Ilz
485Xb66m7sHd9syp2wmXdY4rjTdXV1N3925JM3WjYq/lzBlalkGLGxuzO8fdURjnnPH+yozlzBla
lkGLe+azO8fdrB7nHFcacbfBZyxnzk2gZfcvHvoMpz/z6DPslsbuh4+eczD64cePN/dnJH75ZfP1
15vPP7/9+u67za+/PpyjGL3fjfOCzjd/3kzNG4zOJIzeV1jZOa40/ry5mZoHG50ZG71jsZty5two
Wo54gBOfeRQhu9+PfvjoY4x++OHD5f1u/OWXtw/w88+bZ89uv/nqq1kTFJwXdL68vpzZD/dMI1R2
jiuN68vLQx55fFqsm3Lm3CJa5mQJuzAYTSP2/8ruT09Ey1S5jX7+7t3F6CzEb7/dPuR2FPng87dv
zzk35Xzx8mKky91prCuev1jeOa40Xl5cHISWF+c9lzPn5tAyM77v/vv90X/0V+ZnTnPQsr9Mdz+8
W/H54OvVq80332w++2zz448Pf3R9fca5Kee7dZnzu+LZ8+Wd40rjbp3x/K/nZz2XM+e20LL/7z4K
j0N/ZSZapkh2IlpGB4/ffntr+/33469VOTflPN4J72unNy7uHFcaU0Fp+pF7LmfODaFlii67b8jn
5BNzfmXma/xR86CsZTty3Or330d6+InjdM7FnbvJWoqUhqyFc6Z3LfNnpQ4Cz6ELAR59OT8z35oz
6z31dfrbBc5lnXt613J6aXjXwnlItEJsalZqzruWE7OWgxB1BFoerNW5+7rT/C1snBd07mCFWMHS
sEKM85BrX8vuBNTMFWKnZy0z97Uch5YHOwz2d/JTdnJwDnLuYF9LwdKwr4XzkH03frrDAuxs79XZ
bvz7shufM7S08sDO48ru7Ayx+3KGGOfEaEmnGWfQPpk+g/Yp58adt2O98dU1n+YNnr5u0TmuNLa5
y9Rqse3nr5+uq5w5Q8uSadbUzRmjM92cG3Seut9idD66Eee40pi6r2X0/Ur35cwZWvLN4HHmzJlz
Cmdo0UQ4c+bMGVqghTNnzpyhBVo4c+bMGVpIE+HMmTNnaIEWzpw5c4aWvtFCRLQGQYushTNnzpxl
LdDCmTNnztBCGh9nzpw5Q4smwpkzZ87QAi2cOXPmDC3QwpkzZ87QQuEVOXXO6Ps/3p/oPHW67ceP
nEs6x9VgxrYxdfLxH+/XWM6coWUZtFy9uZq6N3Rbr1O3uc1x/nQnxxfTd3JwLuMcV4MZ28abq6up
m4y3pJm6X7LXcuYMLcugJeNNgpzr1KBbJrOXM2doWQYtGe8/51ynBjO2jW2+Mu+RN1O5i3vme3We
i5bdf/C/Tw760aG2e/7ByP/D///R/nMI5v/Kceajs5lTWedoHjp6v9uo88ePN/fnOn75ZfP115vP
P7/9+u67za+/Ppz9GL1VkPOCNZixbfx5czM1DzY6MzZ642Q35cz5eLTsxtZG0HL/k9E/fcqvHGE+
9eHl9eXMWtyThI46f/hweT9AfPnlbWX9/PPm2bPbb776atbUB+cFazBj27i+vDzkkcenxbopZ84n
ZS2PxtniaDk0js8P9KXQMj9ruXh5MVJhdxqryPMX5zOd3727GJ3f+O23W+/t+PTB52/fcj7GOa4G
M7aNlxcXB6HlxXnP5cwZWoqh5dAJsbtVffMr8uz52Uznu7WkD75evdp8883ms882P/748EfX15yP
cY6rwYxt426d8fyv52c9lzPnU9+1jH4zdczyzHm2/b87nxxTb0Rmsu0gtOz/fxz/cLQK72unLmc6
jw5Lv/321vL778df2HI+wjmuBjO2jamgNP3IPZcz5wKv8R9kMIe+4d8fl/fE9F2Y7SLk0KzlaLQc
kSdVHplux6Rb/f77SOw4MQNYrXM3WUuR0pC1cG4ILUdMiO15pT8XzvOmraLRUn8+ferr9PcW63Tu
6V3L6aXhXQvnofji4yMyj1PQckTmcUT072aF2N3XneZvjuPc5VqduNKwQozzsOC+lv1XXRZBy3D4
1pOpp+pjX8v+8HHKHpGVO3ewr6VgadjXwnmwG7+y7Mbv1dlu/PuyG58ztDSBlsEZYvmdnSF2X84Q
4wwtTaDlbqQwvjbjU9b59PXTo50/nW77ZPp0W85lnONqMGPb2OYuU6vFtp+/frqucuYMLYuhZZi+
HWF0NvMg56k7OUbn0Dk3WIMZ28bUfS2j71e6L2fO0LIYWjhz5sy5b2do0UQ4c+bMGVqghTNnzpyh
BVo4c+bMGVpIE+HMmTNnaIEWzpw5c4aWvtFCRLQGQQsREdUdYSsIIiKCFiIighYiIoIWIiIiaCEi
ImghIiJoISIimoUWIiKigvo/ZnIsJFiPKUsAAAAASUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-05-12 10:04:13 -0700" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-05-12 10:04:13 -0700" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-02-24 07:09:27 -0800" MODIFIED_BY="[Empty name]">Risk of Bias</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-12 10:04:13 -0700" MODIFIED_BY="[Empty name]">
<P>We examined the adequacy of the methods used to generate the allocation sequence; the concealment of allocation; and the level of blinding (clinician, participant or outcome assessor). For each trial, the authors classify the risk of bias as high, moderate, or low. Overall, we considered trials to be at low risk of bias if allocation concealment and blinding of participants are adequate.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We will assess the method as:</P>
<UL>
<LI>adequate (any truly random process e.g. random number table; computer random number generator);</LI>
<LI>inadequate (any non random process e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to conceal the allocation sequence in sufficient detail and determine whether intervention allocation could have been foreseen in advance of or during recruitment or whether it changed after assignment.</P>
<P>We will assess the methods as:</P>
<UL>
<LI>adequate (e.g., telephone or central randomisation; consecutively numbered, sealed, opaque envelopes);</LI>
<LI>inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Studies will be judged at low risk of bias if they were blinded, or if we judge that the lack of blinding could not have affected the results. Blinding will be assessed separately for different outcomes or classes of outcomes.</P>
<P>We will assess the methods as:</P>
<UL>
<LI>adequate, inadequate or unclear for participants;</LI>
<LI>adequate, inadequate or unclear for personnel;</LI>
<LI>adequate, inadequate or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We will state whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.  Where sufficient information is reported, or can be supplied by the trial authors, we will re-include missing data in the analyses which we undertake. We will assess methods as:</P>
<UL>
<LI>adequate;</LI>
<LI>inadequate;</LI>
<LI>unclear.</LI>
</UL>
<P>We will also evaluate the risk of attrition bias, as estimated by the percentage of participants lost to follow up. We will exclude studies with total attrition more than 30%, or where the difference between groups exceeds 10%, or both, from the meta-analysis, but will include them in the review.  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We will assess the methods as:</P>
<UL>
<LI>adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We will describe for each included study any important concerns we have about other possible sources of bias. As an example of some questions related to these concerns: Was there a potential source of bias related to the specific study design? Was the trial stopped early due to some data-dependent process? Was there extreme baseline imbalance? Has the study been claimed to be fraudulent?</P>
<P>We will assess whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We will make explicit judgements about whether studies are at high risk of bias, according to the criteria given in the Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). With reference to (1) to (6) above, we will assess the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings.  We will explore the impact of the level of bias through <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>. </P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>